0001477932-15-003367.txt : 20150519 0001477932-15-003367.hdr.sgml : 20150519 20150519143357 ACCESSION NUMBER: 0001477932-15-003367 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 10 CONFORMED PERIOD OF REPORT: 20150331 FILED AS OF DATE: 20150519 DATE AS OF CHANGE: 20150519 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MANHATTAN SCIENTIFICS INC CENTRAL INDEX KEY: 0001099132 STANDARD INDUSTRIAL CLASSIFICATION: MISCELLANEOUS ELECTRICAL MACHINERY, EQUIPMENT & SUPPLIES [3690] IRS NUMBER: 850460639 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-28411 FILM NUMBER: 15876024 BUSINESS ADDRESS: STREET 1: THE CHRYSLER BUILDING STREET 2: 405 LEXINGTON AVENUE, 26TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10174 BUSINESS PHONE: 212-541-2405 MAIL ADDRESS: STREET 1: THE CHRYSLER BUILDING STREET 2: 405 LEXINGTON AVENUE, 26TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10174 10-Q 1 mhtx_10q.htm FORM 10-Q

 

 

U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

 

FORM 10-Q

 

(Mark One)

 

x

QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934

 

For the fiscal quarter ended March 31, 2015

 

¨

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT

 

For the transition period from ____________to____________

 

Commission file number 000-28411

 

MANHATTAN SCIENTIFICS, INC.

(Exact name of small business issuer as specified in its charter)

 

Delaware

 

000-28411

 

85-0460639

(State of Incorporation)

 

(Commission File Number)

 

(IRS Employer Identification No.)

 

The Chrysler Building

405 Lexington Avenue, 32nd Floor

New York, New York, 10174

(Address of principal executive offices) (Zip code)

 

Issuer’s telephone number: (212) 551-0577

 

None

Securities registered under Section 12(g) of the Exchange Act:

 

Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

¨

Accelerated filer

¨

Non-accelerated filer

¨

Smaller reporting company

x

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

 

There were 519,003,036 shares outstanding of registrant’s common stock, par value $.001 per share, as of May 10, 2015.

 

 

 

TABLE OF CONTENTS

 

PART I

 
         

Item 1.

Financial Statements

  3  
 

Consolidated Balance Sheets as of March 31, 2015 (unaudited) and December 31, 2014

   

3

 
 

Unaudited Consolidated Statements of Operations (unaudited) for the three months ended March 31, 2015 and 2014

   

4

 
 

Unaudited Consolidated Statements of Cash Flows (unaudited) for the three months ended March 31, 2015 and 2014

   

5

 
 

Condensed Notes to Consolidated Financial Statements (Unaudited)

   

6

 

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operation

   

12

 

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

   

15

 

Item 4.

Controls and Procedures

   

15

 
           

PART II

 
           

Item 1.

Legal Proceedings

   

17

 

Item 1A.

Risk Factors

   

17

 

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

   

20

 

Item 3.

Defaults Upon Senior Securities

   

20

 

Item 4.

Mine Safety Disclosure

   

20

 

Item 5.

Other Information

   

20

 

Item 6.

Exhibits

   

21

 

SIGNATURES

   

22

 

 

 
2

 

PART I – FINANCIAL INFORMATION 

 

ITEM 1. FINANCIAL STATEMENTS

 

MANHATTAN SCIENTIFICS, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

 

    March 31,
2015
    December 31,
2014
 

ASSETS

  (UNAUDITED)      

Current assets:

       

Cash and cash equivalents

 

$

9,556,000

   

$

2,528,000

 

Total current assets

   

9,556,000

     

2,528,000

 
                 

Investments

   

2,000

     

2,000

 

Property and equipment, net

   

204,000

     

144,000

 

Assets received in Settlement Agreement – see Note 8

   

6,938,000

     

-

 

Intellectual property, net

   

916,000

     

957,000

 

Other asset

   

2,000

     

2,000

 

Total assets

 

$

17,618,000

   

$

3,633,000

 
                 

LIABILITIES

               

Current liabilities:

               

Accounts payable and accrued expenses

 

$

447,000

   

$

426,000

 

Accrued interest and expenses — related parties

   

19,000

     

19,000

 

Note payable to former officers

   

450,000

     

450,000

 

Convertible notes payable

   

896,000

     

896,000

 

Total current liabilities

   

1,812,000

     

1,791,000

 
                 

Long-term liabilities

               

Convertible notes payable, net

   

1,681,000

     

1,616,000

 

Total long-term liabilities

   

1,681,000

     

1,616,000

 

Total liabilities

   

3,493,000

     

3,407,000

 
                 

Mezzanine equity Series D convertible preferred, authorized 105,671 shares, 105,671 and 105,671 shares issued and outstanding at March 31, 2015 And December 31, 2014, respectively

   

1,058,000

     

1,058,000

 
                 

STOCKHOLDERS’ EQUITY (DEFICIT)

               

Capital stock $.001 par value

               

Preferred, authorized 1,000,000 shares

               

Series A convertible, redeemable, 10 percent cumulative, authorized 182,525, shares; issued and outstanding — none

   

-

     

-

 

Series B convertible, authorized 250,000 shares; 49,999 shares issued and outstanding

   

-

     

-

 

Series C convertible, redeemable, authorized 14,000 shares; issued and none outstanding

   

-

     

-

 

Common, authorized 950,000,000 shares, 518,378,036 and 516,378,036 shares issued, and outstanding, respectively

   

518,000

     

516,000

 

Additional paid-in-capital

   

62,142,000

     

61,894,000

 

Common stock to be issued

   

125,000

     

-

 

Accumulated deficit

   

(49,718,000

)

   

(63,242,000

)

Total stockholders' equity (deficit)

   

13,067,000

     

(832,000

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)

 

$

17,618,000

   

$

3,633,000

 

 

The accompanying condensed notes are an integral part of these consolidated financial statements.

 

 
3

 

MANHATTAN SCIENTIFICS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

 

    THREE MONTHS ENDED  
    March 31,
2015
    March 31,
2014
 
                 

Revenue

 

$

33,000

   

$

180,000

 
                 

Operating costs:

               

General and administrative expenses

   

779,000

     

860,000

 

Research and development

   

554,000

     

396,000

 
                 

Total operating costs and expenses

   

1,333,000

     

1,256,000

 
                 

Operating loss

   

(1,300,000

)

   

(1,076,000

)

                 

Other income and (expenses):

               

Gain on Settlement Agreement (see Note 8)

   

14,938,000

     

--

 

Interest and other expenses

   

(114,000

   

(49,000

                 

NET INCOME (LOSS)

 

$

13,524,000

   

$

(1,125,000

)

                 

BASIC AND DILUTED INCOME (LOSS) PER COMMON SHARE:

               
                 

Weighted average number of common shares outstanding (Basic)

   

517,411,369

     

472,239,467

 
                 

Basic income (loss) per common share

 

$

0.03

   

$

(0.00

)

 

Weighted average number of common shares outstanding (Diluted)

   

588,759,551

     

588,759,551

 
                 

Diluted income (loss) per common share

 

$

0.02

   

$

(0.00

)

 

The accompanying condensed notes are an integral part of these unaudited consolidated financial statements.

 

 
4

 

MANHATTAN SCIENTIFICS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

 

    THREE MONTHS ENDED  
    March 31,
2015
    March 31,
2014
 

CASH FLOWS FROM OPERATING ACTIVITIES:

       

Net income (loss)

 

$

13,524,000

   

$

(1,125,000

)

Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:

               

Gain on Settlement Agreement (see Note 8)

   

(6,938,000

)

   

-

 

Common stock issued for services

   

375,000

     

551,000

 

Debt discount and original issue discount accretion

   

65,000

     

14,000

 

Depreciation and amortization

   

58,000

     

50,000

 

Changes in operating assets and liabilities:

               

Account receivable

   

-

     

(150,000

Prepaid expenses and other assets

   

-

     

6,000

 

Accounts payable and accrued expenses 

   

21,000

     

(48,000

Net cash provided by (used in) operating activities

   

7,105,000

     

(702,000

                 

CASH FLOWS FROM INVESTING ACTIVITIES:

               

Purchase of fixed assets

   

(77,000

)

   

-

 

Net cash used in investing activities

   

(77,000

   

-

 
                 

CASH FLOWS FROM FINANCING ACTIVITIES:

               

Proceeds from notes payable

   

-

     

333,000

 

Proceeds from issuance of common stock

   

-

     

1,487,000

 
                 

Net cash provided by financing activities

   

-

     

1,820,000

 
                 

NET INCREASE IN CASH AND CASH EQUIVALENTS

   

7,028,000

     

1,118,000

 

Cash and cash equivalents, beginning of period

   

2,528,000

     

578,000

 
                 

CASH AND CASH EQUIVALENTS, END OF PERIOD

 

$

9,556,000

   

$

1,696,000

 
                 

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:

               

Interest paid

 

$

-

   

$

-

 
                 

Income taxes paid

 

$

-

   

$

-

 

 

SUPPLEMENTAL DISCLOSURES OF NONCASH INVESTING AND FINANCING ACTIVITIES:

         

Issuance of common stock for prepaid services

 

$

-

   

$

177,000

 

Beneficial conversion feature associated with debt

 

$

-

   

$

212,000

 

Transfer of assets from Carpenter related to Settlement Agreement (see Note 8)

 

6,938,000

   

-

 

 

The accompanying condensed notes are an integral part of these consolidated financial statements.

 

 
5

 

MANHATTAN SCIENTIFICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED NOTES TO THE FINANCIAL STATEMENTS

(UNAUDITED)

 

NOTE 1 – BASIS OF PRESENTATION

 

The foregoing unaudited interim financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions for Form 10-Q and Regulation S-X as promulgated by the Securities and Exchange Commission (“SEC”). Accordingly, these financial statements do not include all of the disclosures required by generally accepted accounting principles in the United States of America for complete financial statements. These unaudited interim financial statements should be read in conjunction with the audited financial statements and the notes thereto included on Form 10-K for the year ended December 31, 2014. In the opinion of management, the unaudited interim financial statements furnished herein include all adjustments, all of which are of a normal recurring nature, necessary for a fair statement of the results for the interim period presented.

 

The preparation of financial statements in accordance with generally accepted accounting principles in the United States of America requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities known to exist as of the date the financial statements are published, and the reported amounts of revenues and expenses during the reporting period. Uncertainties with respect to such estimates and assumption are inherent in the preparation of the Company’s financial statements; accordingly, it is possible that the actual results could differ from these estimates and assumptions that could have a material effect on the reported amounts of the Company’s financial position and results of operations.

 

Operating results for the three month period ended March 31, 2015 are not necessarily indicative of the results that may be expected for the year ending December 31, 2015.

 

NOTE 2 – ORGANIZATION AND OPERATIONS

 

Manhattan Scientifics, Inc. (the “Company” or “Manhattan Scientifics”), a Delaware corporation, was established on July 31, 1992 and has two operating wholly-owned subsidiaries: Metallicum, Inc., (“Metallicum”) and Senior Scientific LLC (“Senior Scientific”). On June 12, 2008, the Company acquired Metallicum, Inc. for 15,000,000 shares of Company’s common stock. 

 

Manhattan Scientifics is focused on technology transfer and commercialization of disruptive technologies in the nano-medicine space. The company is presently developing commercial medical prosthetics applications for its ultra-fine grain metals and plans to commercialize the cancer research work and nano-medical applications developed by Senior Scientific, a unit of the Company.

 

The Company’s business model capitalizes on inventions and technology from which profits are intended to be created through licensing. Manhattan Scientifics is dedicated to earning profit for its 8,600 owner-shareholders by identifying, developing, patenting, supporting and marketing technical innovation by harvesting top technology talent to bring game-changing products to market. Manhattan Scientifics assists and acquires early stage technologies and assists entrepreneurial founders and management to stage them to become commercial. Our investment philosophy is defined by our desire to help build innovative companies with exceptional potential. We emphasize novel technologies in the nano-medicine space with the potential to be disruptive and the ability to establish sustainable businesses. We are patient capital with experienced business-building partners who bring the perspective of merchant-bankers not venture capitalists. Our approach to assist scientists to commercialize their work is by providing a forum within which the commercialization process is fostered through partnerships with existing companies (Fortune 1000 or larger). We believe the entrepreneurial scientists and engineers who join us are enticed in part by the offer to potentially create personal success and wealth by virtue of ownership of our publicly traded shares common stock under the symbol MHTX.

 

On May 31, 2011, we entered into an Agreement and Plan of Reorganization to acquire Senior Scientific and Scientific Nanomedicine, Inc. (“Scientific Nanomedicine” or “SNMI”). We subsequently dissolved Scientific Nanomedicine and transferred all remaining assets to Senior Scientific. The total purchase price was 21,668,000 restricted shares of our common stock (less 7,667,000 shares previously issued pursuant to an option agreement). As a result of this acquisition, we own patented technologies that can use biosafe nanoparticles and sensitive magnetic sensors to detect and measure cancer cells in biopsies or in the human body with the potential to transform how cancer is detected and treated.

 

 
6

 

ADVANCED METALS

 

The goal of our licensed proprietary process will be to enable our commercial partners to build super-strength metals and alloys to make products that weigh far less than in the past and without significant cost premiums 

 

NANOMEDICINE

 

Our acquisition of Senior Scientific gives us the commercial rights to technology and intellectual property with respect to the detection and monitoring of diseases using nanotechnologies. The technology is intended for the early detection of cancers, quantitative in vivo assessments of tumors, and similar applications with other diseases identifiable by cell surface markers. The technology does not require surgery, biopsy, radioactivity, or exotically expensive instruments. Nanoparticles are introduced to the body, for example, by intravenous injection. A sensitive low magnetic field instrument is used to magnetize and measure the nanoparticles that have bound to the specific targets (e.g., cells of a specific type of cancer). Other tissues, bone, scars, etc. are all transparent to the magnetic fields used, so the technology can be used to image detect and measure tumors in places inaccessible to other tests, and including tumors while they are still small enough to be treatable. The nanoparticles are nontoxic, and the low magnetic field instrument is not harmful or expensive, so the tests can be repeated as needed. 

 

NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS

 

BASIS OF CONSOLIDATION:

 

The consolidated financial statements include the accounts of Manhattan Scientific, Inc. and its wholly owned subsidiaries Metallicum and Senior Scientific. All significant intercompany balances and transactions have been eliminated.

 

USE OF ESTIMATES:

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amount of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. A significant estimate includes the carrying value of the Company’s patents, fair value of the Company’s common stock, assumptions used in calculating the value of stock options, depreciation and amortization.

 

CASH CONCENTRATION:

 

The Company’s cash accounts are federally insured up to $250,000 for each financial institution we hold our accounts in. As of March 31, 2015 and December 31, 2014, we had cash balances of $9,108,000 and $2,140,000 exceeding the federally insured limits.

 

INTANGIBLE ASSETS:

 

License Agreements

 

In 2008, the Company obtained licenses to the rights of certain patents regarding nanostructured materials developed by another company as a result of the acquisition of Metallicum. The purchase price paid for these licenses was $305,000, which represented its fair value. The Company obtained an exclusive license on two patents and a non-exclusive license on the third patent. The value attributable to license agreements is being amortized over the period of its estimated benefit period of 10 years. At March 31, 2015 and December 31, 2014, accumulated amortization was $202,000 and $194,000, respectively. Under the terms of the agreement, the Company may be required to pay royalties, as defined, to the licensors.

 

In 2009, the Company entered into a patent license agreement with Los Alamos National Security LLC for the exclusive use of certain technology relating to the manufacture and application of nanostructuring metals and alloys. The purchase price paid for this license agreement was $33,000 based on the fair market value of 2,000,000 shares of common stock issued. The value attributable to license agreements is being amortized over the period of its estimated benefit period of 10 years. At March 31, 2015 and December 31, 2014, accumulated amortization was $21,000 and $20,000, respectively. Under the terms of the agreement the Company is required to pay an annual license fee of $10,000 starting in February 2010 and, may be required to pay royalties, as defined, to the licensors.

 

 
7

 

In 2011, the Company acquired Scientific Nanomedicine, Inc. which holds the commercial rights to technology and intellectual property with respect to the early detection of diseases using nanotechnologies. The acquisition of Scientific Nanomedicine, Inc. has been accounted for as an asset purchase since this company had no tangible assets or liabilities and did not have the business inputs and outputs to be considered a business. The purchase price totaling $1,300,000 (fair value of 21,667,000 shares of common stocks issued) has been allocated to in process research and development and is being amortized over its estimated benefit period of 10 years. At March 31, 2015 and December 31, 2014, accumulated amortization was $499,000 and $467,000. We subsequently dissolved Scientific Nanomedicine and transferred all remaining assets to Senior Scientific LLC.

 

REVENUE RECOGNITION:

 

To date the only revenue generated is from the sale of field technology developed by Metallicum related to the Company’s nanotechnology, services provided and sample materials.

 

Revenue is recognized when the four basic criteria of revenue recognition are met: (i) a contractual agreement exists; (ii) transfer of technology (intellectual property) has been completed or services have been rendered; (iii) the fee is fixed or determinable, and (iv) collectability is reasonably assured. Service revenue is recognized when specific milestones are reached or as service is provided if there are no discernible milestones.

 

FAIR VALUE OF FINANCIAL INSTRUMENTS

 

Effective January 1, 2008, the Company adopted FASB ASC 820, Fair Value Measurements and Disclosures, Pre Codification SFAS No. 157, “Fair Value Measurements”, which provides a framework for measuring fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The standard also expands disclosures about instruments measured at fair value and establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:

 

Level 1 — Quoted prices for identical assets and liabilities in active markets;

 

Level 2 — Quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets; and

 

Level 3 — Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

 

The Company designates cash equivalents (consisting of money market funds) and investments in securities of publicly traded companies as Level 1. The total amount of the Company’s investment classified as Level 3 is de minimis.

 

The fair value of the Company’s debt as of March 31, 2015 and December 31, 2014 approximated their fair value at those times.

 

Fair value of financial instruments: The carrying amounts of financial instruments, including cash and cash equivalents, short-term investments, accounts payable, accrued expenses and notes payables approximated fair value as of March 31, 2015 and December 31, 2014 because of the relative short term nature of these instruments. At March 31, 2015 and December 31, 2014, the fair value of the Company’s debt approximates carrying value.

 

STOCK-BASED COMPENSATION

 

The Company accounts for stock-based compensation based on the fair value of all option grants or stock issuances made to employees or directors on or after its implementation date (the beginning of fiscal 2006), as well as a portion of the fair value of each option and stock grant made to employees or directors prior to the implementation date that represents the unvested portion of these share-based awards as of such implementation date, to be recognized as an expense, as codified in ASC 718. The Company calculates stock option-based compensation by estimating the fair value of each option as of its date of grant using the Black-Scholes option pricing model. These amounts are expensed over the respective vesting periods of each award using the straight-line attribution method. Compensation expense is recognized only for those awards that are expected to vest, and as such, amounts have been reduced by estimated forfeitures. The Company has historically issued stock options and vested and non-vested stock grants to employees and outside directors whose only condition for vesting has been continued employment or service during the related vesting or restriction period. The estimated fair value of grants of stock options and warrants to nonemployees of the Company is charged to expense, if applicable, in the financial statements.

 

 
8

 

BASIC AND DILUTED LOSS PER SHARE

 

In accordance with FASB ASC 260, “Earnings Per Share,” the basic loss per share is computed by dividing the loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Basic net loss per share excludes the dilutive effect of stock options or warrants and convertible notes. Diluted net earnings (loss) per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents, consisting of shares that might be issued upon exercise of common stock options and warrants. In periods where losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive.

 

NOTE 4 – CAPITAL TRANSACTIONS

 

Capital transactions during the three months ended March 31, 2015:

 

 

·

In January 2015, the Company issued 1,000,000 shares of common stock to a party for services with a total value $90,000.

     
 

·

In March 2015, the Company issued 1,000,000 shares of common stock and warrant for 2,500,000 shares of common stock one of the Company’s directors for legal services rendered with a total value of $160,301.

 

Capital transactions during the three months ended March 31, 2014:

 

 

·

In January 2014, the Company entered into a securities purchase agreement with an accredited investor (the “January 2014 Accredited Investor”) pursuant to which the January 2014 Accredited Investor purchased 1,818,182 shares of the Company’s common stock and a warrant to acquire 909,091 shares of common stock for a purchase price of $100,000. The warrant is exercisable for five (5) years at an exercise price of $0.085 per share.

     
 

·

In February 2014, the Company entered into securities purchase agreements with two accredited investors (the “February 2014 Accredited Investors”) pursuant to which the February 2014 Accredited Investors purchased 18,250,000 shares of the Company’s common stock and warrants to acquire 4,562,500 shares of common stock for an aggregate purchase price of $1,368,750. The warrants are exercisable for five (5) years at an exercise price of $0.075 per share.

     
 

·

In February 2014, the Company paid $82,125 and granted a warrant for 4,562,500 shares of common stock to a consulting group as a finder’s fee related to the February 2014 Accredited Investors securities purchase agreement. The cash payment and warrant grant has been accounted for as an offering cost related to the February 2014 Accredited Investors securities purchase agreement and has been netted with the February 2014 Accredited Investors securities offering. The Warrants are exercisable for five (5) years at an exercise price of $0.075 per share.

     
 

·

In March 2014, the Company issued 2,533,334 shares of common stock to two consultants for services with a total value $177,000. The stock issuance is for services performed during the period January 2014 through June 2014.

     
 

·

In March 2014, the Company issued 1,818,182 shares of common stock in a private offering to two parties for cash totaling $100,000.

 

 
9

 

NOTE 5 –FORMER OFFICERS NOTES PAYABLE

 

The former Chief Operating Officer has a notes payable balance totaling $450,000 at March 31, 2015 and December 31, 2014.

 

The loan bears interest at 5.5% per annum and was initially due December 31, 2002 and have been mutually extended. Under the terms of the note extension dated December 12, 2007, the loan bears interest at 5% per annum and are now due. The Company has recorded interest expense for notes payable to the former officer of approximately $6,000 the three months ended March 31, 2015 and 2014. Accrued interest related to this notes payable approximated $273,000 and $268,000 as of March 31, 2015 and December 31, 2014, respectively and is included in accounts payable and accrued expenses in the accompanying consolidated balance sheet.

 

NOTE 6 – NOTES PAYABLE – OTHER

 

From October 21, 2011 to April 26, 2012, the Company issued convertible notes for $600,000 (the "Convertible Notes") of which $200,000 was received on October 21, 2011, $100,000 was received on January 31, 2012 and $300,000 was received on April 26, 2012. The non-interest bearing notes can be converted into the Company’s common stock, at any date after six months from the issuance of each Note, at a conversion price of 67% of the fair value of the Company’s common stock upon the date of conversion notice, subject to a floor price of approximately $0.041 for the note issued in October 2011, approximately $0.044 for the note issued in January 2012 and approximately $0.034 for the note issued in April 2012. The holder of the notes has not converted any portion of the notes as of March 31, 2015 and December 31, 2013. Additionally, the note holder was issued warrants for 6,000,000 shares of the Company’s common stock with an exercise price of $0.05 that expire on October 15, 2015 ("Warrants"). The conversion feature to the note payable has been accounted for as an original issue discount approximating $296,000 which has been fully accreted as of December 31, 2012. The warrant associated with the note has been accounted for as a debt discount with an approximate value of $296,000 which has been allocated to the note’s fully accreted value of $896,000 (original note amount plus original debt discount) on proportionate basis which amounted to $195,000. The warrant value of $252,000 was determined using the Black-Scholes option pricing model based on the following assumptions: 2 year term; volatility rate of 134% to 135%; and discount rate of 2.5%. For the year ended December 31, 2012, the Company has recorded an expense associated with original debt discount and expense associated with the debt discount (warrants) of $422,000. Accordingly, the carrying net value of this note at March 31, 2015 and December 31, 2014 totals $896,000, comprising of $600,000 (original face value) plus the fully accreted original debt discount of $296,000.

 

During 2014 and 2013, the Company issued convertible notes for $2,500,000 through its wholly-owned subsidiary, Senior Scientific, LLC. The convertible notes bear interest at 8%, mature four years from the date of issuance, and are convertible into either: (1) membership interests of Senior Scientific, LLC equal to the quotient of the principal due of the convertible notes divided by $2,500,000 multiplied by 18% of the total equity of Senior Scientific, LLC outstanding as of the date hereof; or (2) the number of shares of common stock of the Company equal to the quotient of the principal and interest payable due of the convertible notes divided by a conversion price of $0.055 per share. The Company may not prepay the convertible notes. In the event of a default and so long as the default exists, interest on the convertible notes will accrue at 10%. The Company must account for all accrued interest on the convertible notes on the first calendar day of each quarter which $50,000 and $49,000 has been recorded as accrued interest payable as of March 31, 2015 and December 31, 2014, respectively. The conversion feature to the note payable has been accounted for as an original issue discount approximating $1,045,000 which $226,000 has been accreted as of March 31, 2015. The Company has recorded the accreted original issue discount as interest expense totaling $64,000 and $14,000 for the three months ended March 31, 2015 and 2014. Accordingly, the carrying net value of these notes at March 31, 2015 and December 31, 2014 totals $1,681,000 and $1,566,000, respectively, comprising of $2,500,000 (original face value) plus the unamortized debt discount of $819,000 at March 31, 2015, and unamortized original debt discount of $884,000 at December 31, 2014.

 

NOTE 7 – TECHNOLOGY SALE AND SUB-LICENSE AGREEMENT

 

On September 12, 2009, the Company entered into a contract with Carpenter Technology Corp. to sell certain nanostructured metal technologies acquired from Metallicum, Inc, its wholly owned subsidiary, to Carpenter and to provide sub-license rights to Carpenter covering license agreements that the Company has from Los Alamos Laboratories. The agreement has two distinct elements: a sale and services agreement and a sub-license agreement. The first element irrevocably transfers the field technology to Carpenter Technology Corporation and Carpenter many develop or use the technology for its own benefit. Carpenter agrees to pay a sales price of $600,000 and pay royalties for products developed using this technology. In addition, the Company can receive additional service income for assisting Carpenter in the production process. These additional services are elective and do not affect the sale of the technology. The second element of the agreement is a sub-license to Carpenter for patents (the LANL patents) that are licensed by the Company from Los Alamos Laboratories. The sub-license agreement obligates Carpenter to pay MSI a running royalty on the sales of products that require license to the LANL patents but does not have any upfront fee or annual minimum royalties.

 

 
10

 

The Company recognized the sales revenue upon transfer of the technology and the service income over the term of the agreement. The royalty income will be recognized as products are developed using the field technology or sub-license.

 

For the three months ended March 31, 2015 and 2014, the Company earned $-0- and $150,000 and recorded such amount as revenue. The amount received by the Company relates to services provided under the first element of the contract regarding additional services. The Company earned service income for time that a consultant to the Company, Dr. Lowe, made himself available to Carpenter in accordance with the Technology Transfer Agreement. The fees earned pursuant to the agreement with Carpenter are being proportionately recognized as revenue based upon the total fees to be collected over a 42 month period. The 42 month period is based on the time periods described in the Agreement (6 months after effective date), (12 months after effective date), and (each of the first 3 anniversaries of Annuity date where the “Annuity date” is the date of the latter of 18 months after the effective date or the date Manhattan Scientific fully satisfies its duties under of the Agreement).

 

In January 2013, the Company entered into a licensing agreement with a party granting certain licensing rights to the Company's nanostructured metal technology. As consideration: the Company received $180,000 in January 2013, and will receive $30,000 by June 1, 2013; $30,000 by December 31, 2013; $30,000 by December 1, 2014; and $30,000 upon commercial launch by the party or the latest December 1, 2015. For the three months ended March 31, 2015 and 2014, the Company recorded the receipt of $-0- and $30,000 as revenue.

 

NOTE 8 – SETTLEMENT AGREEMENT AND MUTUAL GENERAL RELEASES

 

On February 11, 2015, the Company entered into a Settlement Agreement and Mutual General Releases (the "Settlement Agreement") with Carpenter Technology Corporation related to the agreement discussed in Note 7, pursuant to which the parties settled and released each other from any and all liabilities and claims related to the Carpenter Agreements.

 

Under the terms of the Settlement Agreement and as consideration for the full and final settlement and satisfaction of all claims that the Company has or could assert against Carpenter in connection with the Carpenter Agreements, Carpenter will: (1) pay the Company $8,000,000 within 10 days from the date of the Settlement Agreement; (2) transfer and/or assign to the Company all physical and intellectual property which was the subject matter of the Carpenter Agreements free and clear of all liens and encumbrances; (3) provide the Company with follow on technical assistance; and (4) provide the Company with a complete list of all customers and contacts for same related to the technology which was the subject matter of the Carpenter Agreements. In addition, under the terms of the Settlement Agreement, neither party may disparage the other and the Carpenter Agreements were terminated and rendered null and void. As of the date this filing, the Company has received the $8,000,000 portion of the Settlement Agreement, including the physical and intellectual property. The Company has obtained an independent valuation on the physical property which was estimated at $6,938,000. As such, the Company has recorded income on the appraised value of the physical property totaling $6,938,000 and $8,000,000 cash consideration received as a Gain on Settlement Agreement totaling $14,938,000. The Company has not obtained a valuation report with respect to the value of the intellectual property transferred in this transaction.

 

NOTE 9 – SUBSEQUENT EVENTS

 

In April 2015, the Company issued 625,000 shares of common stock as satisfaction of previously accrued legal services totaling $68,750.

 

 
11

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

 

Forward Looking Statements

 

This Form 10-Q contains “forward-looking” statements including statements regarding our expectations of our future operations. For this purpose, any statements contained in this Form 10-Q that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “estimate,” or “continue” or comparable terminology are intended to identify forward-looking statements. These statements by their nature involve substantial risks and uncertainties, and actual results may differ materially depending on a variety of factors, many of which are not within our control. These factors include, but are not limited to, economic conditions generally and in the industries in which we may participate. In addition, these forward-looking statements are subject, among other things, to our successful completion of the research and development of our technologies; successful commercialization of our technologies; successful protection of our patents; and effective significant industry competition from various entities whose research and development, financial, sales and marketing and other capabilities far exceeds ours. In light of these risks and uncertainties, you are cautioned not to place undue reliance on these forward-looking statements. Except as required by law, we undertake no obligation to announce publicly revisions we make to these forward-looking statements to reflect the effect of events or circumstances that may arise after the date of this report.

 

OVERVIEW

 

The Company’s goal is to nurture visionary technologies into life changing success stories and Metallicum and Senior Scientific are pursuing that goal.

 

The Company operates as a technology incubator that seeks to acquire, develop and commercialize life-enhancing technologies in various fields, with emphasis in the areas of nanotechnology. Nanotechnology is the use and manipulation of matter on an atomic and molecular scale. To achieve this goal, the Company continues to identify emerging technologies through strategic alliances with scientific laboratories, educational institutions, scientists and leaders in industry and government. The Company and its executives have a long standing relationship with Los Alamos Laboratories in New Mexico.

 

TWO BUSINESSES EXIST WITHIN MANHATTAN SCIENTIFICS

 

Two nanotechnology businesses exist within Manhattan Scientifics Inc; both “units” are wholly-owned subsidiaries, both focused on nanotechnology applications in medicine.

 

The first (Metallicum Inc.) goal is to demonstrate our business-model, a licensing model, given that we are an inventions commercialization company.

 

Manhattan’s second business is called Senior Scientific LLC, and is at the crossroads of biotechnology and nanotechnology.

 

Our novel bioimaging and nanomagnetic detection systems have been developed specifically to detect cancer and other diseases earlier and with higher specificity than is currently possible. We have developed proprietary hardware and software for the highly sensitive detection of nanomagnetic particles that can be linked to antibodies for the detection and treatment of cancer and other human diseases—all without the use of ionizing radiation or large magnetic fields.

 

Our novel technologies make possible the earlier detection of cancer in vivo, the ability to analyze biopsies with greater sensitivity and accuracy, the ability to monitor the therapeutic effectiveness of anticancer treatments—both in humans and in animal models—and allow us to detect cancer recurrence with significantly improved sensitivity. Please see: www.SeniorScientific.com

 

The technology was developed by Edward R. Flynn, PhD, Senior Scientific’s founder and chief scientist, in collaboration with Richard S. Larson, MD, PhD, Executive Vice Chancellor, UNM Health Sciences Center in New Mexico.

 

 
12

 

In June 2008, we acquired Metallicum, Inc. (“Metallicum”) and its licensed patented technology. We entered into a stock purchase agreement with Metallicum, Inc. to acquire all of the outstanding capital in exchange for 15,000,000 restricted shares of our common stock. An additional 15,000,000 shares of our common stock will be payable to Metallicum in the event of meeting certain milestones. At December 31, 2011, one milestone was met. Metallicum was granted an exclusive license by The Los Alamos National Laboratory on patents related to nanostructured metals. In September 2009, we entered into a technology transfer agreement and sale with Carpenter Technology Corporation, (“Carpenter”) wherein Carpenter was to fully develop, manufacture and market a new class of high strength metals. On February 11, 2015, the Company and Carpenter entered into a Settlement Agreement and Mutual Release pursuant to which the parties provided a full release of one another, Carpenter paid the Company $8,000,000, Carpenter transferred to the Company all intellectual and physical property that was part of the original agreement, Carpenter agreed to provide follow-on technical assistance and Carpenter provided a list of all customers and contacts.

 

On May 31, 2011, we entered into an Agreement and Plan of Reorganization to acquire Senior Scientific. The total purchase price was 21,668,000 restricted shares of our common stock (less 7,667,000 shares previously issued pursuant to an option agreement). As a result of this acquisition, we own patented technologies that can use biosafe nanoparticles and sensitive magnetic sensors to detect and measure cancer cells in biopsies or in the human body with the potential to transform how cancer is detected and treated.

 

For the three months ended March 31, 2015 and 2014, significantly all of our revenue was generated by one customer, Carpenter Technology Corporation. We did not have any significant suppliers.

 

RESULTS OF OPERATIONS

 

THREE MONTHS ENDED MARCH 31, 2015 COMPARED TO THREE MONTHS ENDED MARCH 31, 2014.

 

REVENUE. The $33,000 of revenue recognized for the three months ended March 31, 2015 decreased compared to the $180,000 in revenue earned during the three months ended March 31, 2014. The decrease in revenue is primarily due to the fees earned pursuant to the agreement with Carpenter were proportionately recognized as revenue based upon the total fees to be collected over a 42 month period of which during fiscal year ended 2014 was fully earned. The 42 month period is based on the time periods described in the Agreement (6 months after effective date), (12 months after effective date), and (each of the first 3 anniversaries of Annuity date where the “Annuity date” is the date of the latter of 18 months after the effective date or the date Manhattan Scientific fully satisfies its duties under of the Agreement).

 

GENERAL AND ADMINISTRATIVE. General and administrative expenses consist of consultants, contractors, accounting, legal, travel, rent, telephone and other day to day operating expenses. General and administrative expenses were $779,000 for the three months ended March 31, 2015 compared with $860,000 for the three months ended March 31, 2014.

 

RESEARCH AND DEVELOPMENT. Research and Development was $554,000 for the three months ended March 31, 2015 compared with $396,000 for the three months ended March 31, 2014. The increase in research and development is due to the design, engineering and construction of the next generation instruments to be used for the MD Anderson Cancer Center, continued expenses working with the University of New Mexico, and continued development on intellectual property related to our nan-technology.

 

OTHER INCOME AND (EXPENSES). Other income and (expenses) for the three months ended March 31, 2015 totaled $14,824,000, an increase compared to $(49,000) for the three months ended March 31, 2014. The increase in other income was mainly attributed to a gain of $14,938,000 related to a Settlement Agreement and Mutual General Releases with Carpenter Technology Corporation, as discussed in Note 8 in the notes to financial statements, whereby we received $8,000,000 in cash and $6,938,000 in independently appraised physical assets as part of the overall consideration of the Settlement Agreement.

 

NET INCOME (LOSS). Our net income was $13,524,000 for three months ended March 31, 2015 compared to a net loss of $(1,125,000) for the three months ended March 31, 2014. The increase in net income for the first quarter of 2015 is attributable to the aforementioned factors.

 

LIQUIDITY AND CAPITAL RESOURCES

 

Stockholders’ equity totaled $13,067,000 on March 31, 2015 and the working capital surplus was $7,774,000 on such date.

 

We had an increase of $9,556,000 in cash and cash equivalents for the three months ended March 31, 2015, as a result of cash provided by our operating activities. For the three months ended March 31, 2015, cash provided by operating activities was $7,105,000 compared to cash of $(702,000) (used in) operating activities for the three months ended March 31, 2014. Cash used in operating activities was primarily as a result of our net income of $13,524,000. There was $-0- of cash provided by financing activities in the three months ended March 31, 2015 compared to $1,820,000 cash provided by financing activities during the same period of 2014.

 

 
13

 

Based upon current projections, our principal cash requirements for the next 12 months consists of (1) fixed expenses, including payroll, investor relations services, public relations services, bookkeeping services, consultant services, and rent; and (2) variable expenses, including technology research and development, milestone payments and intellectual property protection, and additional scientific consultants. As of March 31, 2015, we had $9,556,000 in cash. We believe our current cash position is sufficient to maintain our operations for the next twelve months.

 

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

 

Our discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America.

 

Our discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America.

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amount of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. A significant estimate includes the carrying value of our patents, fair value of our common stock, assumptions used in calculating the value of stock options, depreciation and amortization.

 

Impairment of Long-Lived Assets:

 

We assess the impairment of our long-lived assets periodically in accordance with Financial Accounting Standards Board ("FAS") Accounting Standard Codification (“ASC”) Topic 10. Whenever events or changes in circumstances indicate that the carrying amounts of long-lived assets may not be recoverable, we will compare undiscounted net cash flows estimated to be generated by those assets to the carrying amount of those assets. When these undiscounted cash flows are less than the carrying amounts of the assets, we will record impairment losses to write the asset down to fair value, measured by the discounted estimated net future cash flows expected to be generated from the assets. To date there has been no impairment.

 

License Agreements

 

In 2008, the Company obtained licenses to the rights of certain patents regarding nano-structured materials developed by another company as a result of the acquisition of Metallicum. The purchase price paid for these licenses was $305,000, which represents its fair value. The Company obtained an exclusive license on two patents and a non-exclusive license on the third patent. The value attributable to license agreements is being amortized over the period of its estimated benefit period of 10 years. Under the terms of the agreement, the Company may be required to pay royalties, as defined, to the licensors.

 

In 2009, the Company entered into a patent license agreement with Los Alamos National Security LLC for the exclusive use of certain technology relating to the manufacture and application of nanostructuring metals and alloys. The value attributable to license agreements is being amortized over the period of its estimated benefit period of 10 years. Under the terms of the agreement the Company is required to pay an annual license fee of $10,000 and, may be required to pay royalties, as defined, to the licensors.

 

On May 31, 2011, we entered into an Agreement and Plan of Reorganization to acquire Senior Scientific and Scientific Nanomedicine. The total purchase price was 21,668,000 restricted shares of our common stock (less 7,667,000 shares previously issued pursuant to an option agreement. As a result of this acquisition, we own patented technologies that can use biosafe nanoparticles and sensitive magnetic sensors to detect and measure cancer cells in biopsies or in the human body with the potential to revolutionize how cancer is detected and treated.

 

 
14

 

Revenue Recognition

 

Revenue is recognized when the four basic criteria of revenue recognition are met: (i) a contractual agreement exists; (ii) transfer of technology (intellectual property) has been completed or services have been rendered; (iii) the fee is fixed or determinable, and (iv) collectability is reasonably assured. Service revenue is recognized when specific milestones are reached or as service is provided if there are no discernible milestones.

 

Investments: Available-for-Sale Investments

 

Investments that we designate as available-for-sale are reported at fair value, with unrealized gains and losses, net of tax, recorded in accumulated other comprehensive income (loss). We determine the cost of the investment sold based on the specific identification method. Our available-for-sale investments include Marketable equity securities. We acquire these equity investments for the promotion of business and strategic objectives. We record the realized gains or losses on the sale or exchange of marketable equity securities in gains (losses) on other equity investments, net.

 

Stock-Based Compensation:

 

The Company follows the provision of FASB ASC Topic 718 for the measurement and recognition of compensation expense for all share-based payment awards to employees, directors and non-employees. Additionally, the Company follows the SEC’s Staff Accounting Bulletin No. 107 “Share-Based Payment” (“SAB 107”), as amended by Staff Accounting Bulletin No. 110 (“SAB 110”), which provides supplemental application guidance based on the views of the SEC. The Company estimates the expected term, which represents the period of time from the grant date that the Company expects its stock options to remain outstanding, using the simplified method as permitted by SAB 107 and SAB 110. Under this method, the expected term is estimated as the mid-point between the time the options vest and their contractual terms. The Company continues to apply the simplified method because it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected terms due to the limited period of time its equity shares have been publicly traded and the limited number of its options which have so far vested and become eligible for exercise.

 

The estimated fair value of grants of stock options and warrants to our nonemployees is charged to expense, if applicable, in the financial statements. These options vest in the same manner as the employee options granted under each of the option plans as described above.

 

OFF BALANCE SHEET ARRANGEMENTS

 

We have not entered into any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations liquidity, capital expenditures or capital resources and would be considered material to investors.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

As a smaller reporting company, we are not required to include disclosure under this item. 

 

ITEM 4. CONTROLS AND PROCEDURES

 

(a) Evaluation of Disclosure Controls and Procedures

 

We conducted an evaluation under the supervision and with the participation of our management, of the effectiveness of the design and operation of our disclosure controls and procedures. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities and Exchange Act of 1934, as amended (“Exchange Act”), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by the company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission's rules and forms. Disclosure controls and procedures also include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company's management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. Based on this evaluation, our principal executive and principal financial officers concluded as of March 31, 2015 that our disclosure controls and procedures were not effective at the reasonable assurance level due to the material weaknesses in our internal controls over financial reporting discussed immediately below.

 

 
15

 

Identified Material Weakness

 

A material weakness in our internal control over financial reporting is a control deficiency, or combination of control deficiencies, that results in more than a remote likelihood that a material misstatement of the financial statements will not be prevented or detected.

 

Management identified the following material weakness during its assessment of internal controls over financial reporting:

 

Resources: We had one full-time employee in general management and no full-time employees with the requisite expertise in the key functional areas of finance and accounting. As a result, there is a lack of proper segregation of duties necessary to insure that all transactions are accounted for accurately and in a timely manner.

 

Written Policies & Procedures: We need to prepare written policies and procedures for accounting and financial reporting to establish a formal process to close our books monthly on an accrual basis and account for all transactions, including equity transactions, and prepare, review and submit SEC filings in a timely manner.

 

Audit Committee: We do not have, and are not required, to have an audit committee. An audit committee would improve oversight in the establishment and monitoring of required internal controls and procedures.

 

(b) Changes In Internal Control Over Financial Reporting

 

During the quarter ended March 31, 2015, the Company prepared written policies and procedures for accounting and financial reporting to establish a formal process to close our books monthly on an accrual basis and account for all transactions, including equity transactions. There were no other changes in our internal controls over financial reporting during this fiscal quarter that materially affected, or is reasonably likely to have a materially affect, on our internal control over financial reporting.

 

 
16

 

PART II – OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

We are subject from time to time to litigation, claims and suits arising in the ordinary course of business. As of March 31, 2015, we were not a party to any material litigation, claim or suit whose outcome could have a material effect on our financial statements.

 

ITEM 1A. RISK FACTORS

 

An investment in the Common Stock involves a high degree of risk. In addition to the other information in this Report, the following risk factors should be considered carefully in evaluating the Company and our business. If you decide to buy our securities, you should be able to afford a complete loss of your investment.

 

WE MAY NOT BE ABLE TO SUCCESSFULLY DEVELOP AND COMMERCIALIZE OUR NEW TECHNOLOGIES WHICH WOULD RESULT IN CONTINUED LOSSES.

 

We are currently developing new technologies and a commercial product. We have generated our first revenues but we are unable to project when we will achieve regular profitability, if at all. As is the case with any new technology, we expect the development process to continue. We cannot assure that our resources will be able to develop and commercialize our technology fast enough to meet market requirements. We can also not assure that our technology will gain market acceptance and that we will be able to overcome obstacles, such as potential FDA approvals. The failure to successfully develop and commercialize the technologies would result in continued losses and may require us to curtail operations.

 

THE SUCCESS OF OUR BUSINESS MAY REQUIRE CONTINUED FUNDING. IF WE CANNOT RAISE THE MONEY WE NEED TO SUPPORT OUR OPERATIONS UNTIL WE EARN SIGNIFICANT REVENUES, WE MAY BE REQUIRED TO CURTAIL OR TO CEASE OUR OPERATIONS AND YOU COULD LOSE YOUR ENTIRE INVESTMENT.

 

Our ability to develop our business depends upon our receipt of money to continue our operations while we introduce our products and a market for them develops. If this funding is not received as needed, it is unlikely that we could continue our business, in which case you would lose your entire investment. Our ability to access the capital markets has been hindered generally by the general difficult economic climate, beginning in 2008, for small technology concept companies, without significant revenues or earnings.

 

To the extent that we need additional funding, we cannot assure you that such financing will be available to us when needed, on commercially reasonable terms, or at all. If we are unable to obtain additional financing, we may be required to curtail the commercialization of our products and possibly cease our operations.

 

OUR ABILITY TO EFFECTUATE OUR BUSINESS MODEL MAY BE LIMITED, WHICH WOULD ADVERSELY EFFECT OUR BUSINESS AND FINANCIAL CONDITIONS.

 

Our future performance will depend to a substantial degree upon our ability to effectuate and generate revenues from our licensing and royalty business model. As a result, we may continue to incur substantial operating losses until such time as we are able to generate revenues from the sale or license of our products. There can be no assurance that businesses and customers will adopt our technology and products, or that businesses and prospective customers will agree to pay for or license our products. In the event that we are not able to significantly increase the number of customers that purchase or license our products, or if we are unable to charge the necessary prices or license fees, our financial condition and results of operations will be materially and adversely affected.

 

 
17

 

WE MAY FACE STRONG COMPETITION FROM LARGER, ESTABLISHED COMPANIES.

 

We likely will face intense competition from other companies, both globally and within the United States, in the development of our cancer detection technology and nano-metal technologies, virtually all of which can be expected to have longer operating histories, greater name recognition, larger installed customer bases and significantly more financial resources and research and development facilities than Manhattan Scientifics. There can be no assurance that developments by our current or potential competitors will not render our proposed products obsolete.

 

WE MAY NOT BE ABLE TO ADEQUATELY PROTECT OUR INTELLECTUAL PROPERTY OR WE COULD BECOME INVOLVED IN LITIGATION WITH OTHERS REGARDING OUR INTELLECTUAL PROPERTY. EITHER OF THESE EVENTS COULD HAVE A MATERIAL ADVERSE EFFECT ON OUR BUSINESS.

 

We rely on a combination of intellectual property law, nondisclosure, trade secret and other contractual and technical measures to protect our proprietary right. Our success will depend, in part, on our technology’s commercial viability and on the strength of our intellectual property rights. However, we cannot assure you that these provisions will be adequate to protect our intellectual property. In addition, the laws of certain foreign countries do not protect intellectual property rights to the same extent as the laws of the United States.

 

Although we believe that our intellectual property does not infringe upon the proprietary rights of third parties, competitors may claim that we have infringed on their products.

 

We could incur substantial costs in defending ourselves in suits brought against us for alleged infringement of another party’s intellectual property rights as well as in enforcing our rights against others, and if we are found to infringe, the manufacture, sale and use of our or our customers’ or partners’ products could be enjoined. Any claims against us, with or without merit, would likely be time-consuming, requiring our management team to dedicate substantial time to addressing the issues presented. Furthermore, the parties bringing claims may have greater resources than we do.

 

OUR MANAGEMENT IS ABLE TO EXERCISE SIGNIFICANT INFLUENCE OVER ALL MATTERS REQUIRING SHAREHOLDER APPROVAL.

 

Our existing directors and executive officers are the beneficial owners of approximately 18% of the outstanding shares of common stock, excluding stock options and warrants. As a result, our existing directors, executive officers, principal shareholders and their respective affiliates, if acting together, would be able to exercise significant influence over all matters requiring shareholder approval, including the election of directors and the approval of significant corporate transactions. Such concentration of ownership may also have the effect of delaying or preventing a change in control of our company.

 

THE TRADING PRICE OF OUR COMMON STOCK MAY DECREASE DUE TO FACTORS BEYOND OUR CONTROL.

 

The trading price of our common stock is subject to significant fluctuations in response to numerous factors, including without limitation:

 

 

·

variations in anticipated or actual results of operations;

     
 

·

announcements of new products or technological innovations by us or our competitors;

     
 

·

changes in earnings estimates of operational results by analysts;

     
 

·

inability of market makers to combat short positions on the stock;

     
 

·

an overall downturn in the financial markets and stock markets;

     
 

·

the use of stock to pay employees and consultants if sufficient working capital is not available;

     
 

·

inability of the market to absorb large blocks of stock sold into the market; and

     
 

·

developments or disputes concerning our intellectual property.

 

 
18

 

Moreover, the stock market from time-to-time has experienced extreme price and volume fluctuations, which have particularly affected the market prices for small technology companies without significant revenues. These broad market fluctuations may adversely affect the market price of our Common Stock. If our shareholders sell substantial amounts of their common stock in the public market, the price of our common stock could fall. These sales also might make it more difficult for us to sell equity or equity-related securities in the future at a price we deem appropriate.

 

ALL OF OUR CURRENT REVENUE IS GENERATED FROM ONE CUSTOMER.

 

For the three months ended March 31, 2015, all of our revenue was generated by one customer, Carpenter Technology Corporation. If Carpenter Technology Corporation was unable to satisfy its obligations under our agreements, it would materially impact our revenue, net income and financial position.

 

WE HAVE NOT PAID CASH DIVIDENDS AND IT IS UNLIKELY THAT WE WILL PAY CASH DIVIDENDS IN THE FORESEEABLE FUTURE.

 

We plan to use all of our earnings, to the extent we have significant earnings, to fund our operations. We do not plan to pay any cash dividends in the foreseeable future. We cannot guarantee that we will, at any time, generate sufficient surplus cash that would be available for distribution as a dividend to the holders of our Common Stock. You should not expect to receive cash dividends on our Common Stock.

 

WE MAY NOT HAVE SUFFICIENT CAPITAL TO RUN OUR OPERATIONS.

 

If we are unable to obtain further financing, it may jeopardize our ability to continue our operations. To the extent that additional capital is raised through the sale of equity and/or convertible debt securities, the issuance of such securities could result in dilution to our shareholders and/or increased debt service commitments. If adequate funds are not available, we may be unable to sufficiently develop or maintain our existing operations.

 

WE HAVE THE ABILITY TO ISSUE ADDITIONAL SHARES OF OUR COMMON STOCK WITHOUT ASKING FOR SHAREHOLDER APPROVAL, WHICH COULD CAUSE YOUR INVESTMENT TO BE DILUTED.

 

Our Certificate of Incorporation currently authorizes the Board of Directors to issue up to 950,000,000 shares of Common Stock and 1,000,000 shares of Preferred Stock. The power of the Board of Directors to issue shares of Common Stock or warrants or options to purchase shares of Common Stock is generally not subject to shareholder approval. Accordingly, any additional issuance of our Common Stock may have the effect of further diluting your investment.

 

We require substantial working capital to fund our business. If we raise additional funds through the issuance of equity, equity-related or convertible debt securities, those securities may have rights, preferences or privileges senior to those of the holders of our Common Stock. The issuance of additional Common Stock or securities convertible into Common Stock by our management will also have the effect of further diluting the proportionate equity interest and voting power of holders of our Common Stock.

 

LIMITED PUBLIC MARKET FOR OUR COMMON STOCK MAY AFFECT OUR SHAREHOLDERS' ABILITY TO SELL OUR COMMON STOCK.

 

Our Common Stock currently is quoted on the Over-The-Counter Bulletin Board, which is generally considered to be a less efficient market than national exchanges. Consequently, the liquidity of our securities could be impaired, not only in the number of securities which could be bought and sold, but also through SEC regulations, delays in the timing of transactions, difficulties in obtaining price quotations, reduction in security analysts' and the new media's coverage of us, if any, and lower prices for our securities than might otherwise be attained. This circumstance could have an adverse effect on the ability of an investor to sell any shares of our common stock as well as on the selling price for such shares. In addition, the market price of our common stock may be significantly affected by various additional factors, including, but not limited to, our business performance, industry dynamics or changes in general economic conditions.

 

 
19

 

APPLICABILITY OF "PENNY STOCK RULES" TO BROKER-DEALER SALES OF OUR COMMON STOCK COULD HAVE A NEGATIVE EFFECT ON THE LIQUIDITY AND MARKET PRICE OF OUR COMMON STOCK.

 

A penny stock is generally a stock that is not listed on national securities exchange and is quoted on the "pink sheets" or on the OTC Bulletin Board, has a price per share of less than $5.00 and is issued by a company with net tangible assets less than $5 million.

 

The penny stock trading rules impose additional duties and responsibilities upon broker-dealers and salespersons effecting purchase and sale transactions in Common Stock and other equity securities, including determination of the purchaser's investment suitability, delivery of certain information and disclosures to the purchaser, and receipt of a specific purchase agreement before effecting the purchase transaction.

 

Many broker-dealers will not affect transactions in penny stocks, except on an unsolicited basis, in order to avoid compliance with the penny stock trading rules. When our Common Stock is subject to the penny stock trading rules, such rules may materially limit or restrict the ability to resell our Common Stock, and the liquidity typically associated with other publicly traded equity securities may not exist.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

· In January 2015, the Company issued 1,000,000 shares of common stock to a party for services with a total value $90,000.

 

· In March 2015, the Company issued 1,000,000 shares of common stock and warrant for 2,500,000 shares of common stock one of the Company’s directors for legal services rendered with a total value of $160,301.

 

The above securities were offered and sold to the parties in private placement transactions made in reliance upon exemptions from registration pursuant to Section 4(2) under the Securities Act of 1933 and Rule 506 promulgated thereunder. Each of the parties are accredited investors as defined in Rule 501 of Regulation D promulgated under the Securities Act of 1933.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

None.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable.

 

ITEM 5. OTHER INFORMATION

 

On April 20, 2015 the Company released as an exhibit to Form 8-K pursuant to Item 7.01 a letter to shareholders from the CEO providing a general overview of the Company’s operations.

 

On May 7, 2015 the Company released as an exhibit to Form 8-K pursuant to Item 7.01 a letter from Robert Proulx, President and Chief Operating Officer of Senior Scientific. The letter provides a brief overview and a description of future plans. 

 

 
20

 

ITEM 6. EXHIBITS

 

Index to Exhibits

 

31.1

 

Certification of Chief Executive Officer under Rule 13(a) — 14(a) of the Exchange Act.

     

31.2

 

Certification of Chief Financial Officer under Rule 13(a) — 14(a) of the Exchange Act.

     

32

 

Certification of CEO and CFO under 18 U.S.C. Section 1350

 

EX-101.INS**

 

XBRL Instance Document

     

EX-101.SCH**

 

XBRL Taxonomy Extension Schema Document

     

EX-101.CAL**

 

XBRL Taxonomy Extension Calculation Linkbase

     

EX-101.DEF**

 

XBRL Taxonomy Extension Definition Linkbase

     

EX-101.LAB**

 

XBRL Taxonomy Extension Labels Linkbase

     

EX-101.PRE**

 

XBRL Taxonomy Extension Presentation Linkbase

_________________ 

** XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

 

 
21

 

SIGNATURES

 

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 19th day of May 2015. 

 

 

MANHATTAN SCIENTIFICS, INC.

 
       
 

By:

/s/ Emmanuel Tsoupanarias

 
 

Name:

Emmanuel Tsoupanarias

 
 

Title:

Chief Executive Officer

(Principal Executive and Accounting Officer)

 
       
 

By:

/s/ Chris Theoharis

 
 

Name:

Chris Theoharis

 
 

Title:

Treasurer

(Principal Financial Officer)

 

 

 

22


EX-31.1 2 mhtx_ex311.htm CERTIFICATION

EXHIBIT 31.1

 

Certifications

 

I, Emmanuel Tsoupanarias, certify that:

 

1.

I have reviewed this quarterly report on Form 10-Q of Manhattan Scientifics, Inc. for the period ended March 31, 2015;

 

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

 

4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

 

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

 

 
 

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

 

 
 

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

 

 
 

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

 

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

 

 
 

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

 

Date: May 19, 2015

By:

/s/ Emmanuel Tsoupanarias

 
   

Emmanuel Tsoupanarias

 
   

Chief Executive Officer

 
   

(Principal Executive Officer)

 

 

EX-31.2 3 mhtx_ex312.htm CERTIFICATION

EXHIBIT 31.2

 

Certifications

 

I, Chris Theoharis, certify that:

 

1.

I have reviewed this quarterly report on Form 10-Q of Manhattan Scientifics, Inc. for the period ended March 31, 2015;

 

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

 

4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

 

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

 

 
 

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

 

 
 

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

 

 
 

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

 

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

 

 
 

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

 

Date: May 19, 2015

By:

/s/ Chris Theoharis

 
   

Chris Theoharis

 
   

(Principal Financial Officer)

 

 

EX-32 4 mhtx_ex32.htm CERTIFICATION

EXHIBIT 32

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the quarterly report of Manhattan Scientifics, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2015 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, in the capacities and on the date indicated below, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

 

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

May 19, 2015

By:

/s/ Emmanuel Tsoupanarias

 
 

Name:

Emmanuel Tsoupanarias

 
 

Title:

Chairman and Chief Executive Officer

(Principal Executive Officer)

 

 

 

 

May 19, 2015

By:

/s/ Chris Theoharis

 
 

Name:

Chris Theoharis

 
 

Title:

Principal Financial Officer

 

 

A signed original of this written statement required by Section 906 has been provided to Manhattan Scientifics, Inc. and will be retained by Manhattan Scientifics, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

 

EX-101.INS 5 mhtx-20150331.xml XBRL INSTANCE DOCUMENT 0001099132 2014-12-31 0001099132 mhtx:LosAlamosNationalSecurityLLCMember 2015-03-31 0001099132 mhtx:LosAlamosNationalSecurityLLCMember 2014-12-31 0001099132 mhtx:ScientificNanomemdicineIncMember 2014-12-31 0001099132 mhtx:ScientificNanomemdicineIncMember 2015-03-31 0001099132 2015-05-10 0001099132 mhtx:ConsultantMember 2014-01-01 2014-03-31 0001099132 2015-03-31 0001099132 2014-01-01 2014-03-31 0001099132 2015-01-01 2015-03-31 0001099132 us-gaap:DirectorMember 2015-01-01 2015-03-31 0001099132 mhtx:ConvertibleNotesMember 2015-03-31 0001099132 mhtx:ConvertibleNotesMember 2014-12-31 0001099132 2013-12-31 0001099132 2014-03-31 0001099132 mhtx:RelatedPartyMember 2015-01-01 2015-03-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure 0.001 0.001 950000000 950000000 516378036 518378036 516378036 518378036 0.001 0.001 1000000 1000000 .10 0.10 182525 182525 0 0 0 0 49999 49999 49999 49999 14000 14000 0 0 0 0 194000 21000 20000 467000 499000 202000 150000 0 6000 6000 519003036 2140000 9108000 268000 273000 30000 0 14000 64000 1566000 1681000 896000 896000 884000 819000 2500000 2500000 600000 600000 250000 250000 MANHATTAN SCIENTIFICS INC 0001099132 10-Q 2015-03-31 false --12-31 No No Yes Smaller Reporting Company Q1 2015 -0.00 0.03 472239467 517411369 -1125000 13524000 1256000 1333000 396000 554000 860000 779000 180000 33000 49000 50000 2533334 1000000 1000000 177000 160301 90000 296000 296000 3633000 17618000 2000 2000 957000 916000 144000 204000 2000 2000 2528000 9556000 1791000 1812000 450000 450000 19000 19000 426000 447000 3407000 3493000 1616000 1681000 1058000 1058000 3633000 17618000 -832000 13067000 -63242000 -49718000 61894000 62142000 516000 518000 6938000 896000 896000 1616000 1681000 125000 0.00 0.02 588759551 588759551 -702000 7105000 -48000 21000 -6000 150000 50000 58000 14000 65000 -551000 -375000 77000 -77000 333000 1487000 1820000 2528000 9556000 578000 1696000 1118000 7028000 177000 212000 6938000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The foregoing unaudited interim financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions for Form 10-Q and Regulation S-X as promulgated by the Securities and Exchange Commission (&#147;SEC&#148;). Accordingly, these financial statements do not include all of the disclosures required by generally accepted accounting principles in the United States of America for complete financial statements. These unaudited interim financial statements should be read in conjunction with the audited financial statements and the notes thereto included on Form 10-K for the year ended December 31, 2014. In the opinion of management, the unaudited interim financial statements furnished herein include all&#160;adjustments, all of which are of a normal recurring nature, necessary for a fair statement of the results for the interim period presented.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in accordance with generally accepted accounting principles in the United States of America requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities known to exist as of the date the financial statements are published, and the reported amounts of revenues and expenses during the reporting period. Uncertainties with respect to such estimates and assumption are inherent in the preparation of the Company&#146;s financial statements; accordingly, it is possible that the actual results could differ from these estimates and assumptions that could have a material effect on the reported amounts of the Company&#146;s financial position and results of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Operating results for the three month period ended March 31, 2015 are not necessarily indicative of the results that may be expected for the year ending December 31, 2015.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Manhattan Scientifics, Inc. (the &#147;Company&#148; or &#147;Manhattan Scientifics&#148;), a Delaware corporation, was established on July 31, 1992 and has two operating wholly-owned subsidiaries: Metallicum, Inc., (&#147;Metallicum&#148;) and Senior Scientific LLC (&#147;Senior Scientific&#148;). On June 12, 2008, the Company acquired Metallicum, Inc. for 15,000,000 shares of Company&#146;s common stock.&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Manhattan Scientifics is focused on technology transfer and commercialization of disruptive technologies in the nano-medicine space. The company is presently developing commercial medical prosthetics applications for its ultra-fine grain metals and plans to commercialize the cancer research work and nano-medical applications developed by Senior Scientific, a unit of the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#146;s business model capitalizes on inventions and technology from which profits are intended to be created through licensing. Manhattan Scientifics is dedicated to earning profit for its 8,600 owner-shareholders by identifying, developing, patenting, supporting and marketing technical innovation by harvesting top technology talent to bring game-changing products to market. Manhattan Scientifics assists and acquires early stage technologies and assists entrepreneurial founders and management to stage them to become commercial. Our investment philosophy is defined by our desire to help build innovative companies with exceptional potential. We emphasize novel technologies in the nano-medicine space with the potential to be disruptive and the ability to establish sustainable businesses. We are patient capital with experienced business-building partners who bring the perspective of merchant-bankers not venture capitalists. Our approach to assist scientists to commercialize their work is by providing a forum within which the commercialization process is fostered through partnerships with existing companies (Fortune 1000 or larger). We believe the entrepreneurial scientists and engineers who join us are enticed in part by the offer to potentially create personal success and wealth by virtue of ownership of our publicly traded shares common stock under the symbol MHTX.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 31, 2011, we entered into an Agreement and Plan of Reorganization to acquire Senior Scientific and Scientific Nanomedicine, Inc. (&#147;Scientific Nanomedicine&#148; or &#147;SNMI&#148;). We subsequently dissolved Scientific Nanomedicine and transferred all remaining assets to Senior Scientific. The total purchase price was 21,668,000 restricted shares of our common stock (less 7,667,000 shares previously issued pursuant to an option agreement). As a result of this acquisition, we own patented technologies that can use biosafe nanoparticles and sensitive magnetic sensors to detect and measure cancer cells in biopsies or in the human body with the potential to transform how cancer is detected and treated.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>ADVANCED METALS</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The goal of our licensed proprietary process will be to enable our commercial partners to build super-strength metals and alloys to make products that weigh far less than in the past and without significant cost premiums&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>NANOMEDICINE</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our acquisition of Senior Scientific gives us the commercial rights to technology and intellectual property with respect to the detection and monitoring of diseases using nanotechnologies. The technology is intended for the early detection of cancers, quantitative in vivo assessments of tumors, and similar applications with other diseases identifiable by cell surface markers. The technology does not require surgery, biopsy, radioactivity, or exotically expensive instruments. Nanoparticles are introduced to the body, for example, by intravenous injection. A sensitive low magnetic field instrument is used to magnetize and measure the nanoparticles that have bound to the specific targets (e.g., cells of a specific type of cancer). Other tissues, bone, scars, etc. are all transparent to the magnetic fields used, so the technology can be used to image detect and measure tumors in places inaccessible to other tests, and including tumors while they are still small enough to be treatable. The nanoparticles are nontoxic, and the low magnetic field instrument is not harmful or expensive, so the tests can be repeated as needed.&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">BASIS OF CONSOLIDATION:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The consolidated financial statements include the accounts of Manhattan Scientific, Inc. and its wholly owned subsidiaries Metallicum and Senior Scientific. All significant intercompany balances and transactions have been eliminated.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">USE OF ESTIMATES:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amount of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. A significant estimate includes the carrying value of the Company&#146;s patents, fair value of the Company&#146;s common stock, assumptions used in calculating the value of stock options, depreciation and amortization.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">CASH CONCENTRATION:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#146;s cash accounts are federally insured up to $250,000 for each financial institution we hold our accounts in. As of March 31, 2015 and December 31, 2014, we had cash balances of $9,108,000 and $2,140,000 exceeding the federally insured limits.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">INTANGIBLE ASSETS:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">License Agreements</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In 2008,&#160;the Company obtained licenses to the rights of certain patents regarding nanostructured materials developed by another company as a result of the acquisition of Metallicum. The purchase price paid for these licenses was $305,000, which represented its fair value. The Company obtained an exclusive license on two patents and a non-exclusive license on the third patent. The value attributable to license agreements is being amortized over the period of its estimated benefit period of 10 years. At March 31, 2015 and December 31, 2014, accumulated amortization was $202,000 and $194,000, respectively. Under the terms of the agreement, the Company may be required to pay royalties, as defined, to the licensors.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In 2009, the Company entered into a patent license agreement with Los Alamos National Security LLC for the exclusive use of certain technology relating to the manufacture and application of nanostructuring metals and alloys. The purchase price paid for this license agreement was $33,000 based on the fair market value of 2,000,000 shares of common stock issued. The value attributable to license agreements is being amortized over the period of its estimated benefit period of 10 years. At March 31, 2015 and December 31, 2014, accumulated amortization was $21,000 and $20,000, respectively. Under the terms of the agreement the Company is required to pay an annual license fee of $10,000 starting in February 2010 and, may be required to pay royalties, as defined, to the licensors.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In 2011, the Company acquired Scientific Nanomedicine, Inc. which holds the commercial rights to technology and intellectual property with respect to the early detection of diseases using nanotechnologies. The acquisition of Scientific Nanomedicine, Inc. has been accounted for as an asset purchase since this company had no tangible assets or liabilities and did not have the business inputs and outputs to be considered a business. The purchase price totaling $1,300,000 (fair value of 21,667,000 shares of common stocks issued) has been allocated to in process research and development and is being amortized over its estimated benefit period of 10 years. At March 31, 2015 and December 31, 2014, accumulated amortization was $499,000 and $467,000. We subsequently dissolved Scientific Nanomedicine and transferred all remaining assets to Senior Scientific LLC.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">REVENUE RECOGNITION:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To date the only revenue generated is from the sale of field technology developed by Metallicum related to the Company&#146;s nanotechnology, services provided and sample materials.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Revenue is recognized when the four basic criteria of revenue recognition are met: (i) a contractual agreement exists; (ii) transfer of technology (intellectual property) has been completed or services have been rendered; (iii) the fee is fixed or determinable, and (iv) collectability is reasonably assured. Service revenue is recognized when specific milestones are reached or as service is provided if there are no discernible milestones.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">FAIR VALUE OF FINANCIAL INSTRUMENTS</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective January 1, 2008, the Company adopted FASB ASC 820, Fair Value Measurements and Disclosures, Pre Codification SFAS No. 157, &#147;Fair Value Measurements&#148;, which provides a framework for measuring fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The standard also expands disclosures about instruments measured at fair value and establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 1 &#151; Quoted prices for identical assets and liabilities in active markets;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 2 &#151; Quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets; and</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 3 &#151; Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company designates cash equivalents (consisting of money market funds) and investments in securities of publicly traded companies as Level 1. The total amount of the Company&#146;s investment classified as Level 3 is de minimis.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of the Company&#146;s debt as of March 31, 2015 and December 31, 2014 approximated their fair value at those times.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Fair value of financial instruments: The carrying amounts of financial instruments, including cash and cash equivalents, short-term investments, accounts payable, accrued expenses and notes payables approximated fair value as of March 31, 2015 and December 31, 2014 because of the relative short term nature of these instruments. At March 31, 2015 and December 31, 2014, the fair value of the Company&#146;s debt approximates carrying value.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">STOCK-BASED COMPENSATION</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for stock-based compensation based on the fair value of all option grants or stock issuances made to employees or directors on or after its implementation date (the beginning of fiscal 2006), as well as a portion of the fair value of each option and stock grant made to employees or directors prior to the implementation date that represents the unvested portion of these share-based awards as of such implementation date, to be recognized as an expense, as codified in ASC 718. The Company calculates stock option-based compensation by estimating the fair value of each option as of its date of grant using the Black-Scholes option pricing model. These amounts are expensed over the respective vesting periods of each award using the straight-line attribution method. Compensation expense is recognized only for those awards that are expected to vest, and as such, amounts have been reduced by estimated forfeitures. The Company has historically issued stock options and vested and non-vested stock grants to employees and outside directors whose only condition for vesting has been continued employment or service during the related vesting or restriction period. The estimated fair value of grants of stock options and warrants to nonemployees of the Company is charged to expense, if applicable, in the financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">BASIC AND DILUTED LOSS PER SHARE</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with FASB ASC 260, &#147;Earnings Per Share,&#148; the basic loss per share is computed by dividing the loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Basic net loss per share excludes the dilutive effect of stock options or warrants and convertible notes. Diluted net earnings (loss) per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents, consisting of shares that might be issued upon exercise of common stock options and warrants. In periods where losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Capital transactions during the three months ended March 31, 2015:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 60px; text-align: justify">&#160;</td> <td style="width: 60px; text-align: justify"><font style="font: 10pt Symbol">&#183;</font></td> <td style="text-align: justify"><font style="font-size: 10pt">In January 2015, the Company issued 1,000,000 shares of common stock to a party for services with a total value $90,000.</font></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify"><font style="font: 10pt Symbol">&#183;</font></td> <td style="text-align: justify"><font style="font-size: 10pt">In March 2015, the Company issued 1,000,000 shares of common stock and warrant for 2,500,000 shares of common stock one of the Company&#146;s directors for legal services rendered with a total value of $160,301.</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Capital transactions during the three months ended March 31, 2014:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 60px; text-align: justify">&#160;</td> <td style="width: 60px; text-align: justify"><font style="font: 10pt Symbol">&#183;</font></td> <td style="text-align: justify"><font style="font-size: 10pt">In January 2014, the Company entered into a securities purchase agreement with an accredited investor (the &#147;January 2014 Accredited Investor&#148;) pursuant to which the January 2014 Accredited Investor purchased 1,818,182 shares of the Company&#146;s common stock and a warrant to acquire 909,091 shares of common stock for a purchase price of $100,000. The warrant is exercisable for five (5) years at an exercise price of $0.085 per share.</font></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify"><font style="font: 10pt Symbol">&#183;</font></td> <td style="text-align: justify"><font style="font-size: 10pt">In February 2014, the Company entered into securities purchase agreements with two accredited investors (the &#147;February 2014 Accredited Investors&#148;) pursuant to which the February 2014 Accredited Investors purchased 18,250,000 shares of the Company&#146;s common stock and warrants to acquire 4,562,500 shares of common stock for an aggregate purchase price of $1,368,750. The warrants are exercisable for five (5) years at an exercise price of $0.075 per share.</font></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify"><font style="font: 10pt Symbol">&#183;</font></td> <td style="text-align: justify"><font style="font-size: 10pt">In February 2014, the Company paid $82,125 and granted a warrant for 4,562,500 shares of common stock to a consulting group as a finder&#146;s fee related to the February 2014 Accredited Investors securities purchase agreement. The cash payment and warrant grant has been accounted for as an offering cost related to the February 2014 Accredited Investors securities purchase agreement and has been netted with the February 2014 Accredited Investors securities offering. The Warrants are exercisable for five (5) years at an exercise price of $0.075 per share.</font></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify"><font style="font: 10pt Symbol">&#183;</font></td> <td style="text-align: justify"><font style="font-size: 10pt">In March 2014, the Company issued 2,533,334 shares of common stock to two consultants for services with a total value $177,000. The stock issuance is for services performed during the period January 2014 through June 2014.</font></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify"><font style="font: 10pt Symbol">&#183;</font></td> <td style="text-align: justify"><font style="font-size: 10pt">In March 2014, the Company issued 1,818,182 shares of common stock in a private offering to two parties for cash totaling $100,000.</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The former Chief Operating Officer has a notes payable balance totaling $450,000 at March 31, 2015 and December 31, 2014.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The loan bears interest at 5.5% per annum and was initially due December 31, 2002 and have been mutually extended. Under the terms of the note extension dated December 12, 2007, the loan bears interest at 5% per annum and are now due. The Company has recorded interest expense for notes payable to the former officer of approximately $6,000 the three months ended March 31, 2015 and 2014. Accrued interest related to this notes payable approximated $273,000 and $268,000 as of March 31, 2015 and December 31, 2014, respectively and is included in accounts payable and accrued expenses in the accompanying consolidated balance sheet.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">From October 21, 2011 to April 26, 2012, the Company issued convertible notes for $600,000 (the &#34;Convertible Notes&#34;) of which $200,000 was received on October 21, 2011, $100,000 was received on January 31, 2012 and $300,000 was received on April 26, 2012. The non-interest bearing notes can be converted into the Company&#146;s common stock, at any date after six months from the issuance of each Note, at a conversion price of 67% of the fair value of the Company&#146;s common stock upon the date of conversion notice, subject to a floor price of approximately $0.041 for the note issued in October 2011, approximately $0.044 for the note issued in January 2012 and approximately $0.034 for the note issued in April 2012. The holder of the notes has not converted any portion of the notes as of March 31, 2015 and December 31, 2013. Additionally, the note holder was issued warrants for 6,000,000 shares of the Company&#146;s common stock with an exercise price of $0.05 that expire on October 15, 2015 (&#34;Warrants&#34;). The conversion feature to the note payable has been accounted for as an original issue discount approximating $296,000 which has been fully accreted as of December 31, 2012. The warrant associated with the note has been accounted for as a debt discount with an approximate value of $296,000 which has been allocated to the note&#146;s fully accreted value of $896,000 (original note amount plus original debt discount) on proportionate basis which amounted to $195,000. The warrant value of $252,000 was determined using the Black-Scholes option pricing model based on the following assumptions: 2 year term; volatility rate of 134% to 135%; and discount rate of 2.5%. For the year ended December 31, 2012, the Company has recorded an expense associated with original debt discount and expense associated with the debt discount (warrants) of $422,000. Accordingly, the carrying net value of this note at March 31, 2015 and December 31, 2014 totals $896,000, comprising of $600,000 (original face value) plus the fully accreted original debt discount of $296,000.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">During 2014 and 2013, the Company issued convertible notes for $2,500,000 through its wholly-owned subsidiary, Senior Scientific, LLC. The convertible notes bear interest at 8%, mature four years from the date of issuance, and are convertible into either: (1) membership interests of Senior Scientific, LLC equal to the quotient of the principal due of the convertible notes divided by $2,500,000 multiplied by 18% of the total equity of Senior Scientific, LLC outstanding as of the date hereof; or (2) the number of shares of common stock of the Company equal to the quotient of the principal and interest payable due of the convertible notes divided by a conversion price of $0.055 per share. The Company may not prepay the convertible notes. In the event of a default and so long as the default exists, interest on the convertible notes will accrue at 10%. The Company must account for all accrued interest on the convertible notes on the first calendar day of each quarter which $50,000 and $49,000 has been recorded as accrued interest payable as of March 31, 2015 and December 31, 2014, respectively. The conversion feature to the note payable has been accounted for as an original issue discount approximating $1,045,000 which $226,000 has been accreted as of March 31, 2015. The Company has recorded the accreted original issue discount as interest expense totaling $64,000 and $14,000 for the three months ended March 31, 2015 and 2014. Accordingly, the carrying net value of these notes at March 31, 2015 and December 31, 2014 totals $1,681,000 and $1,566,000, respectively, comprising of $2,500,000 (original face value) plus the unamortized debt discount of $819,000 at March 31, 2015, and unamortized original debt discount of $884,000 at December 31, 2014.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 12, 2009, the Company entered into a contract with Carpenter Technology Corp. to sell certain nanostructured metal technologies acquired from Metallicum, Inc, its wholly owned subsidiary, to Carpenter and to provide sub-license rights to Carpenter covering license agreements that the Company has from Los Alamos Laboratories. The agreement has two distinct elements: a sale and services agreement and a sub-license agreement. The first element irrevocably transfers the field technology to Carpenter Technology Corporation and Carpenter many develop or use the technology for its own benefit. Carpenter agrees to pay a sales price of $600,000 and pay royalties for products developed using this technology. In addition, the Company can receive additional service income for assisting Carpenter in the production process. These additional services are elective and do not affect the sale of the technology. The second element of the agreement is a sub-license to Carpenter for patents (the LANL patents) that are licensed by the Company from Los Alamos Laboratories. The sub-license agreement obligates Carpenter to pay MSI a running royalty on the sales of products that require license to the LANL patents but does not have any upfront fee or annual minimum royalties.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognized the sales revenue upon transfer of the technology and the service income over the term of the agreement. The royalty income will be recognized as products are developed using the field technology or sub-license.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the three months ended March 31, 2015 and 2014, the Company earned $-0- and $150,000 and recorded such amount as revenue. The amount received by the Company relates to services provided under the first element of the contract regarding additional services. The Company earned service income for time that a consultant to the Company, Dr. Lowe, made himself available to Carpenter in accordance with the Technology Transfer Agreement. The fees earned pursuant to the agreement with Carpenter are being proportionately recognized as revenue based upon the total fees to be collected over a 42 month period. The 42 month period is based on the time periods described in the Agreement (6 months after effective date), (12 months after effective date), and (each of the first 3 anniversaries of Annuity date where the &#147;Annuity date&#148; is the date of the latter of 18 months after the effective date or the date Manhattan Scientific fully satisfies its duties under of the Agreement).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In January 2013, the Company entered into a licensing agreement with a party granting certain licensing rights to the Company's nanostructured metal technology. As consideration: the Company received $180,000 in January 2013, and will receive $30,000 by June 1, 2013; $30,000 by December 31, 2013; $30,000 by December 1, 2014; and $30,000 upon commercial launch by the party or the latest December 1, 2015. For the three months ended March 31, 2015 and 2014, the Company recorded the receipt of $-0- and $30,000 as revenue.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 11, 2015, the Company entered into a Settlement Agreement and Mutual General Releases (the &#34;Settlement Agreement&#34;) with Carpenter Technology Corporation related to the agreement discussed in Note 7, pursuant to which the parties settled and released each other from any and all liabilities and claims related to the Carpenter Agreements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under the terms of the Settlement Agreement and as consideration for the full and final settlement and satisfaction of all claims that the Company has or could assert against Carpenter in connection with the Carpenter Agreements, Carpenter will: (1) pay the Company $8,000,000 within 10 days from the date of the Settlement Agreement; (2) transfer and/or assign to the Company all physical and intellectual property which was the subject matter of the Carpenter Agreements free and clear of all liens and encumbrances; (3) provide the Company with follow on technical assistance; and (4) provide the Company with a complete list of all customers and contacts for same related to the technology which was the subject matter of the Carpenter Agreements. In addition, under the terms of the Settlement Agreement, neither party may disparage the other and the Carpenter Agreements were terminated and rendered null and void. As of the date this filing, the Company has received the $8,000,000 portion of the Settlement Agreement, including the physical and intellectual property. The Company has obtained an independent valuation on the physical property which was estimated at $6,938,000. As such, the Company has recorded income on the appraised value of the physical property totaling $6,938,000 and $8,000,000 cash consideration received as a Gain on Settlement Agreement totaling $14,938,000. The Company has not obtained a valuation report with respect to the value of the intellectual property transferred in this transaction.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In April 2015, the Company issued 625,000 shares of common stock as satisfaction of previously accrued legal services totaling $68,750.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The consolidated financial statements include the accounts of Manhattan Scientific, Inc. and its wholly owned subsidiaries Metallicum and Senior Scientific. All significant intercompany balances and transactions have been eliminated.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amount of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. A significant estimate includes the carrying value of the Company&#146;s patents, fair value of the Company&#146;s common stock, assumptions used in calculating the value of stock options, depreciation and amortization.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#146;s cash accounts are federally insured up to $250,000 for each financial institution we hold our accounts in. As of March 31, 2015 and December 31, 2014, we had cash balances of $9,108,000 and $2,140,000 exceeding the federally insured limits.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">License Agreements</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In 2008,&#160;the Company obtained licenses to the rights of certain patents regarding nanostructured materials developed by another company as a result of the acquisition of Metallicum. The purchase price paid for these licenses was $305,000, which represented its fair value. The Company obtained an exclusive license on two patents and a non-exclusive license on the third patent. The value attributable to license agreements is being amortized over the period of its estimated benefit period of 10 years. At March 31, 2015 and December 31, 2014, accumulated amortization was $202,000 and $194,000, respectively. Under the terms of the agreement, the Company may be required to pay royalties, as defined, to the licensors.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In 2009, the Company entered into a patent license agreement with Los Alamos National Security LLC for the exclusive use of certain technology relating to the manufacture and application of nanostructuring metals and alloys. The purchase price paid for this license agreement was $33,000 based on the fair market value of 2,000,000 shares of common stock issued. The value attributable to license agreements is being amortized over the period of its estimated benefit period of 10 years. At March 31, 2015 and December 31, 2014, accumulated amortization was $21,000 and $20,000, respectively. Under the terms of the agreement the Company is required to pay an annual license fee of $10,000 starting in February 2010 and, may be required to pay royalties, as defined, to the licensors.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In 2011, the Company acquired Scientific Nanomedicine, Inc. which holds the commercial rights to technology and intellectual property with respect to the early detection of diseases using nanotechnologies. The acquisition of Scientific Nanomedicine, Inc. has been accounted for as an asset purchase since this company had no tangible assets or liabilities and did not have the business inputs and outputs to be considered a business. The purchase price totaling $1,300,000 (fair value of 21,667,000 shares of common stocks issued) has been allocated to in process research and development and is being amortized over its estimated benefit period of 10 years. At March 31, 2015 and December 31, 2014, accumulated amortization was $499,000 and $467,000. We subsequently dissolved Scientific Nanomedicine and transferred all remaining assets to Senior Scientific LLC.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To date the only revenue generated is from the sale of field technology developed by Metallicum related to the Company&#146;s nanotechnology, services provided and sample materials.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Revenue is recognized when the four basic criteria of revenue recognition are met: (i) a contractual agreement exists; (ii) transfer of technology (intellectual property) has been completed or services have been rendered; (iii) the fee is fixed or determinable, and (iv) collectability is reasonably assured. Service revenue is recognized when specific milestones are reached or as service is provided if there are no discernible milestones.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective January 1, 2008, the Company adopted FASB ASC 820, Fair Value Measurements and Disclosures, Pre Codification SFAS No. 157, &#147;Fair Value Measurements&#148;, which provides a framework for measuring fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The standard also expands disclosures about instruments measured at fair value and establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 1 &#151; Quoted prices for identical assets and liabilities in active markets;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 2 &#151; Quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets; and</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 3 &#151; Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company designates cash equivalents (consisting of money market funds) and investments in securities of publicly traded companies as Level 1. The total amount of the Company&#146;s investment classified as Level 3 is de minimis.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of the Company&#146;s debt as of March 31, 2015 and December 31, 2014 approximated their fair value at those times.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Fair value of financial instruments: The carrying amounts of financial instruments, including cash and cash equivalents, short-term investments, accounts payable, accrued expenses and notes payables approximated fair value as of March 31, 2015 and December 31, 2014 because of the relative short term nature of these instruments. At March 31, 2015 and December 31, 2014, the fair value of the Company&#146;s debt approximates carrying value.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for stock-based compensation based on the fair value of all option grants or stock issuances made to employees or directors on or after its implementation date (the beginning of fiscal 2006), as well as a portion of the fair value of each option and stock grant made to employees or directors prior to the implementation date that represents the unvested portion of these share-based awards as of such implementation date, to be recognized as an expense, as codified in ASC 718. The Company calculates stock option-based compensation by estimating the fair value of each option as of its date of grant using the Black-Scholes option pricing model. These amounts are expensed over the respective vesting periods of each award using the straight-line attribution method. Compensation expense is recognized only for those awards that are expected to vest, and as such, amounts have been reduced by estimated forfeitures. The Company has historically issued stock options and vested and non-vested stock grants to employees and outside directors whose only condition for vesting has been continued employment or service during the related vesting or restriction period. The estimated fair value of grants of stock options and warrants to nonemployees of the Company is charged to expense, if applicable, in the financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with FASB ASC 260, &#147;Earnings Per Share,&#148; the basic loss per share is computed by dividing the loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Basic net loss per share excludes the dilutive effect of stock options or warrants and convertible notes. Diluted net earnings (loss) per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents, consisting of shares that might be issued upon exercise of common stock options and warrants. In periods where losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive.</p> 6938000 -1076000 -1300000 49000 114000 14938000 1818182 100000 226000 The fees earned pursuant to the agreement with Carpenter are being proportionately recognized as revenue based upon the total fees to be collected over a 42 month period. The 42 month period is based on the time periods described in the Agreement (6 months after effective date), (12 months after effective date), and (each of the first 3 anniversaries of Annuity date where the &#147;Annuity date&#148; is the date of the latter of 18 months after the effective date or the date Manhattan Scientific fully satisfies its duties under of the Agreement). As consideration: the Company received $180,000 in January 2013, and will receive $30,000 by June 1, 2013; $30,000 by December 31, 2013; $30,000 by December 1, 2014; and $30,000 upon commercial launch by the party or the latest December 1, 2015. 2500000 EX-101.SCH 6 mhtx-20150331.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 00000006 - Disclosure - BASIS OF PRESENTATION link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - ORGANIZATION AND OPERATIONS link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - CAPITAL TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - FORMER OFFICERS NOTES PAYABLE link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - NOTES PAYABLE - OTHER link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - TECHNOLOGY SALE AND SUB-LICENSE AGREEMENT link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - SETTLEMENT AGREEMENT AND MUTUAL GENERAL RELEASES link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Policies) link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - CAPITAL TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - FORMER OFFICERS NOTES PAYABLE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - NOTES PAYABLE - OTHER (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - TECHNOLOGY SALE AND SUB-LICENSE AGREEMENT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 mhtx-20150331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 mhtx-20150331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 mhtx-20150331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Los Alamos National Security LLC Member FiniteLivedIntangibleAssetsByMajorClass [Axis] Scientific Nanomemdicine, Inc [Member] Related Party [Axis] Consultant [Member] Equity Components [Axis] Director [Member] Convertible Notes [Member] Debt Instrument [Axis] Related Party [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Is Entity a Well-known Seasoned Issuer? Is Entity a Voluntary Filer? Is Entity's Reporting Status Current? Entity Filer Category Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Consolidated Balance Sheets ASSETS Current assets: Cash and cash equivalents Total current assets Investments Property and equipment, net Assets received in Settlement Agreement - see Note 8 Intellectual property, net Other asset Total assets LIABILITIES Current liabilities Accounts payable and accrued expenses Accrued interest and expenses - related parties Note payable to former officers Convertible notes payable Total current liabilities Long-term liabilities Convertible notes payable, net Total long-term liabilities Total liabilities Mezzanine equity Series D convertible preferred, authorized 105,671 shares, 105,671 and 105,671 shares issued and outstanding at March 31, 2015 And December 31, 2014, respectively STOCKHOLDER'S EQUITY (DEFICIT) Capital stock $.001 par value Preferred, authorized 1,000,000 shares Series A convertible, redeemable, 10 percent cumulative, authorized 182,525, shares;issued and outstanding - none Preferred, authorized 1,000,000 shares Series B convertible, authorized 250,000 shares; 49,999 shares issued and outstanding Preferred, authorized 1,000,000 shares Series C convertible, redeemable, authorized 14,000 shares; issued and none outstanding Common, authorized 950,000,000 shares, 518,378,036 and 516,378,036 shares issued, and outstanding, respectively Additional paid-in-capital Common stock to be issued Accumulated deficit Total stockholder's equity (deficit) TOTAL LIABILITIES AND STOCKHOLDER'S EQUITY (DEFICIT) Consolidated Balance Sheets Parenthetical STOCKHOLDERS' DEFICIT Preferred stock, par value Preferred stock, shares authorized Series A, Percent Series A, authorized Series A, issued Series A, outstanding Series B, authorized Series B, issued Series B, outstanding Series C, authorized Series C, issued Series C, outstanding Common Stock, par value Common Stock, shares authorized Common Stock, shares issued Common Stock, shares outstanding Consolidated Statements Of Operations Revenue Operating costs: General and administrative expenses Research and development Total operating costs and expenses Operating loss Other income and (expenses): Gain on Settlement Agreement (see Note 8) Interest and other expenses NET INCOME (LOSS) BASIC AND DILUTED INCOME (LOSS) PER COMMON SHARE: Weighted average number of common shares outstanding (Basic) Basic income (loss) per common share Weighted average number of common shares outstanding (Diluted) Diluted income (loss) per common share Consolidated Statements Of Cash Flows CASH FLOWS FROM OPERATING ACTIVITIES: Net income (loss) Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: Gain on Settlement Agreement (see Note 8) Common stock issued for services Debt discount and original issue discount accretion Depreciation and amortization Changes in operating assets and liabilities: Account receivable Prepaid expenses and other assets Accounts payable and accrued expenses Net cash provided by (used in) operating activities CASH FLOWS FROM INVESTING ACTIVITIES: Purchase of fixed assets Net cash used in investing activities CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from notes payable Proceeds from issuance of common stock Net cash provided by financing activities NET INCREASE IN CASH AND CASH EQUIVALENTS Cash and cash equivalents, beginning of period CASH AND CASH EQUIVALENTS, END OF PERIOD SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: Interest paid Income taxes paid SUPPLEMENTAL DISCLOSURES OF NONCASH INVESTING AND FINANCING ACTIVITIES: Issuance of common stock for prepaid services Beneficial conversion feature associated with debt Transfer of assets from Carpenter related to Settlement Agreement (see Note 8) Notes to Financial Statements Note 1. BASIS OF PRESENTATION Note 2. ORGANIZATION AND OPERATIONS Note 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS Note 4. CAPITAL TRANSACTIONS Note 5. FORMER OFFICERS NOTES PAYABLE Note 6. NOTES PAYABLE - OTHER Note 7. TECHNOLOGY SALE AND SUB-LICENSE AGREEMENT NOTE 8. SETTLEMENT AGREEMENT AND MUTUAL GENERAL RELEASES Note 9. SUBSEQUENT EVENTS Summary Of Significant Accounting Policies And Related Matters Policies BASIS OF CONSOLIDATION: USE OF ESTIMATES CASH CONCENTRATION INTANGIBLE ASSETS REVENUE RECOGNITION FAIR VALUE OF FINANCIAL INSTRUMENTS STOCK-BASED COMPENSATION BASIC AND DILUTED LOSS PER SHARE Statement [Table] Statement [Line Items] Finite-Lived Intangible Assets by Major Class [Axis] Cash exceeding federally insured limits Accumulated amortization Shares granted to directors Shares issued for service Shares issued for service, Value Common stock issued private offering for cash, shares Common stock issued private offering for cash, value Former Officers Notes Payable Details Narrative Interest expense for notes payable Accrued interest related to notes payable Accrued interest payable Interest expense Carrying net value of notes payable Unamortized debt discount Original face value of notes payable Debt discount Accreted amount of convertible notes Technology Sale And Sub-License Agreement Details Narrative Revenue Revenue receipt Description of agreement Description of revenue Custom Element. Custom Element. Custom Element. Custom Element. Revenue receipt. Custom Element. Custom Element. Custom Element. Custom Element. Custom Element. Custom Element. Custom Element. Custom Element. Custom Element. Custom Element. Custom Element. Custom Element. Custom Element. Custom Element. Description of revenue. Issuance Of Common Stock For Prepaid Services Beneficial Conversion Feature Associated With Debt Interest expense for notes payable. Accrued interest related to notes payable. Original face value of notes payable. Description of agreement. Cash exceeding federally insured limits. TECHNOLOGY SALE AND SUB-LICENSE AGREEMENT Assets, Current Assets Liabilities, Current Liabilities, Noncurrent Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity Operating Expenses Operating Income (Loss) Interest Expense GainOnSettlementAgreement1 Stock Issued Increase (Decrease) in Accounts and Notes Receivable Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Accounts Payable and Accrued Liabilities Net Cash Provided by (Used in) Operating Activities, Continuing Operations Payments to Acquire Property, Plant, and Equipment Net Cash Provided by (Used in) Investing Activities, Continuing Operations Net Cash Provided by (Used in) Financing Activities, Continuing Operations Cash and Cash Equivalents, Period Increase (Decrease) Revenues EX-101.PRE 10 mhtx-20150331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0#67\;=M@$``#,/```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,E\M.PS`41/=(_$/D+6I< MES=JRH+'$BH!'V#LVR:J8UNV*>W?+,Z,7*AEPMLPYEZJB1P#[W6[%UPYF\"F3FHTV*!_#R/Y M85+V,,/'"Y(`)K+L;K&P\2J8]-Y42B8DY5.K?[ATE@XY[FS7Q++R\00Q&-_H MT,S\;K#<]XQ'$RH-V5"&]"1KQ.`SPS]=F+P[-\FWBVR@=*-1I4`[]5'C">31 M!Y`ZE@"I-GD[YK6L[(I[BW^[./)V$`<&:=ZO%=Z3HT>$XY0(QQD1CG,B'!=$ M."Z)<%P1X;@FPB&Z5$"H)*J@$JF"2J8**J$JJ*2JH!*K@DJN"BK!*J@D:^^_ MDC5A)0#>7O^>J:W,CG_2F.8&XH&_(PO170'V!UBUN&9WQZ,0A%3!NL=MZD-K1RR(^QO^*&30 M5%`->H,W;ROOX`L``/__`P!02P,$%``&``@````A`+55,"/U````3`(```L` M"`)?]=J>*V?5@^@8B)G:13'&HX<85?=WFQ?>*24FV+7 M^ZBRBXL:NI3\(V(T'4\4"_'L)MI<3_3_MCAQ(DN)T$C@\SS?BG-`Z^N!+I]HJ?B]SCSBIX3A363X M8<'%#U1?````__\#`%!+`P04``8`"````"$`^'8)1)(!``#0#0``&@`(`7AL M+U]R96QS+W=O\>)5YOWMDE>E76UT1F#4E+F1CM,K843FV65]?K1Y5(WUXR55UYY)01;N,5=YWMYR[ MO%*M="/3*1U6]L:VTH>A+7DG\X,L%1=I.N/V9PVV/JN9;(N,V6T1]M\=N[#S MW[7-?E_GZM[D+ZW2_L(6_,W8@ZN4\J&HM*7R&>NG'#^M+$9!,>.7Q<"86`V, M43G4<`"E0PT'92,@IE4^!%H-H3D-^>D)F$'SF!KZI`XZ^JFO\,XQ,2"(U8!` MY5##`90.-1R&PO=V]R:V)O;VLN>&ULE%5=<*5!NL[N$]Q\G)Q[[LG-P^-ADVB_>%Z(+!WHYI6A:SQ= M9K%(7P=Z2"??;G6MD%$:1TF6\H'^S@O]:;J+C*MCR%F566;R()8?[:*;8YC^)BS;G<)!W+,/J=3212_8APG_\+ M1K9:B24?9\O=AJ?R")+S)))`OUB+;:$/'U8BX4_'C+1HN_6B#?`^)+J61(7$ ML9`\'NC7$&9[WAC(=]O13B0P>]YR+68KZ)=(BFD=T('O:R>9?7+ ME:443X+OBX]-9:@=GD4:9_MR*4C[7D==(+"OIIY%+-=S%+R4V1-GZCD3QT8>9G6^>^,$:7VT,L^52.)O@[R%X@N>I_*5E-5 M$X*SFW:YI."H^L):=RJ'ECLO`X&M:B"S(6[+J)^Y@XVYC$12,-7O9D/&PO=V]R:W-H965T&ULE%?1;JLX$'U?:?\!\=Z` M(02(DEPU5-V]TEYIM=J]]YD0)T$%'&'2M'^_,PPAMDDC\I(6N>US$6UM-G$M2U>96*;5_NE_=^_KT^1;+,3=9DV\%CO'7FL>;IM)Y6% MX[GNS"G3O+*)85Z/X1"[79[Q%Y&=2EXU1%+S(FU`OSSD1WEA*[,Q=&5:OYV. M3YDHCT"QR8N\^6Q);:O,YM_WE:C330%Q?[!IFEVXVXTG]D\89'MK!:M03]S?I;*_Y8\B/,?=;[]*Z\X MN`UYP@QLA'A#Z/W/)D'H^@S@UH;+YC5' M2MO*3K(1Y2\"L8Z*2+R.Q`?UW7MO+(E#@MKX7M(F72UJ<;:@:&!)>4RQ!-D< MB"^!D8P^U*\BA1"1Y!E9EC94.P0A(3WOJS!8.._@:-9!UD,(TQ')!8&)`'6] M1(A;E7C;\XL2!*,2S`%*6],` M*@+"L*J(EC2&O5')VKC.T\XR/!JT9>JZ7?ZFL8^[7!>:=#RP!_L> MZE_K4Q?Z4+-FU'K5%A5=6R\EL<-'?56Q\7[Q,^K"FCJS M!'YIG:-/SV^8G,3L\(HQ:;,J*+P&:K MN#12!+5HS2VSK>.5"38MY3)@X90Q?V:`$@TT#3W/CZ>SJ^^ZU(?Z/QL>`+%1 MZ^L.`SL1;S'NQ#6:2M(!*)O7V;HLH_N/='!X#,37;=;M!K7-!U$4!G$0&*"$ MW0?I4HWS8*34X<$0FP<#W,V!%PVTFZBM-5M>3UGB>\**25B1-> MLSW(3C_:?P(\>WCM,\;7^&F`XT[_`F[FQW3/?Z3U/J^D5?`=4+J3$*JSIKL] M/33BV%Z0-Z*!.WG[[P&^P3CPH;:16JJI>GM>PF%6`1;OK./G[ MSC`8PY):Q)9L6,Z>.7/9859WKWGFO'"EA2S6;C#R78<7D8Q%<5B[OW\]WMRZ MCC:LB%DF"[YVW[AV[S:?/ZU.4CWKE'/C`$.AUVYJ3+GT/!VE/&=Z)$M>P)-$ MJIP9N%4'3Y>*L[C:E&=>Z/LS+V>B<(EAJ89PR"01$7^0T3'GA2$2Q3-F0+]. M1:G/;'DTA"YGZOE8WD0R+X%B+S)AWBI2U\FCY=.AD(KM,_#[-9BPZ,Q=W?3H MK-W[8+D+)JZW654!^B/X2;>N M'9W*TQ11(Z3K141N9_R504%,125B3C$%]_3P<2N*1H,J_!V;89J7DR8&B M`9.Z9%B"P1*(SXZ1C,;5_WD*+B+)/;*L7:AV<$)#>EXVH;]8>2\0TJC&;/N8 MH(O8G1&8"9#7:`3'VQK?#_I9"H)1"B8!M6UI`;@OVBR[?<1\UD`Z2B!"PY4@ M&!+=-ASX#2^)(\R<0C;U\=-%[`A1%55'RJ0K!1,WAKJ^'AS<9$NRLK`E#$D* M;O$;6I((T9<$I=R.SC!)N,F69!G<$F9112EX+T@$Z"N:=15=#PZ";27CKNM; MPM`1Q^K:M18ZZ9E_Q#*";"RH'W:M7Z),91$0Z-IAJ2'OR+$:Z_7C`D-'OTI[ MJ2$0]:\%GMUNM'!T09:6&)I$Z$V=,$#IAL]I,0/&PO=V]R:W-H965TOY_M M;.[?R@*]4B$9KT+L6@Y&M(IYPJHLQ#^^/]ZM,)**5`DI>$5#_$XEOM]^_+`Y M$TK&$FY*(F"ILAL60M*DF926=B>X_AV M25B%C4,@;O'@:(?&QO-TT^/QD]R=XSDCD_?1(L^<(J"F%#F70!#IR_:.E3 MHKM@LCV9_=@4X*M`"4W)L5#?^.DS95FNH-H+6)!>5Y"\1U3&$"C86-Y".\6\ M``#X1B73.P,"(6_-[XDE*@_QS+<62V?F@AP=J%2/3%MB%!^EXN4O(W+/5L;$ M.YO,@/X\[OVWR?QL`K\7$V^ULY@NL+_E!4%IDP?M$F(X,A"%A!J_;CUWM;%?H3#Q6;.;:MRA8M\J=!6T M;60ZFBQMX.V@(<\^])]KV;)IL69K77>F`[POL".0J6+I#R715.+-.\D`%HK> MA]4)SV`;7X?6DT(,!;DPNNO.OTEG9S1FT^JX]N..J-DGC$`P``L`L``!D```!X;"]W;W)K&ULE)9=;]HP%(;O)^T_1+DO(0'"AX"J$'6;M$G3M(]KDQBPFL21 M;4K[[W?L$\!V6$=[48C]^N7Q>QS;\_N7J@R>J9",UXLP[O7#@-8Y+UB]6X2_ M?C[>3<)`*E(7I.0U782O5(;WRX\?YD4A6`0RT7X5ZI9A9%,M_3BL@> M;V@-/5LN*J+@4>PBV0A*"C.H*J.DWT^CBK`Z1(>9N,6#;[^8KG@DF]5#^PB!.W.>1I-(W!:S@L&,]"Q!X)N%^%#/,OB)(R6R#T_?A*L^,IJ"FE#G70%-IP_:>F70C?!X*@S^M%4X+L("KHEAU+] MX,?/E.WV"LH]@AGIB-O3U6I[8 MM%BSG5Q7V`#>%U@/I*L8IZXDZTJ2X5GBP$+1;X?58EAB-ELR./N:5%:HF9J8 M1WWX<_O7V(^+V<1H#QA.[0$.*)3_=E`M]D$O`2`H:L8&-!W:OVOZUW9_W.W/ ML-],Q`&%%^]V4"WV04=N8BO4(&B<3N(N*BJL3)TAHS2UASBPZ7M@M=B']5;> M"C4(.XF=5"WV4<=>KJA!U,0L57^MHL)B?6N(`ZL/ M:&OC>GL/T&(?=N+!HJ:%39R"8JXHL%BM!@=M^AXT+?;1IAX::BZ_O/8;,JO! M08GAP+P])J/V8?R7I16U"W!Z):A6<>'-WAKC\NHM_^:RQGA`N-NEOPA;$?)J MVLZ&V2IL7C2^.L;EU>?`[;QX:CB\`^^56,%M2*\(W-^3J_FBPN9]8PSRX@4) MC_Z*BAU=T[*40O<`?>EANSH-R)V MK)9!2;=@V>^-88\4>./"!\4;<^'8<`4W)?-U#S=C"D=]OP?B+>?J]*!_X'S7 M7OX%``#__P,`4$L#!!0`!@`(````(0"E2KQ1RP(``'X'```9````>&PO=V]R M:W-H965T;SI_5>JB==,680.#0ZQ94Q[S=!S[$31#WMV@LJ10L66UYS\]J98B3HZK%LI"+;&N)^ M"2\)[;V[AQ-[P:F26A;&`SO?@9[&?.U?^^"T6><<(K!I1XH5*;X-5UF"_,TTAH6#C10OK1&4-`/")!+>=`0DA+RF.X&*> MFRK%\=);)$$<@AQMF38/W%IB1'?:2/'7B<*#E3.)#R;P_V`21N>:^`ZHB^^> M&+)9*[E'T#-PI6Z)[1[8I67:J2):# M9$("&1J3V&S%T$P?$]E#*;X<`\31X.\@G<:UCJ7.1@L3`K`9$WQ\LQ4#X>CF MY&IVL9-<=S4+IGO9>"]"*9*EK&ZUHC*G9UE$33%L#J,V=O(OEJS]3L8O]VP\H<- M&'\M*=EWHDK>:%2S`BP#+P%$Y0:H>S"R[:;05AH8?-W7"G[G&+P$@0?B0DK3 M/UCPX9=S\P\``/__`P!02P,$%``&``@````A`/MBI6V4!@``IQL``!,```!X M;"]T:&5M92]T:&5M93$N>&UL[%E/;]LV%+\/V'<@=&]M)[8;!W6*V+&;K4T; MQ&Z''FF9EEA3HD#227T;VN.``<.Z89UC1"SF67"72(6=L#/F-^-"0/E(<8E@HFVE[5_+S*UM4* MWDP7,;5B;6%=W_S2=>F"\73-\!3!*&=:Z]=;5W9R^@;`U#*NU^MU>[66\/7.=K?;=/`&9/'-)7S_2JM9=_$&%#(:3Y?0VJ']?DH] MATPXVRV%;P!\HYK"%RB(ACRZ-(L)C]6J6(OP?2[Z`-!`AA6-D9HG9()]B.(N MCD:"8LT`;Q)__/QY M.1`R:"'1BR^?_/;LR8NO/OW]N\*1R5D1SBB!4-?A.KL$S( MP5SX15Q/*O!T0!A'O3&1LFS-;0'Z%IQ^`T.]*G7['IM'+E(H.BVC>1-S7D3N M\&DWQ%%2AAW0."QB/Y!3"%&,]KDJ@^]Q-T/T._@!QRO=?9<2Q]VG%X([-'!$ M6@2(GIF)$E]>)]R)W\&<33`Q509*NE.I(QK_7=EF%.JVY?"N;+>];=C$RI)G M]T2Q7H7[#Y;H'3R+]PEDQ?(6]:Y"OZO0WEM?H5?E\L77Y44IABJM&Q+;:YO. M.UK9>$\H8P,U9^2F-+VWA`UHW(=!O-29#`P<7""P68,$5Q]1 M%0Y"G$#?7O,TD4"FI`.)$B[AO&B&2VEK//3^RIXV&_H<8BN'Q&J/C^WPNA[. MCALY&2-58,ZT&:-U3>"LS-:OI$1!M]=A5M-"G9E;S8AFBJ+#+5=9F]B(K5"MQ:FNP;<#N+DXKLZBO89=Y[$R]E$;SP$E`[F8XL M+B8GB]%1VVLUUAH>\G'2]B9P5(;'*`&O2]U,8A;`?9.OA`W[4Y/99/G"FZU, M,3<):G#[8>V^I+!3!Q(AU0Z6H0T-,Y6&`(LU)RO_6@/,>E$*E%2CLTFQO@'! M\*])`79T74LF$^*KHK,+(]IV]C4MI7RFB!B$XR,T8C-Q@,'].E1!GS&5<.-A M*H)^@>LY;6TSY1;G-.F*EV(&9\F_W4`BA;JI)6@8,[F3\N>]I!HT"W>04 M\\VI9/G>:W/@G^Y\;#*#4FX=-@U-9O]2!=(.SB"QLD.VF#2I*QIT]9)6RW;K"^XT\WY MGC"VENPL_CZGL?/FS&7GY.)%&CNUL&-K.[;2U.#9DRD*0Y/L(&,<8[Z4%3]F M\=%]6QEC' MCX1VX&973&S?F\8>NVQN!YZ_R0X;[``/C/RZP(.;V,%&)N&ZR?=N@DR.HM4F:SLNMFQXCJS25T1. MO)@.=4"[C,=>K`_"53T?+^A';FY;!!W>Y!DGD>S/&8C'ADZE\,)O3HSZR)9XFFIQQ8_S=MN MO]_OM>YZO5[?;+=,DQMYFD>T%\[09UV[2CJ_8J8:#(JX2!(J_R^7>CALR?]Q24(A3W M5<)`D5<)`T5>[=:<@;O*O4H8*/(J8:#(J[QJ5&-?18E/<5\E#!1YE3!0Y-7: M)I]Y!NXK]RIAH,BKA,'97N6K*ZSGIE$\PSV+HA#?:F(ME1T;#7QWGF+E%GN+ M%_:;1DO\.XW2%!7^T6#FV8LHM'UL-HH6Q>^!EK@'@ML=0SU]\9Q7"!.6V-D< M.Q-Q*0EE=C#9K-OLFLVNV3'NLH5-3:(#=^:M@FWM2MD[_05YS8,"R% MY"O?JLS38%[(W2?9@KN:>UJR`6*B"`G)%G7H6)4\974D+>1T)`TD=20M9'5$ MU]G5N0I+SJ(5;K^]=;!E]9K-K+HD*^:;!#RR,M9'44XZ;PK@!>+O%9>M[!Y(V]A#A^H7(P&ZSFYX8J[X.R.)+N?RS91'LPWLZ$BVP'' M?8V,O8TT>[GT-T^K8.K&%K\USD7PHZP,6>V-^1A7[;_WO448N+SVHF4-,]63]G*$;[@:RFRE&:OL=A%[51[B6+O M%RPRV>LL#HJI;JRSUY]2SZ%'OL3V\ME=8RF:W;)8S]_4>OGJ,J\0RW,4R[X% MU^LRA^&.E[;?V':O-2O+H5BO:T?-1H3+6TW2/F=P8;3R4B`VA=0N!ME>0QS5 MG`:,M+C=\?+K2;"RU-';&F]\7S>'2X9`39V;Y1S59L+PKIP#KQ:K-@2-%V84 MJ7XJF3)HO/RT2E)OOCDMB4GWY+U]]HRLA6'W*S,'6[=?WD%GF(RMJ+]J@M+\ M]@;4T9'HJ^A0?$*)*22Y(2_>CB\GG!I[=PGO6C=_K]UH[QTV9\/$*1N660^8 MKCP?3TZRF21;##CHQE$PS@[FT[=#6)@X9U@&6^(3+*RV3\4"0H[%%H@$"]WB M5"R(S[#:;'E18>%9A9.QL&C/L=CRG6!AH#N5%YKD6*+M.Y*V-W?YD1>Z*EY, M91E>%*OR(RN3$"RH?"I6Y414K,J/\`+%0KB=BE7Z MT83C"%9'TO9W._THQBI;E,[0ZD\!3RBD8D3,E[/4$H?M47KFI+6'=NS(NN*`6-( MF@1?Y7!6/KZ6$K%OK?"J"S[E015B-789A28OKO.J3?`070DD]@%$IW$G,I&[IE(#YZ MX:L[$R-'M+`!DC)(3^XJC>TR_L0N94@:YHD]>EEBB"DB>Q.]>$XTGW\^X4G+ MPHBLED.2`5LFRQ#_VRHE9N3//U3S%+PY*@7R[*5XN+KHQ"(/T)+A\1RA^EE" MO,DHDAC_L..0]1:AZ[Z)T3T:5;5DS/YGZ^HQ7&[WE'V[B3^@6ZX'8-Z9.[=7 M?OIC=EV.S?]SOCAIF-.Q@\/5K]I-"?_@\G8AZ[N\:6D M,SXDQ3]XA6IRR[Q/?'QN*LZ5SX1O\' M``#__P,`4$L#!!0`!@`(````(0`ZRW)P\S```+V2```4````>&POOO7=<24E9==J#[C,H ME)*,V)=U7_]:>_/;WW^:3J(/R2)/L]GOGG5W]YY%R6R4C=/9W>^>O;]^LW/\ M+,J7\6P<3[)9\KMGGY/\V>^_^Z__Y=L\7T:\.\M_]^Q^N9Q__=57^>@^F<;Y M;C9/9GQSFRVF\9)_+NZ^RN>+)![G]TFRG$Z^VM_;>_'5-$YGSZ)1MIHM?_?L MX.CP6;2:I7]9)2?ND_V#XV???9NGWWV[_.XT&ZVFR6P9L8SH;+9,EY^C_LR- MS[*__6KYW;=?Z5'W^$%TD+$;'70[T?Y>]ZCY93%3[TDS M^;5<)7=IOES$K'`03Y/FH!>]P?>]Z^O>(!J>],\&U_TW_9-AU!^<-!_TPYVP MU44\88OCY%/TA^1S\[EBE=>?YZW9NGL[?]SXPKMDD6:BX3@ZC9>M=WM0>6R4 M?C.)[YJCG*P6"Y86O4GS$TT@P++ M;/13)QK>QXLDCRY72U,NUME<1,%D3V[/NC?H0FO!?^P^]K8Q:^V[)Y>#X>5Y M_[1W?78:O>Z=]P8G9]'P^[.SZV&T_7YX&FT];PV>C`H5.FQ^&:0DSO-DF7_= M^CK.[TV/1_HC^3Q,@1CT:+%1M-/F&I\[4OV?Z>T>=%R^[46[FI%/\6T)?_RY*97'' MQO^LM#I1O(SPB*/[PB5&GY'%E&0R:M%9_$\U3:FLNX M15N[>WM="4>$:J]:3N;=^IUT]O;V])_?"RIH5.A5J:!5C-%&2;(V&Z'B(]0: M,S%=(9,LKDZ>X_W.T?Y1QX_YS08:["!WLU^YSM?U=59XM']4W=&KSJM7 MK\(VUR^I*?I?1K.3^EJJ-*NLJWM8(?Y$1#%2V,T//&40IS.;QZA(TH:'7E>%=_,S#T[$&(]/=/*$B7CF MP8GX_H&)ZG'E1JM;?^Q1CJU]?/TJUS[ZT(*K`>?PFKCSXFQ`L'GY)KI\=W;5 MN^[S`*(\Z+T_[1.4;A3K:B;7#D.S69Y-TK$%*DH!+(8CXKZ-+O$:^`H>:'+^ M*OF0S-H>R[]`+C'*\C4Q[=MDQH@3%UN-I^G,LD%YHXTAUE62DS[A=F7YQDP[ MR2Q`;:[(61V%LJPX+,!>"O%8\XURL9,L;^W019HI&?[4Q8+;89SGK5#]+1EZ MI)1E73"\7<;"+9.EP+>(&S.+;<,LS=4.SJZ5"5]>G$7;YY?#86NLU[UA_\3, MYFG__+URE-KC$1(3\?K%Y8"DI7=UUMK%GY+T[E[1:DR4&=\18ZXLLLENX::E M9%X9*B(;;;^.\W347HP^)3\PZFV+OL\5@M0&:N[PE\U_FDY6++JU`O_Y%ZZA MYD/J*G?2&WX?O3F__-.35*[R])NKRXN@L(.W4>_DNO^#^;@6!P;)LK[>)HEZ MXS^O?!H7X:5)Q++9B`Q?R5K]37VM#RUY)*7ZD(+P1#>XX%7.'^GL>53J2JQH MU;*BUI*\S7+QJC-K2E-(\!8?2%)::G.:W"RC,;B'P"D7K2S2NU0AB+U=^8[< M"G?<1J5.DSD;2\WP.$LQ%4#Q5_N@29&3^WAV1PX@!2QTWR6!]FXEKVGMS:=\ M(B/YK$+EYNBX>@5.A7%R&RIST-;VQ<$O)'ESSJ;D]`<_G`VO^P]+SKL5)C+. M"49OH]OTDY3872[ MR*8/IZL@$)5')2;Q;&1;"79'V5)S5<56JM)]BZ2A$0]NQUO2J[/>\`P;&=GV M%&[:'XHR?^B=R]$V9SS9A,ATB)>1<3+5.S$`.00[;+TM^[%NFDYTQN0X=2QT M__*T^=[P_;MWY^;YB9!/^\,3K/_[JS.]4#"&;;RYO+JPB*`EYH63D2@W1^\[ M$[V,/QF)1W\#E\VXH/^F=IN,S&O""*4>&!67 M^0N3CVX3X,L%SCK/,YD/E.!CNKPG:+A9-K=]#0:=`Q.(7=Y:F)R>Q`N0'IPR M1L%!-]C1+W;KZAZ/N+K#C$T:^ MOD]$1L!8">1J%J](`\WHL[%TBH$P)6%"(-40[MWC]1'C9`8`!_5)A653`<"R MQ=C4T6AYYP*X"6CA:)3,-:H>P=9KJOD"CY_.)XB2?(2A8K7YTK(68:;4QL2< M\BAE@15NB%C3WGT#%`9NL?-'>XZZ@:$6BK%V_A6."24$R+@S+N/5-,8P`0,U M+V;OG'W"(N(;(KDPC(I$9/L??_M?P[.3?_SMWY_O1C+_BS'KGGSN:`"LYUK* MC/&DF;G7R6J,>$TFDAK-*#]';(/0Y<@+*:ZHQFJ>3"4HK''>SXP_QOY<@U-> M6)"H&B6P@5`4*'7=XG:C:UOX$YFK"4M,6&YL#$9__KR:&>&=MF@]06#6 MS6BTU4/0A&WS%UX\@X$C40=P8A8%WOW!UJ]G/ZL"0L6$[UN`V2[E&Z-"-B[6I!1G'/+%H5Q/6K$L]^_GMT)\H`EC,6MK_&HU\3-:\`!M+(\(#;4JA`:5)^*SL M"T.YFLZ=CB[OP4/CVUN`3F,>BR=(@_+Q5-;`I-@;5KU:"<,Z%;71'$B@C`>$ M"9:X\4+D*F((6?*)?%':SVNBKW)6^V,ML<35^>IF8A(!QUF&7EJWTH5+9]TV M0P86C3$GR$#YDO[E>+F+SH[`XDG\!.P[U8&]`GX5>NTIEDE$U[ MOC38KTDQ7'/*9/_XV[\A4FML]C?>/+,LF;"4L3",Y%I6(3`.:1@".]55@G!B MK3$!XQ3>+5QPQD.P>]-J)1#PVKUF7B)&/^5)Q$H#6EE2J"\'FC;!20R>- M,V%U<-;'\7B"EIZ4*7MX7NJH*9;W%)\BZH8X?*]NSMXT,'L)A:QY4.@45Y;. MQAA;0R&\8(71;>?3^+,LIL1B)`D/4P:C)JEH6K6C]M*OWO8&_?]FH8"%@26$ MT[0&`Q7.]G>CRZ>_%1WL&R4G_<%GUP?(4X_7L$T?A@ M[4ORC2@+.YK$'T4MG"2J;7:I$WU$^1`4O]HV7)"+1 M\F,6&`EY/@($3S[O4-B&?OGJ)D_'::RJQ=?114(]9)*"*KOE=LQ)EY]J/3;J M,,$[+"K[B\[/3YQ';W[C_/NEU@8^W]U7"\/>L3GYH%1HA??7Y52>7N)O]ZA9 M94$R"@*BCWAE%:DM+]YM5S37DE;J>:NJ-$20QB2C^UDVR>X(7T(X*B.EH0%_ M42^?\\K<$6HL5MA>@K3B/1D>;ST(Z+*=:8(G":UR1`:D''LXG\,;8[YS:RFF'1^WB'>P2$ETMQ#T-14/ MG?&<3PBL90'+@:F_F8J.%$8JL/:`WL=L\9-QMEP\L]=F]`N%7D15+0&0F-(* MLPSNX,3MM:5ZUPU;>K/*67N>8R[&"2F$*XFP3!R+8@:@3>?DS&647+(,P44, MT.A6I)""R,M;:,.NL1.@&A:58I&RU=T]KF]$[1A:[U(_7*.E8@V!D:C,/N7E M8J(8>1J;P\R-ICKNO*#F)Q5:[!@0YXHKN4@#N".=_\QKN%<'DMK?YOQ83FMLG[=.ZC/0M&-4/)\^TWQ,#FQXU,XL5=LB#7A.,WR21%,\T4 M-L6WLCWF23Z.+[ZW]M6>#+&;;/10DT$Q(K?$0#K/:AK8C'LZAL']("W^%' MM(ZKA*Y(-,JAOR8.SG&WW8'I?AG^T&$X0]6=2PRAD/+_(D"J/4',X,.BX>"B M[R((N*9@AQ:"-@PR6\FBZY]BORU?YKSU MTEJYY@',!4\9)19S[7<[+U[0((!8X3^7?"YG86[`LB&QJ\:7;4"8/'K)6R\K MK0;H1?(AS58YFQ'.RAA,)KS5LA:1W,Q5%(=>+N$DB)YFQ>V+(\M[5,RLM0O? MC9EJ672^AB%KMLPE#XQ,V!/=I%D>WV+S8(WD-QT)*Q*_B4PT'/HQC>\H7%`] MTD<9A@)RC<$_2*STX)3&2&8 M3<,D(UH[EC3B7U,B*.19V[)=._T!W4`GD879_0NM,!B!1UW&7;? M*Y,+`T1P^MLPIM:=&2S.QQ0Y(79@JXDSS8&A+A`T93<;RQ/.Z>#.%0BPNMD= MFEP)P9"Y[+/WOC\)5PCN6&G<1Q7Y@"^P31(0N*.(QQ1X'BNY9L="Y:CQ17EZ M-U,B(>E0/5?2,TU7T[P=[U(0H#)Y2E_&X*R9SEPBFQ5Y$4%:XA_=P7HB2ZVH M:IHCBD?WSN(74N4Z%15UM7H&'9^1U9"':S0G/$*63'XR(D::PE!'%H)&(T\V MLSZ17!;S($Q>*\L0$.$HPKV0![J`I9R%89THY9WH+U(M.KY,LJ'SA_2#.31H M;\V8IE`KZEL\J]7EZ33%:=2C8$-)776X6*^/^.B=DQ_'V$,,C-7BELC?Q7:+ M]NK'&3N5W_58CU[`/X$=F/;P?PQ]BM]EN;3KT$T!:OT*RRGIF\LQJ%NQ((DB M0$\-<@"7;($X$#`1I*S)Q8?O+RYZ5S^J8#;LOQWH4$%O<$T=_N3R/6<,**R^ MHZV;`P>NZ>SJ[-PZO"\XB7!VU;+K`X$S![O1?^RH15VG;$"@N:=5RKLVXUCI MUUD'"\)QP^)-\7QUQD1X7?KI`R/IC)),!]18EHDQJ@`U%9S&Q*UEP5%;24G% M9&)`)F6H+7.]OW0"IXJA,.7L^%:RN"> MT"T7RZ.>&VB#*[,JE/H1S;*N+V"MJ>%X/[FQ6E,@Z/4$=!KCA5&W)R+I#D"7 M??'AHBA6P<^-@OB!HO(D2_0HAH[KE_X98LX+^GLM?8P]?/D`2FX+>!I(CB6O M"$2@01!0[^SCQ4+`A>N!-H?(_"<5[-L%EE@KJ[I8J_2ZQZKQ+Q:G4JPPHPGW M<&,CJR/*UC%),91K;W&Q+_.,'^I`:06"5@)';T^H]+JFO+726=V1M8@4JBE3 M>8OQHC-.TX6@&Y9-%6:(I6M)$H(R[9)B^<+E=2(R54PH,L;RL&3N5, MO>K7.M?%Y=-VY[H&H2QHJRL4%FG9>M7I@I\J^]";6_N=[J%KU1;`08KEZ=G> MA#2:G/[;QL&S/C7QP=O^Z_.SJ#<<>GZDD@O@LJ]N,&,),3M/V4CPK-?!1Y,D2<7*!;9O'7!P M`<*395FITE`O,B-E)S+8I4JXH5MT(&R`21-0&^(V/[2ASP#T7K&,J2I^SG;6 M/PI]R?H6.L;;S+,N4P MD/]'Y+E;BO.^6>3`F%MJKO!ZJ^L/[I`\64D! M7_LFN5FLU#`!X&=NHT.*9H74YK"_2C\$)E;MOR\C;$3H?+SKC*D\YO\-Q&$- M(E`D[H+/-P$-#;>Q`63T6U"5U?JUO+M'%Z3.\D;P24BCL#TP=S2:.8$%#+D+ M7DN.?H8FTR)E[0(^V&2$=JRI)Y66X4%$ZU`"P`C-.2!G[@.\R/[&*I$9$H]2 MXC5#%1>/KU5X0SQ%D:UNY\"?:]LNG9JDR[#/&HHI`U518[D889G/66*@"1A8 M45!#&@/0AGF'.6KYP6)YKVY(@OZ]R5']TUW3X:M7I2X?.@37:@C_+#1:SJ'E MCZ[.?C@;O#^+KLY.+DFC=?JD%;9=@]42(YB89#.B6=]9XUOB+&HA:%%+L"0I MIY`H%CM@I^)L:@%7&3XQW$3Y87">WEA9ATP-NP-L"LVCXKWK?A>/#P*JXZ,?[VF,U(HI-"Y(9G6Z842SH0;1!L(V_2L6DBNL MQ^M]'6VGSW'5RM$6OA>G"""(S53T^H9G>,CR8M^56B'&MC+I%M99D7;IM%H$ M\89E9WXEL09O,F6T:32/-H+I9H^N69S7A%\NE'Z#YSB\9CO]\)Q5V\2AE&A4 MT@9`"=Q'A`9A@,*@2%Q&X:M'.7U3-/*"K:E MEJ[RJ(.4A-D2PL_,:I6#M<3U3:]_%=')C<2"_/BF9%JH^X/A]=5[.TG53$O. MK)M)@?*_$-S(>=GM%ZW6D3&9(DM^TQN^)G\YB8[QM]$;M03^H'.\Q/M6HW`( MKP6G9;K.R3ZVD4&M&%%7I'O;Z[W;=R9=0? M^S";E";+S]'`FZA=H((HX7^6']7'[,<`$@+`9BKK2G2S M^R*267[9*^>:*(QS>PMI#G9!S8:\0GA0A5KB&]5%*NBWIS?"`,!2H;B8CI2C M)>J3,C9)/!S=[U-2?9P0^)//Z:P528Y455$!4U!S&G\B>?:],SXLSRA&+NRD M2M7WZAQ=\\G5K/VL&;%U`M+8/DT.V+8;ENVZZB;*?BWY\0[?Y,)' M<2^)T'(.YQHGZB+A_S/ZXPH.,EODG74-46:N=AI&:2/>H8P9Y@"3F)*,J7'3^V@;P\/,!+SQ"*,LIM,O3)LBG-'U!348!$&'4?8)5JDQ@,'%&Q@!:3?FS M*2)O2B/&?'4DTI7DZ.C4FJE].5#74<:6M_9QVI:M6B%N.52453=Y2C#'/1Y+ M=U-)2=&<.,4=/BEN0K%/:E>V&+-GZ''Q#.I1I4%U]T\GXTTRBKU1%D<<.()I MLH527:.GP)T=\#R#I!6W\04@ED:O+'&C!)1;DDY4(?46%^V6@QU*3C0O<"+X MW=E@N/:$DA@9-*X@M%RRP>4T<@E_D6I0HG-&H0W)."5GU;)COKF$IE'SQ7X@ M5,"=^)/;1Q=P)G3'T<.0P#-F&]-Q-Z)DSS_D\#EU`'D-+TP5]LJ)N]DM\[!N MY]IQO%N"+[R*[E)[CGQ0Y%*MG/\#GR%50L\]5>MT-K0]],,@E:Y(8(M_;*&X M-1:JD`@2KENE.80"RW7!U\IZ$"%I?55*WW5IC:>WFK*)2IS&VS&#->,;NG@C ML2PR&.U74+"8I0`?*;$8E/EPK(IB7W:/G4T+/`_E$MC@]NZ(L9;Q=`=@? MC7=-(PJ!]W/*BE=H;9FOBUUE2SW+BB!`+UE[$0*B=<$-Q`N.B)W\PY^@*0NC M`+XKZ[TLJ`S7&/\VH?S#)NML$PA"CY::7."@*DJ&CM1X*&$@WF!R1M*?`O_] M/RMRCF!6E5$/ZO`_T$Y%*ZD9LTG;,ZZ7HX:BEG8?:%Z@,DJ!4ZZ-(#8V!;?X MFP=#UE<[<#,Q#Q7&X"DV:HUO&MZQT>U;G'7NK*Z_P@-:;;9QP4P!X-A$@W4G"68M0U]R$Z$04-Y41$Q3KE7\U1VN23VHGE++6`51O8IU1".2S M]=7_=*498GQ#FQ^W*:^C4@-(P.,>M/>#;A[`)]T[VJ]NN&9:96>A^I:J*QJ@[K547+E[:MO7(_1 M:-U!YT*SK5=6NVG1CG6X?.*7KT+ZYZ7)EL$5<_6;ZUIBB,OUH9B/00S9+0-` M;69"N9Z4V-\_@B`Z;-/W\M3VQEA;76SDP5ZWM;]?R\O#%B_KG.,B0)E'OP_A M.M6Z;27=+(HT)2CLVI+,\./Z_=E]>4*V'T[S583D4$?9PX-]BR*SA3K8:\W= M#D[0FAY[M:@;<35BYYB[Z;K'^\YS6-Q4V9:QIZ:^XGE<<%URZ-OU7^U1TWC5 MK8Q3>T^<161#PV70.$O\=N..25^4R@8^UR=8Q,G^` MDX^_7)`47AYW0C.1]Q1K=*W&E(H"6R08>'G8.7IAROP@-Y'?.XX1Z(Z&8A4. M\'.,[1QPHN'ET9Z+XH+;,>_R*YC[\ILYZQQ@F[^&Y@G!9A&.>L)['Q0YAPE#3VA\<2B MZPH+?9I51.,^I?>QAY:G1)CRD]9L_?[_P:$K_2RS#8\)3>,2&6?!^&9V@-^7@X'"37B`9,@A>-@P%D405SLP9 M_IH/V^J^M-JWVZC+S32=W=(J?RZERQ/`T4G0O6U?I/82B>`-_G-T$A7''&)W>4; M.KCIS(X&EW0"1^]Z/_9H)&P^;''=$?6N+WGI&CDT`BZB$ZHTQ0V(*,2ENY39 M6@S4*UF4^MD`D'6XE'1_3`6R@?ON[7O=PT=:S\ATI3LA>#CY1$K& M7C?MU#UED;<@FPJL[,_64[:4"F]:<7.]TE)NN==*G5B?&+ZN(\<.1Z&J)UC* M;SJ`+!*5.N$E2R7+$#&J2>Y.IQ(.99-;+RQ8UJ./ANA&*-,(<\8"*XJ%U.PA MNE=?3`U5WMI_Z;K49("W]OW9/;:'SWV*1-1[MVQ13.BP,`K)UENWJK/ME1,$OL\7B\5/3K3DL*9BT4YT>?W]V=6WC6[> M@43D!0>!JOJXZ>$WZOVX'"TS79I-:X_ZP[IH3M3#4H#2OK!/N+)!W`IRX>UK M*YDWZ['%N7CCKX54STXJ&;]6EC_CJL-;7VK=`@6V9Z4R(';N'GM2X^:*.D7D M:3V'U4=#^.QO_':J19_N^H'KVW+B+K"M$"IIN+CBA,D?;/$[=<+GA-S3HA5R M@R$HUD7O968=.)ZGGU3XTD][%+TVA=.`&`9]BCCN98^2F((7D?*+E[\1W4R_ M:F6?"F-:BZ%K'6+JB8#MNIW8T.P0_:28L[K162\QG8AHDJ'6Q:P5)9+B$JT? M=HW+&E,D"H`&@EWPS(X4KWGS<-.;@87(GF-?^V6)")(?\L\**"/6+($41!Y+#*N@JAHCM"*Z#H4;3]+`1DSS@==PWG*E(0KNGS MMMMX&DQ8$1RNC4TW721:V'ISO?NOG+7W+9Z0USP>!\H0*$O%C!UFB1MN,G#4 M4X^0O7Z38"$,#ZP3N+!Z`VH@947`RO[DK0UKQ3.7W8MA4IVCOVN MMT']W76K1EA?F)[3_T_IS']36R'&T=HCO6S*A@@S%N1G5Z-9,0+YA5U;W5=V M%L&Q-!"I7,/^D>NHEQRN!4T?K^MH;B;S-N26YK/LH[@*)U;^ZK&OHWUWGQS1 MP?2;Z$,VH>C$;WK0:^CBS*A[_T:][4LJ<;B,U<(C4(7C#9XP.&!\KD`RGO9> MWCH9B0P+K7'054B&PZETM!7.,&**!577](8AW&" MA#&&\S;631M:,%V(^B$=04=Z/WSE>H;5.>,3)&\NVPRU>R7D\^`Z@MK=P^A= M,U*QR)5R2LR);*-"!3R/^LN.E!8N%+5SRWO8[=NR6LXQG<,_>4)U#\]"J%$7;'Z-A3\=C]3,X[U_O<$$!;5K\^^W5F5T&_NVZ)/PE!QG5=UIXN1JA:QL#=40DGD+,@]*:[.OB[O2SGA\LA=>:5` M,SJ=6SL;B%>QHX'TS/GK$(4*%L>XS(N6!T#L[).N.@W>O'E5`;+`;.5:).-\ MX/OEE7K2V3-2#U3D3P37'A_I9*H<57BH*,KYNKJT+UA/J:6M[[P\9WE.BSAQ M*.(0VG**$W%=\Y0W)H% M]L-%*;]^]H$$0D*0+H7R!WFIKQ?B86MG/>YTK-LY*)8ZP67"D^YVP?*(4.C*(&DI5V&^-?;YP5):4,9Q8$\.!%=;[ M]HIR^1Y1\^NP9B1W;YRQ`FJTAT2>B?9@S\AZ5[2QL;M4O'*# M50EK<5>ED#G<1U-6<+BG`2)(P@QQUBM9YK$/1"OEIIR'5% MV16>^,-@FM6M,1S[7/27D1*X[!*Y5M<=6Q/M#&OQ)N M"JLL!RM4$$IL;"L&PMQ4?,A085IKYV_X7@M^>CA05S'U56'9MW;V=FSS6]U* MZ%=$>M:^ZB$*=N&IZ?;M/_9ZVI))!\6;%2FJ9U#!Y2\K%5EM_77#Z!E3^*WR MYHH^FQ)3;NC@9H6")!^(^ZG`5Y=RA-@?6Z1-!F1BEOE-C:J4&68"(>1X?[ M#H^N-6XV/I05J\$_1MG0@3;VAY*4%!AKBWU'VR\"V.W0;]<;J'X0)9G/N5$: ME-?#X1N>D$G>=DW*'O(VCWH@6\%`B]QNJY:*]C`>`ILL?W5M<2(M79C5;]1^ M*7?$-R']U]\3&BN13(;I'M=7I&_KZY:E*MZ_6'-SL,=9U'J?H]]$_-CW,>V1 M_.DTP,M[0:GG+3WOU[K-&AA+(]QS[L&R^"!RH>E*Q5Q^]D(MM?H^Q'GE&V6L MI2UYI>!W(:NW1+0CP<]@7>I3=X?)K&H@/ML2)PU MH^F?U8TJEHB!9;CKP0VT/OBF^L5IX]C,AF]=]>K088QA7-.*$8B%NA`(*R8Q MOZ]A5ZUJZXY2GK6(@XJZQ6QNO*,2F/REYE=::[FTIK2-SPU>*.VQ)T+%ZC83 M"J[EN7:_.U0F'9:.7+R_?D]3Y=NS`;]!>!YQ7YI^2:E]41K5P(@3!;]V'/*2 MHC5$MSVHPM!P-O6T9.W/]4@,+JSH';WE;AFN6HJN",CB'&5Q=<-UKU$Z?#BW M"3%RK3)<-;3*R%<<.#2S-5#]BEIYU2Z7;7D2#>DN-S4K@C`"WO0/N#UOO"<"DDL"-.[ MZVCCIF^H9U$S$P9L3Z@I7NV:Q<^$:X7.9ND@)"$?5DJ[\*LV3VKKK?0$H"_N M]R<(R,DA<62DD6A.S6%B)_A5!QO2F+9ITYW*:[(,#FX-(%TP+5MVWY59"HV& M7>$:$Z"M2D6U:MG748CC]@(U@Z-FXU^Q$>44=[BP6E77*,"5X]PK`+5$(L$W MK3/_'DQ2@46[(X*S0BK@LWVMT=549"]:5LKL56Z*DMYTQW#Y\8`#%23JYA3)P/-KAGA(` MP$@2+U)56RF]N4F>U MG5O*7KK9WR:H:$OA%?5%18Y]8!<&6B>RU>.8>OMQD7119]`:02+%%6RDV6IW MI$*FH]WEZ>:0YQ6#*^A$K<-Y>#$2O^@/]1!8T[_SZL#TT0CACDFMV;7S>2&Y MR3,X( MMP)#,,]PKT_]B`A9M$QT7#%S2^H>`# M99O^8DXBXJ\Q#Z6"QK&`DMB^R;@5WORJ6V&C[7?\9C(WR>>M'YX=KJ9371UR M24&LY@VHS>_;MU`VGVA=NMA\ M8,T%/\U'?MVMM_QV._>>I]PE,5##KL"PC;]9?6+G^HOK)3==+=E<(&1>>^=? M\[G6W5K3L?UVC@',T7^_,!C\?S3?J@"]ZR_4<^\U7UMWMNA+:#'4D;[9(&Q_LN.MVFL^?E"#,)CX&I7MG>>NFIQYL'?X2_H&F$=>$%F*DWZKM[^+/ M!ORT=**YH;[E-P1*H9(G8LUL#*)6C=%\`RVP-M"B!EC)!1Y\<;"NA?-+MMJ: M><,*FWMJ[H#(WET@42LE/KCV]YMJ>]+^%1!$H5^8__Y_7"SL"TN<)G@G)5D M8[\1;M]N/W]:'UC]Q#-"A`4.)=_8F1#5RG%XG)$"\PFK2`DC*:L++."RWCN\ MJ@E.FIN*W/%<=^X4F):VMR7K,:['-;]BF8X/GHW%QW[@L8UXRP5 M$[!S%&AWS4MGZ8#3=IU06($,NU63=&/?H56$%K:S73<^=O*FY%=0<D3ATJ"4,/F3HSAZ.*P!C4?`R7%!I11N:&2M/%: M>+[GZ]31@$`#"\:`2;$!9M1/J"2^"I;!U#^FX3S=CHW^WBK:3?BK)O0 M`8&.)AOOU96/5)O6T(Q\A:VFO_8O#.I(HYH\ZG;YP*CNL-5<0%(&YJ".-*JY MRT.6L2,#HWV'K0:*6YXA>AZ(`P(=;52+1]T>'Y@]OM6HVEHVW:*GOLX;?5>D M(XYJ]JC;[0.SV[<:A>BCQ318N%.CLT2&:&Z(=,11#P`XM7<2;#X!6LT'B,KH M*.I'5`=\=72M\)[\P/6>EMS*20H'/7<20+G5ZGBO+@2KFB/JC@DXEC=?,_@; M1N"\YTY`G#(FCA?R#\3IC]WV/P```/__`P!02P,$%``&``@````A`+.XX]`Q M!0``Q18``!@```!X;"]W;W)K&_`YI(0)3DZ3=69(\V11J.Y/%/B)*@!1T!O_WZVV4[J;0B%EZ8A'YO% MLKTV>/7MO3@YKZ*J4F=SEY6'M_O/WX]W"=>HF+7?I299B[7Z( MVOVV^?67U9NLGNNC$(T#%!K=?#J MD>:EBQ66U9@:ZD;6?R'$-.EL`C71>!3%V%\"*_/J9K(;`F5E3T!F-QO#_BBSOFN3FI/ M!;J&,7W=\&#EO<(P9!JY[T$HL>TAPBOB@;RK1K#-U#BL3<%K-W2=3VW1M6PK M_QX1'&UU/UOC`+DP&#+^P@H&\\P+Q]:%$4E:QY(HBGW?I\36)'C$%R9!I,$- MCI>F8$O:G%[X'I'Y@#23&)0&ZV*\-`5;TA:6-$10&J2G;=G-GXE?\111"K9$ M)98H1"ZBPJXL$V`A`8BP.14V;@&JDZC`P++E'A$4&"D:3,$$Q`U8R1J.81:HX5YN/F.\.$-L,UL,-5,VA2&)))@\-'"4[F'16I8MB8\"-% M8G@3D7;,,F3T2";F&&F-MP$J<5(#8-T.$-@QJQGM7P32K$C9#A%4G,IDP[\O M9A@F./'-CEOUR`:+%\4M$C)TVK@!@HJ;U`I8MQ>$EB_WFM&#NF`]38HB\X29 M[E)Y5D/XPCL,<1C>:XB'GR&NT^,2].KIMGW>8<81>O%)2<^Z41_:4:\9[4V\ M(#>NU9AISV+:#ZB\27G/NH$?VH&OF4%Y9NH/RN.3@K^E:?"'=O!K!N4%84)" M'=VS$)_D'G&/3\K]EJ:Y']JYKQDC]\TC].(]N3^')3L\O7DW]T,[]S6CA]"/ M>GKC($)EJO@=G5PU1^C%K4Q7;6>$1]UL#^ULY\B`W]>8 M,)[U]$0:9*A0E;6&2TIH_.5;HWI+M1[`0COG-3,L%.O<8*A0*^M'"NUF?F1G M/D?FA@CMZ"!#A5JI/U(HYKC9.2,[_3DRN#RBOB='BR"]E8J^%(H#3EVF$B?UB`#W<,C\LWN$9K2#@1^3!H4+ MA3!WBX#,`JJOIXVH^_O"RFX;B>PV`IN0*IUP<^;&.Q9A^M^Q<",2M]C.Z4'\ M3*M#7M;.2>PA)/V9RO,*MR'Q2R//[5;:DVQ@^[#]]PC;Q0+VI?P9P'LIF\L7 MM=%YW8#>_`\``/__`P!02P,$%``&``@````A`*3LN>[*`P``F@P``!@```!X M;"]W;W)K5\\8Z4?(F M=HD7N`YK,IZ7S25V__KS9?7)=82D34XKWK#8_6#"_7SZ\8?CG7>OXLJ8=("A M$;%[E;(]^+[(KJRFPN,M:^!.P;N:2KCL+KYH.T9S]5!=^6$0;/V:EHVK&0[= M$@Y>%&7&GGEVJUDC-4G'*BI!O[B6K1C8ZFP)74V[UUN[RGC=`L6YK$KYH4A= MI\X.7RX-[^BY@GV_DS7-!FYU,:.ORZSC@A?2`SI?"YWO>>_O?6`Z'?,2=H"V M.QTK8O>)'%*R=?W341GT=\GN8O+;$5=^_ZDK\U_*AH';D"=)SW^PBF62Y9`Y MU\&,G#E_Q4>_P%(`080"8!#Q[Q#F*<0H_AAF^GL(^:+2]EOGY*R@MTK^SN\_ ML_)RE1!I`S:@&X?\XYF)#-(`L;QP@ZP9KX`"/IVZQ'H"&^F[5E?F\AJ[T=;; M[(*(`-PY,R%?2J1TG>PF)*__T2#24VF2L">![[N^'^Z\'0GVT6XY2=23P'=/ M0HA'UL'V^T)\O2GEUS.5]'3L^-V!:@79HJ58^^0`O-\V!=Q`[!."8Q>Z"?8K M(#-OI^#HOX'W68](-`(^1P0Q$>F`P/2!AE$(.+-<"()1"&8+E25Z81HWM.)J M1*A4KT,2KK+;:&35NC1"EQ4*32<+1EP@61X7P5"&D[A? M=Z/C:@24UIB'C:DL'1!V'N"9Y4(0;`K9FF$2C=@HVZ'<]R2R$S,@;"';1X0@ MV!2RLX1H!`0;'?ED(M(!80O9/2($P::0O1DFT8AM7XC!WDI=JN^KDC$J!%]B MBSL5P:8,8K>JAFA#SM]JYG1`V(;L'U&"8$N)-1(2#<$:*4ZK%0E7$2`*'"\K M8KF7#EA;$X&7R=0>G/(1K'UGH.%3ECJK/A/%'+O3RB%6FZ-3:SR2'K,_\O1//,:(@]-686VW+'&2-)C##G6#$A'S,P=G(;+W=&STW#' M[G*B,88N3GS[)U*R[L)15E7`R?L.3'`%7Q]7Q:/JDSXSC#3CDM?3"?J7=I6R$4[$" M'@T\/)!U^IBH+R1OU3GIS"4<[]3/*_P'8/`Z#SP`%YS+X0*]&O]5G/X#``#_ M_P,`4$L#!!0`!@`(````(0"!;YD3M0(``'X'```9````>&PO=V]R:W-H965T MGATP MP0I@9#N;W;_OV,X%DW2;OF`,9X[/G!F&V?UK7:$7)A47S1Q'08@1:S*1\V8S MQS]_/-U-,%*:-CFM1,/F^(TI?+_X^&&V%W*K2L8T`H9&S7&I=3LE1&4EJZD* M1,L:>%,(65,-6[DAJI6,YC:HKD@Q39KF:-=B22 M552#?E7R5AW9ZNP6NIK*[:Z]RT3=`L6:5UR_65*,ZFSZO&F$I.L*\GZ-AC0[ M<>J5+L/TF>?^$-`[.A3*8`:R&V!OJY[KTJ'\[4'2@LKB#.)`3TG42";UV1UVMW%&?`4"6,.N)&_M%+ATFM]#0* M)V$8^HA5%Q%'0P"<$9XV..AV;0;">HK3$[\5L#28=S78OIAU7G@*8!&NMT;`^Z?W/?&89PW MPS3MINZ\\0#CI`OPE(U]9;=Y8X+Z"B<];QRFXTWG@:<@\16\7Q4#[I_<]\9A M7$_'43=S9XWW'E[WN\:-4#<<6KIA7ZG<\$:ABA70.6&0@+?2#5"WT:*U0V`M M-`P^>UO"?XY!1X0!@`LA]'%C1O3IS[GX`P``__\#`%!+`P04``8`"````"$` M5&<[T%$"```L!0``&0```'AL+W=OZAI2>P-+G M^?MWLX,V6UL".((,M4UIZ5PS92X%K+38*:A=(#%0<8?UVU(V]L*FQ"-TBIOMKGD26C5( ML9&5=*>6E!(EIB]%K0W?5*C[&`^XN'"WBSMZ)8715N&=@0?FS?!YFY,J4).F,#UJVEIZ)$[*S3ZEWQ2=7WI`Y8-KI_J$'HV[U>&L,XVC\5W=H*DN$WGE'QCBO;K>[+(ND]7MW@&9M>`&OW!2R MMJ2"'$-[K0H3[!X63C>M=S;:H5W;SQ+_2H"CZ44H.=?:71;^0G7_N?EO```` M__\#`%!+`P04``8`"````"$`(T$WOCL%``!*%@``&````'AL+W=OG MN>-4R9'F<35F)UK`G3TK\[B&R_+@5*>2QCLQ*<\U/QT'H^@3@UI96]4O*0]I6\E;5+/^%(+&B M)H@G@_C`7M[WA@9QD)!8WW-6BDL MD0=YXE&6-E0[+**"]+RO(G_AO(.BB82LVQ"B(S87!$\$L&LHPKI5BMV:7YAP M,&?"<\"IK7$`8C?4/..Y;40X;2`:$Q!(9<+%\J&6^AGQ24M[HA"()DUXY(@0 M+!Q.>J,,:`0@BDJ@_\$<#`35!P?&@Q$2B8P1/_`FKNOJD(T*&1&H5Q6BD8-* M5LEQ=28W]\@E7WR2H"GWB=:`6KT(IU>OVX<;-"*#%H(05I!1T:U^R#: M=5]HM`CL_\=E$[/TLH?$&`PE2"E\=41GP7NGDKQ^=0AV6K4S$/=:KKCK).A& M26-I28S<&80G][H(G>!#39Q@2]8)&FU[+4']!#&0++[;['B_5>0;UM@)GZ57 MF6_V+HE!`IZV^:2$&$1*.-$*45?0Z/T#.;9-@+@M:T80<@B)V[%)B0H9A2Z\ M?][*-._.CVO)9YD;PK1)_L8%('5#*".Z6H87W-D0;1,`%Q8>: M/FEW?>*:;B1!-S20>51[O^_[:J8U?MZ7FK^896;3M"<)ZN4I,;AOR62FE:1. MU/"'8K?'<-MPWO(-@3::#3$M`T)ZF,PS., M8V`;Z3`08AJ(",U?0CI-5!:^:B!$MV*MXO@'UN-U+V:9>34-1()Z>4J,;#7D M]DL=G*VU>-[/JIAE\/2NC1_]0X+P#*+[XUI";BP%!<6C.SS:RFEYH!N:9965 ML#=^+.?!MWLSVAP9/GG\F,@87\-1HCAWTJ*R,KJ'D.XX M!$(EG@7B1,]8?;G@AUS-*?#J?P```/__ M`P!02P,$%``&``@````A`,*PI.:J`@``Y@8``!@```!X;"]W;W)K><\^U?5E?/\D&/7)MA&IS'$_ M?MY=K#`REK8%;53+<_S,#;[>?/RP/BC]8&K.+0*&UN2XMK;+"#&LYI*:2'6\ MA2^ETI):>-45,9WFM/!)LB');+8DDHH6!X9,OX=#E:5@_%:QO>2M#22:-]1" M_:86G3FR2?8>.DGUP[Z[8$IV0+$3C;#/GA0CR;+[JE6:[AKP_10O*#MR^Y<3 M>BF85D:5-@(Z$@H]]7Q%K@@P;=:%``>N[4CS,L?;.+M98;)9^_[\%OQ@1L_( MU.KP68OBJV@Y-!N6R2W`3JD'![TO7`B2R4GVG5^`[QH5O*3[QOY0AR]<5+6% MU4[!D/.5%<^WW#!H*-!$2>J8F&J@`+@B*=S.@(;0)W\_B,+6.9X#-O1..$R.V-U;)/P$5]UR!)>E9X'YD64;IY6P>_YN$A(J\P5MJZ6:MU0'! MI@%)TU&W!>,,B-]V!%8<=NO`.89-#;4:6(7'39S$:_((K6,]YB9@X/J"&1`$ M1`=E4'N_L@,[9==;5\I-"(QEDK=EYO\CX\`Y7HR+3UYX@W+`^&6>^(&LL1^W M1Y(K")YOJ MQLNUG/)Z>PLH^[R`RYH*])&IE_1M+Y=3S?-2#CR5ZB.G7MQ8'FUZYR6-HTOP M?E["Y4TE^LC4S?*5FS!7PK&37%?\$V\:@YC:NYF1P$$:HL,XV_JJ7\<7V=:? M`3)\@#'3T8I_H[H2K4$-+X%RYKWH,*C"BU4=5`ZS1EF8+_ZQAO\)A[,TB\!X MJ90]OKA1./RA-G\!``#__P,`4$L#!!0`!@`(````(0`.,WOQ00,``*\*```8 M````>&PO=V]R:W-H965T&ULE%;);MLP$+T7Z#\(O$>KE]BP M'#@-T@9H@:+H%\T:X MH*R*4>#ZR"%5PE):;6+TY_?SW3URA,15B@M6D1A]$($>EI\_+7:,OXJ<$.D` M0R5BE$M9SSU/)#DIL7!932IXDS%>8@F/?..)FA."9=(%.L\DVO<\\V8>,"T7*04'JNP. M)UF,5L'\,;A'WG*A"_27DIWH_'=$SG9?.4V_TXI`M:%/J@-KQEX5]"55(5CL M]58_ZP[\Y$Y*,KPMY"^V^T;H)I?0[C$X4L;FZ<<3$0E4%&C<<*R8$E9``O#K ME%1M#:@(?H]1",(TE7F,HHD[GOI1`'!G381\IHH2.*A?>M&2/:@,!U!S1K058BH-A-Y'Q+%5BK MMY5M(J'>-MV&36S>JPVJ=;9$$['<1/ZPFZFM>MZ-`MM23:3O1DW5SL97;D;^ MS(74SDNH=;9$$['=!,-N9K;J>2D%MJ6:2-]-`-/HV$X8Z4%RP8]>::OL0[:C MPSFP=EN@#GRGD.+(8$OJZ^V9<:8W#_`UO/:J^;R/P`` M`/__`P!02P,$%``&``@````A`(:[TTF!!```31$``!D```!X;"]W;W)K&ULE%A;CZLV$'ZOU/^`>#\!<\LF"CG:[6K;([525?7R MS(*3H`4<8;+9_?>=L;G9F)!]B1(S,]]\,^//.+OO'V5AO=.:YZR*;;)R;8M6 M*<-\[&@4C[798#`RR[ M5=-#;#^2[9-/;&>_$P7Z-Z=7/OIN\1.[_EKGV>]Y1:':T"?LP"MC;VCZ(\,E M<'8FWB^B`W_65D8/R:5H_F+7WVA^/#70[A`8(;%M]OE,>0H5A3`K+\1(*2L@ M`?BTRAQ'`RJ2?,2V!\!YUIQBVX]6X=KU"9A;KY0W+SF&M*WTPAM6_B>-!"-' MQA*I/2=-LM_5[&I!O\&:GQ.<'K*%P)B3#\QDA#[+N20A.PSRB%%B&P85W#E4 M]GU/-@\[YQVJD;8V3](&/@>;WL*!;/J4((UQ2N;R=,AHC,A8+DSE22Z,83PS MC*_"=,QOPZ%3;`=C$IM-'U]F(&U$!Q5>X#7FA8#K-;9Z9@(ZBN@'71EC^CJF MM"%`?JANX/:)*7D`H)X'V8#G;>;HI68!\M$#2.;21LMBIOS1-(L-#-[M)-!) M3X)H24@;+8F@-U)*L5:3N`V.QK!-QHWPW(&=+$%KI#8B,J.CL(_VWFUT-!;H M_:2W*YX0G?$&VJAQ<=`\7XC*0GG14<5H5U0Z:S,=`NV[GX^P5L&ZI2DC@N(Q M*I6@%$`G;M=,N&D8K0RIC`:M4L8#AV@,NX"&UAI:NV1@A"JA,WH@=\@!#J`. MTRZII`:-4$D9="@*5HLR1%J-`:Q>8SS7[V=!SG]GI:02#GM43463HH7ZMO+B M#V*/QR?6PE!?@[Z0`)J_@-&JQQC#)"CAL.]51IJBB$&-'NZHKD%=2#BIKDE> MPAEQ(U_2%V&M3>^LPA"3Q$3W#.]48D0LT<-AKD@8]G.EU-?[DL8(:Y53MS2= M&,^@,!IRG,`J=>5_J3302`!`Q-TA3C[I88\+ZD#L):&XE9=?`,ZG"']@HW#:.5"Z5%T?#: MJ6@#WEO&6PEG(W`W*^C%[5(*1_6UDD3#D=6^U6-TT;^13$4SQP!<(R>I>&%X MQ]X3GGHN^C'0&JGON)%^#,B+J+SME;0^TE]H47`K91>\9`9P3>M7^POPH]AR M^OIZ^PAO'3!G^@,2P)/(^`1\H*'@X_1.<)D])T?Z1U(?\XI;!3U`'JXH2BVO MP_)'P\Y0:+C2L@:NL>+K"?ZVH'"]<_$D/3#6=#\0H/\C9/\_````__\#`%!+ M`P04``8`"````"$`[+S5+E<%``!A&0``&````'AL+W=O]355YP;YA^05!4U^E3U75<-)OOGT7NO+.JSGBY=?W9W'58F?)]5AZW[C]_ MOWQ[<)VZ2G)U8D M]8R?60G?''A5)`U\K(Y>?:Y8LJ=%1>X%\_G"*Y*L=-L(Z^J>&/QPR%+VS--+ MP4%V<(\9KE6?-%05VG2-<_CB6O MDM<<>'_Z49+VL>F#$K[(THK7_-#,()S7;E3EO/)6'D3:;?89,,"T.Q4[;-U' M?_T41ZZWVU""_LW81SUZ[]0G_O%KE>U_STH&V88Z805>.7]#UQ][-,%B3UG] M0A7XLW+V[)!<\N8O_O$;RXZG!LH=`R,DMMY_/;,ZA8Q"F%D08Z24Y[`!>'6* M#(\&9"3YW+H!`&?[YK1UP\4L7LY#']R=5U8W+QF&=)WT4C>\^*]U\FE3;2S: MVG/2)+M-Q3\O"087E-63V M?>>'RXWW#ME(.Y^GU@=>KSZ#AP>[&;8$VQAO29^>'AF=$1G3A5MY:@UCF$`/ M$]K`H//6C<:;#ZYQ6^36ARHG\(%5]_-!9Z@%Q+JF*7P8&+1(G1-0'3FM!BCH3.A#.CM+0(=H7*6%&!=^%\^=C7=Z>.O"6T3A@TC&`#%J'16PK=F40BH;XNV',6:&VW MPZ*A52@`;$!#1)(`+,T*RC51F4$+KA"ZSH\B`R&KULI-(ZOI`%P0@L!(`\I;0C`(08/^.M`7[)HB@\VZ?-UHF86`D MY;Q=GZLB(RLE"%0EZ$V:,FF4('CP[WAN!JH:]":Q3(8Y`)_,XUQ.I%!5`PI` M*00Y$O-EI0:!J@:]22`2&T:`P$H-R%LZ"\8I()#4`,_;(II!+B:RI>H"A9(/ M7&P8"0(K72!OB9)Q*L!A?EQVF@HBZ+C;C&B9B-&;Q"(9IH+02A3(6T(SBD*( MK2R+PN*.#J*%$@K&`I/(R3`@A%:R0-X26J<4JBR$.EE8/$R?/%HHH>AFA-@P M(X16JD#>$EHG%!I.DBJ0>-]5)U4@PLXDULDP+H16`D'>$B>C0(0:@9@>Y&B5 M!-$IADC(,#:$5O)`WA*:41XBC3S$_FPY*7FT4$3I32(GP]2`$C3NXMMR1-X2 MFE$@(MC`.#0>O+M^FM)""05C@4GD9)@;<#(9`T]P4N<&"D!H\B,VT@@$%GH" M0IT9*)!"R#`S1%;J0-Y2^HSJ$&G4P9]^+M$R"4.G#0O#\!!9:0-Y2VA&;8@D M;9@HC3HR4`"Y-`O#R!!9:0)Y2T2,FA!K-"&:KV:0Y]N<:*&(TIN$_ED8AH;8 M2A/(6T(S:D(L:<($D:[K1S_N*8!2',.D$%L)`7E+1(R3`EQ0"QI#3]4XOD.Q M::4$HQL5%O*HT%YHM[?&!:N.[!>6Y[63\@M>5@=PW3M8AXOT1YH'9'NT?FPO MV+WA&[C@/B=']D=2';.R=G)V@)ASHE.U5^3MAX:?8>]PS\&PO=V]R:W-H965TJ(W=@K-1]2;,DI01ZH2O9-R7]]?/ZY)P2ZWA?\4[W4-('L/1B_?'#:J_- MK6T!'$&&WI:T=6XH&+.B!<5MH@?H\4NMC>(.CZ9A=C#`JW!)=2Q/TSE37/8T M,A3F/1RZKJ6`*RUV"GH720QTW*%_V\K!/K(I\1XZQWKT(#OAE10\UWG?NC]%Y!-Z[#;9YB0SZNH'J[`"BPHTB3YF6<2ND,#^"1* M^LG`@O#[DN8H+"O7EG0V3\X6Z2Q#.-F"==?24U(B=M9I]2>"LF`J<@5K5]SQ M]%O"WC@4.D:-&ULE%1; M;YLP&'V?M/]@^;T8R*4+"JF25=TJ;=(T[?+L&`-6,$:V<^F_WV<[(:1-J^X% MX8_C\YWS79C?'62#=EP;H=H<)U&,$6^9*D1;Y?CWKX>;3Q@92]N"-JKE.7[B M!M\M/GZ8[Y7>F)ISBX"A-3FNK>TR0@RKN:0F4AUOX4NIM*06CKHBIM.<%OZ2 M;$@:QU,BJ6AQ8,CT>SA460K&[Q7;2M[:0*)Y0RWH-[7HS(E-LO?02:HWV^Z& M*=D!Q5HTPCYY4HPDRQZK5FFZ;L#W(1E3=N+VAQ?T4C"MC"IM!'0D"'WI>49F M!)@6\T*``U=VI'F9XV62K::8+.:^/G\$WYO!.S*UVG_1HO@F6@[%AC:Y!JR5 MVCCH8^%"<)F\N/W@&_!#HX*7=-O8GVK_E8NJMM#M"1AROK+BZ9X;!@4%FBB= M.":F&A``3R2%FPPH"#WD.(7$HK!UCD?3:'(;CQ*`HS4W]D$X2HS8UE@E_P90 MXD4%+B_MGEJZF&NU1]!N0)N.NN%),B`^:0H,O#\6G9]Z0.6!\YR[\P*VA'U_B9!*]VOF3-711!^.X6[=YGB&+ET,W[F M)BQ8F&+)=<4_\Z8QB*FM6YX4QJ^/]GN]]*J?Q\?9TN\[Z3_`OG6TXM^IKD1K M4,-+H(RC6_"NP\:&@U4=*(>M4Q8VS;_6\&/E,(&QZVRIE#T=W#^A_U4O_@$` M`/__`P!02P,$%``&``@````A`%7XO2')`@``D@<``!D```!X;"]W;W)K&ULE%5;;YLP%'Z?M/]@^;WADCL*J=)5W2IMTC3M\NP8 M`U8!(]MIVG^_XG"R>?OKW]^&%S5/K!Y$)8`@R5B6EN;1UYGN&Y*)F9 MJ%I4\$NJ=,DL/.K,,[46+&D.E847^O["*YFLJ&.(]'LX5)I*+FX5/Y2BLHY$ MBX)9\&]R69N.K>3OH2N9?CC45UR5-5#L92'M!@L:4XVJLW3++MANMC@3F#6A3,[P]003$ MG2?'T+M\S22X0Y(=LL04+BKH&^CLXS98S3?>(W2#MY@;AX'/$Z9'>."FMP0V MAI8NMZ=31C`J8[O0RHTK#&7"RS+3_Y%!<$QG0_/AB=.#7,@RV> M^:O)\M71=]GP(,P%>$\M6RWZ-$ZU!4'L`6C9@T9.0''HY.W.(KA1[UO;5L+F M0@TGMACS8L+E$B_Q*W>["XCGQA)M99QF=3G->'!L49;&<=97XZS'LN^'0?!8ZFVM_@8U8LTQ\ M8SJ3E2&%2('3;Z:CW4YU#U;5X!WVHK*P"YNO.;S[!.P('[.G2MGN`;=V_S;= M_@4``/__`P!02P,$%``&``@````A`#RU)O:0!```R!```!@```!X;"]W;W)K M9'(@3CP$G[9BJI(:KBM=IX\5#S9J*0B]P+?#[TBR4JWJ1!5 MC]00VVV6\EBDQX*7=5.DXGE2`W^YSP[25"O21\H52?5Z/'Q.17&`$B]9GM4? MJJCK%>5>**GG)8=[O;)2DIK:ZZ94OLK024FSK`93S&J+].4^]J0>5%K-- M!C-`V9V*;^?NDD5QX+O>8J8$^I7QDR3?';D7IZ]5MODC*SFH#>N$*_`BQ"N& M?ML@!,E>+_M9K>[?8U+/<89H03BS8?,94.=!U>=%SR2-M)I<#5;L]?,6\D8)W6R MF%7BY$!OP@SE(<%.9Q$4-OHULVX5O28H*(E%EEAE[L)#!9I)Z(*W!0O',^\- M5B[5,:L+,7;$VD3@,F'9F``>\&U)@^#_`VFL@J3-<"L#=+,(SAB:"),2$\!B M"$M+&5YN1Z,>!L]=4+]3+S@;>=7$L$G+=MU#8HI8;*`T98.+'(P';9,^O,Q8 M!QH%QNF8AJ&MT4H'V#R5VA,,^FH1%"0R.WA6K3B%`3_[)04YOL M;:$PV&:H$=)1/22FB"44@]?+N5+_Z5E4A6QB!@(MNI::L%8$9:KK+LH\([$% MV731@LG"WM:*-88-!F%*KPQ$U.I#L079!-!A"0'U@AJIM_F=9Y`UWFR1T1!I M+A-UN[M,%/0S4;;S:)LR^C"A?$$U.(!@<$(3-9PDU=<]_&/`81/HX\.R%:(V M-T#*:_^#6/P#``#__P,`4$L#!!0`!@`(````(0#O-5)8>P(``!,&```9```` M>&PO=V]R:W-H965TV!7`$&7I; MTM:YH6#,BA84MXD>H,<_M3:*.UR:AMG!`*]"D.I8GJ8+IKCL:60HS#$+F;CN<"*T&I-C(3KK'0$J)$L5MTVO# M-QWZ?LCF7!RXP^(5O9+":*MKER`=BXF^]GS!+A@RK9:51`>^[,1`7=)U5EPM M*%LM0WU^2]C9R3>QK=Y]-K+Z*GO`8N,Q^0/8:'WGH;>5W\)@]BKZ)AS`=T,J MJ/FV04D[<-]Y68'$;QM!!QZ[]N"28B]CKA:+?[_*SK,EN\>*B3WF M*F+P^809$0Q%1V54.U[9@[VR+ZE/Y2IN3&7RMV5F_R/CP26=3Y//GWBC47T<5A]IGRIV_E)T#T+7$]#L;<_77(^N7^O%B'.X&-/W`F!][`-VX:V5O208V4:7*&WDVL#,<;BT MPZD,GRU>OH`=F"8(KK5VAX6_-\;K?/47``#__P,`4$L#!!0`!@`(````(0`' MJG^0D`(``+(&```0``@!9&]C4')O<',O87!P+GAM;""B!`$HH``!```````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M`````````````````````````````````)Q576^;,!1]G[3_$/'>DF;5-%6$ MRB%.@D2`8=.I>[$\XC16"2#;C=+]^EU@:9+-Z]2^W8_CQDY.9Q=?G($VO%KQLJ[$V'D6VKGU/W[P4E4W0ADI M]``H*CUV-L8T-ZZKBXW8BT+,:V+IZVHC#L:#C^[ M8F]$M1*KB^:%T.D9;W;FO:2KNFCUZ3OZW(!@WT--4\J"&[BEOY2%JG6]-@.\ M+T3IN:=)#]0143PI:9[]H>>>NAXI>"D"(/;7O-3"VO/9'H!7`8)TCVV"O!!+G&JDTI=#).N7*V"3#4SAJ[E3TBGM!ARDR M>!L,5P;ZQ<*JG[:L3Y6_W"%(8I)$X111/&43%*$XP(PL,*;DK7B6\O\?(10J M+7%,"4MF+$GQ6X\$R"YL@DC8<:89)L"/:)C$5O(DFZ,X_-X!&(JGK8JL\^S, M)%\N47;?ZB7A/`YG88!BRE`0)'E,K24"E(8418QF*"8H:*78N6=)ML094`,I MS@B+$XH)2]$]FD3VUIPA6$(7.+-*H#A8Q$F4S.\901'N+DKR201U8F*G)IC2 MJ!L.0_,,_[:@0E M9O;'\.H`F+6*90+'(O9/X/5AG#7@;#G\L0XB63WJO*'UE!MQV'?G08]LN!(K MV`2'_#'@+6#5J;(E"3:\>A"K`^;O1+N=[_I?D']U?3G\-(1E=A+SW.//QO\% M``#__P,`4$L#!!0`!@`(````(0"GG[SWE0```*D````0````>&PO8V%L8T-H M86EN+GAM;#R.00H",1`$[X)_&.;N9O4@*DD6%'R!/B!D1Q-()DLFB/[>>/'2 M4#14MY[>.<&+JL3"!K?#B$#LRQSY:?!^NVX."-(J6]2_X2 M7&3H!A:#H;7EI)3X0-G)4!;BWCQ*S:YUK$\E2R4W2R!J.:G=..Y5[@*TVD,U M>#XBQ/X!(?U26:W^(_8+``#__P,`4$L#!!0`!@`(````(0`9<7:`,@$``$`" M```1``@!9&]C4')O<',O8V]R92YX;6P@H@0!**```0`````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````"&>TOILF62EB5J=G*)B3,N MWA"^K<1"":#=_KVLZ^J,GCR2]^7A^3[*Q5XWR2M`8J=`"/%NSZJA26BM;!HVLMN*#`)Y%D/!6V0G4(EF+L10V: M^RPV3`RWK=,\Q*/;8027R/ MGNS.R`:SW_OGG M[`L``/__`P!02P$"+0`4``8`"````"$`UE_&W;8!```S#P``$P`````````` M````````````6T-O;G1E;G1?5'EP97-=+GAM;%!+`0(M`!0`!@`(````(0"U M53`C]0```$P"```+`````````````````.\#``!?&PO=V]R M:W-H965T&UL4$L!`BT`%``&``@````A`.<0KW!J`P``&0L` M`!D`````````````````-1$``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`*5*O%'+`@``?@<``!D````````````` M````HAL``'AL+W=O&PO=&AE;64O=&AE M;64Q+GAM;%!+`0(M`!0`!@`(````(0#!(9UFNPD``,Y+```-```````````` M`````&DE``!X;"]S='EL97,N>&UL4$L!`BT`%``&``@````A`#K+&UL4$L! M`BT`%``&``@````A``P1X0^B`P``'0X``!@`````````````````=&```'AL M+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`(%O MF1.U`@``?@<``!D`````````````````LVT``'AL+W=O&PO=V]R:W-H965T^.P4``$H6```8`````````````````"=S``!X;"]W;W)K```>&PO=V]R:W-H965T&UL4$L!`BT` M%``&``@````A``XS>_%!`P``KPH``!@`````````````````>'L``'AL+W=O M&UL M4$L!`BT`%``&``@````A`.R\U2Y7!0``81D``!@`````````````````IX,` M`'AL+W=O&UL4$L!`BT`%``&``@````A`,MH+B)^`@``[P4``!D````````````` M````WXL``'AL+W=O&PO=V]R:W-H965T M&PO=V]R M:W-H965T&UL4$L!`BT`%``& M``@````A`*>?O/>5````J0```!``````````````````TIP``'AL+V-A;&-# M:&%I;BYX;6Q02P$"+0`4``8`"````"$`&7%V@#(!``!``@``$0`````````` M``````"5G0``9&]C4')O<',O8V]R92YX;6Q02P4&`````!X`'@#[!P``_I\` #```` ` end XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 R9.htm IDEA: XBRL DOCUMENT v2.4.1.9
CAPITAL TRANSACTIONS
3 Months Ended
Mar. 31, 2015
Notes to Financial Statements  
Note 4. CAPITAL TRANSACTIONS

Capital transactions during the three months ended March 31, 2015:

 

  · In January 2015, the Company issued 1,000,000 shares of common stock to a party for services with a total value $90,000.
     
  · In March 2015, the Company issued 1,000,000 shares of common stock and warrant for 2,500,000 shares of common stock one of the Company’s directors for legal services rendered with a total value of $160,301.

 

Capital transactions during the three months ended March 31, 2014:

 

  · In January 2014, the Company entered into a securities purchase agreement with an accredited investor (the “January 2014 Accredited Investor”) pursuant to which the January 2014 Accredited Investor purchased 1,818,182 shares of the Company’s common stock and a warrant to acquire 909,091 shares of common stock for a purchase price of $100,000. The warrant is exercisable for five (5) years at an exercise price of $0.085 per share.
     
  · In February 2014, the Company entered into securities purchase agreements with two accredited investors (the “February 2014 Accredited Investors”) pursuant to which the February 2014 Accredited Investors purchased 18,250,000 shares of the Company’s common stock and warrants to acquire 4,562,500 shares of common stock for an aggregate purchase price of $1,368,750. The warrants are exercisable for five (5) years at an exercise price of $0.075 per share.
     
  · In February 2014, the Company paid $82,125 and granted a warrant for 4,562,500 shares of common stock to a consulting group as a finder’s fee related to the February 2014 Accredited Investors securities purchase agreement. The cash payment and warrant grant has been accounted for as an offering cost related to the February 2014 Accredited Investors securities purchase agreement and has been netted with the February 2014 Accredited Investors securities offering. The Warrants are exercisable for five (5) years at an exercise price of $0.075 per share.
     
  · In March 2014, the Company issued 2,533,334 shares of common stock to two consultants for services with a total value $177,000. The stock issuance is for services performed during the period January 2014 through June 2014.
     
  · In March 2014, the Company issued 1,818,182 shares of common stock in a private offering to two parties for cash totaling $100,000.
EXCEL 14 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%]B,34U9&8T,E\S,38S7S0Y-3A?83`X-U]A8V,S M8V9F-S1F9&4B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I% M>&-E;%=O#I%>&-E;%=O#I% M>&-E;%=O#I7 M;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DY/ M5$537U!!64%"3$5?3U1(15(\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I7;W)K#I7;W)K#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/E-534U!4EE?3T9?4TE'3DE&24-! M3E1?04-#3U5.5#$\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O6QE#I!8W1I=F53:&5E=#X-"B`@/'@Z4')O=&5C=%-T#I0#I0#I0&UL/CPA6V5N9&EF72TM/@T*/"]H96%D/@T*("`\8F]D>3X-"B`@ M(#QP/E1H:7,@<&%G92!S:&]U;&0@8F4@;W!E;F5D('=I=&@@36EC'1087)T7V(Q-35D9C0R7S,Q-C-?-#DU.%]A,#@W7V%C M8S-C9F8W-&9D90T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]B,34U M9&8T,E\S,38S7S0Y-3A?83`X-U]A8V,S8V9F-S1F9&4O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M'0^34%.2$%45$%.(%-#245. M5$E&24-3($E.0SQS<&%N/CPO'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^665S/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$2!#;VUM M;VX@4W1O8VLL(%-H87)E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^,C`Q-3QS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M2!A;F0@97%U:7!M96YT+"!N970\+W1D/@T*("`@("`@("`\ M=&0@8VQA2P@;F5T/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$;G5M<#XY,38L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3PO=&0^ M#0H@("`@("`@(#QT9"!C;&%SF5D(#(U,"PP,#`@F5D M(#$L,#`P+#`P,"!S:&%R97,@4V5R:65S($,@8V]N=F5R=&EB;&4L(')E9&5E M;6%B;&4L(&%U=&AO3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$F5D/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M<#XY-3`L,#`P+#`P,#QS<&%N/CPO3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]B,34U9&8T,E\S,38S7S0Y-3A?83`X M-U]A8V,S8V9F-S1F9&4-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO M8C$U-61F-#)?,S$V,U\T.34X7V$P.#=?86-C,V-F9C'0O:'1M;#L@8VAA M'!E;G-E'!E;G-E3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%]B,34U9&8T,E\S,38S7S0Y-3A?83`X-U]A8V,S8V9F-S1F9&4- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8C$U-61F-#)?,S$V,U\T M.34X7V$P.#=?86-C,V-F9C'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%RF%T:6]N/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$;G5M<#XU."PP,#`\'!E;G-E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^)FYB'0^)FYB&5S('!A:60\+W1D/@T*("`@("`@("`\=&0@ M8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^)FYB3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]B,34U M9&8T,E\S,38S7S0Y-3A?83`X-U]A8V,S8V9F-S1F9&4-"D-O;G1E;G0M3&]C M871I;VXZ(&9I;&4Z+R\O0SHO8C$U-61F-#)?,S$V,U\T.34X7V$P.#=?86-C M,V-F9C'0O:'1M;#L@8VAA'0M86QI9VXZ(&IU2!G96YE'0M86QI9VXZ(&IU'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU2!A8V-E<'1E9"!A8V-O=6YT:6YG('!R:6YC:7!L97,@ M:6X@=&AE(%5N:71E9"!3=&%T97,@;V8@06UE'!E;G-E7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'`@2`S,2P@,3DY,B!A;F0@:&%S M('1W;R!O<&5R871I;F<@=VAO;&QY+6]W;F5D#0IS=6)S:61I87)I97,Z($UE M=&%L;&EC=6TL($EN8RXL("@F(S$T-SM-971A;&QI8W5M)B,Q-#@[*2!A;F0@ M4V5N:6]R(%-C:65N=&EF:6,@3$Q#("@F(S$T-SM396YI;W(@4V-I96YT:69I M8R8C,30X.RDN($]N($IU;F4-"C$R+"`R,#`X+"!T:&4@0V]M<&%N>2!A8W%U M:7)E9"!-971A;&QI8W5M+"!);F,N(&9O'0M86QI9VXZ(&IU'0M M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU2!396YI;W(@4V-I96YT:69I8RP@82!U;FET(&]F('1H92!#;VUP M86YY+CPO<#X-"@T*/'`@6QE/3-$)V9O;G0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE2!H87)V97-T:6YG('1O<"!T96-H;F]L;V=Y M('1A;&5N="!T;R!BF4@;F]V96P@=&5C:&YO;&]G:65S(&EN('1H M90T*;F%N;RUM961I8VEN92!S<&%C92!W:71H('1H92!P;W1E;G1I86P@=&\@ M8F4@9&ES2!T:&4@;V9F97(@=&\@<&]T96YT:6%L;'D@8W)E M871E('!E2!V:7)T=64@;V8@ M;W=N97)S:&EP(&]F(&]U0T*=')A9&5D('-H87)EF%T M:6]N('1O(&%C<75I2!D:7-S;VQV960@4V-I96YT:69I8R!.86YO;65D:6-I;F4@86YD M('1R86YS9F5R6QE/3-$ M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^)B,Q-C`[/"]P/@T*#0H\ M<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E'0M86QI9VXZ(&IU6QE/3-$)V9O;G0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V M,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE2<^5&AE(&=O86P@;V8@;W5R(&QI8V5N'0M86QI M9VXZ(&IU'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T* M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E'0M86QI9VXZ(&IU6QE/3-$)V9O;G0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V M,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE2<^3W5R(&%C<75I2!A M;F0@:6YT96QL96-T=6%L('!R;W!E2!I2P@8FEO<'-Y+`T*2P@;W(@97AO=&EC86QL>2!E>'!E;G-I=F4@:6YS=')U;65N=',N($YA;F]P M87)T:6-L97,@87)E(&EN=')O9'5C960@=&\@=&AE(&)O9'DL(&9O&%M M<&QE+"!B>2!I;G1R879E;F]U7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA6QE/3-$)V9O;G0Z M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^0D%325,@3T8@0T].4T],241!5$E/ M3CH\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^5&AE(&-O;G-O M;&ED871E9"!F:6YA;F-I86P@2!B M86QA;F-E6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE3L@ M=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$ M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^0T%32"!#3TY#14Y44D%4 M24]..CPO<#X-"@T*/'`@28C,30V.W,@8V%S:"!A8V-O=6YT&-E961I;F<@ M=&AE(&9E9&5R86QL>2!I;G-U6QE M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE3L@=&5X="UI;F1E;G0Z M(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE'0M86QI9VXZ(&IU'0M M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU2!A;F]T:&5R(&-O;7!A;GD@87,@82!R M97-U;'0@;V8@=&AE(&%C<75I&-L=7-I=F4@;&EC96YS92!O;B!T:&4@ M=&AIF5D(&]V97(@=&AE('!E M2!E;G1E2!,3$,@9F]R M('1H92!E>&-L=7-I=F4@=7-E(&]F(&-E2!R96QA M=&EN9R!T;R!T:&4@;6%N=69A8W1U7,N(%1H92!P=7)C:&%S M92!P2X@ M56YD97(@=&AE('1E2`R,#$P(&%N9"P@;6%Y(&)E M(')E<75I2!R;WEA;'1I97,L(&%S(&1E9FEN960L('1O('1H M92!L:6-E;G-O'0M M86QI9VXZ(&IU2!A8W%U:7)E9"!38VEE;G1I9FEC($YA;F]M961I8VEN92P-"DEN8RX@=VAI M8V@@:&]L9',@=&AE(&-O;6UE2!W:71H(')E2!H860@;F\@=&%N9VEB M;&4@87-S971S(&]R(&QI86)I;&ET:65S(&%N9"!D:60@;F]T(&AA=F4@=&AE M(&)UF%T:6]N('=A2!D:7-S;VQV960@ M4V-I96YT:69I8R!.86YO;65D:6-I;F4@86YD('1R86YS9F5R'0M86QI9VXZ(&IU'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU'0M86QI9VXZ M(&IU'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\ M<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E'0M86QI9VXZ(&IU2!D979E;&]P960@8GD@365T86QL:6-U M;2!R96QA=&5D('1O('1H92!#;VUP86YY)B,Q-#8[2P@2D@:&%S(&)E96X-"F-O;7!L971E9"!O M2!I6QE/3-$ M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE3L@=&5X="UI;F1E;G0Z(#`N M-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE2<^1D%)4B!604Q512!/1B!&24Y!3D-)04P@24Y35%)5 M345.5%,\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP M('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^169F96-T M:79E($IA;G5A&ET('!R:6-E*2!I M;B!T:&4@<')I;F-I<&%L(&]R(&UO0T*:6X@86X@;W)D97)L>2!T&EM:7IE('1H92!U6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^3&5V96P@,2`F(S$U M,3L@475O=&5D('!R:6-E'0M86QI M9VXZ(&IU'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T* M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E'0M86QI9VXZ(&IU2!D97-I9VYA=&5S(&-A6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H- M"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M2<^5&AE M(&9A:7(@=F%L=64@;V8@=&AE($-O;7!A;GDF(S$T-CMS(&1E8G0-"F%S(&]F M($UA6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M3L@=&5X M="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^1F%I6EN9PT*86UO=6YT28C,30V.W,@9&5B="!A<'!R;WAI M;6%T97,@8V%R6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE3L@=&5X="UI M;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^5&AE($-O;7!A;GD@86-C;W5N=',@ M9F]R('-T;V-K+6)A'!E M;G-E9"!O=F5R#0IT:&4@'!E;G-E(&ES(')E8V]G;FEZ960@ M;VYL>0T*9F]R('1H;W-E(&%W87)D'!E8W1E9"!T;R!V M97-T+"!A;F0@87,@2!E65E2!C;VYD:71I;VX@9F]R('9E'!E;G-E+"!I9B!A<'!L:6-A M8FQE+"!I;B!T:&4@9FEN86YC:6%L('-T871E;65N=',N/"]P/@T*#0H\<"!S M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E M'0M86QI9VXZ(&IU'0M:6YD M96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU'0M86QI M9VXZ(&IU'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T* M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E'0M86QI9VXZ(&IU2!D:79I9&EN9R!T:&4@;&]S2!T:&4@=V5I9VAT960-"F%V97)A M9V4@;G5M8F5R(&]F(&-O;6UO;B!S:&%R97,@;W5T&-L=61E7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE2<^0V%P:71A;"!T6QE/3-$)W9E'0M86QI M9VXZ(&IU6QE/3-$)V9O;G0Z(#$P<'0@4WEM8F]L M)SXF(S$X,SL\+V9O;G0^/"]T9#X-"B`@("`\=&0@2<^/&9O;G0@6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&IU6QE/3-$)W1E>'0M86QI9VXZ M(&IU6QE/3-$)V9O;G0Z(#$P<'0@4WEM8F]L)SXF M(S$X,SL\+V9O;G0^/"]T9#X-"B`@("`\=&0@2<^/&9O;G0@2!I28C M,30V.W,@9&ER96-T;W)S(&9O'0M86QI9VXZ M(&IU'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\ M<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E'0M86QI9VXZ(&IU6QE/3-$)V9O;G0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V M,#L\+W`^#0H-"CQT86)L92!C96QL6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M'0M86QI9VXZ(&IU6QE/3-$)W=I9'1H.B`V,'!X.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\9F]N M="!S='EL93TS1"=F;VYT.B`Q,'!T(%-Y;6)O;"<^)B,Q.#,[/"]F;VYT/CPO M=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU6QE/3-$)V9O;G0M2`R,#$T M+"!T:&4@0V]M<&%N>2!E;G1E6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&IU M6QE/3-$)V9O;G0M2`R,#$T($%C8W)E9&ET960@26YV97-T;W)S('!U28C,30V.W,@8V]M;6]N('-T;V-K M(&%N9"!W87)R86YT&5R8VES86)L92!F M;W(@9FEV92`H-2D@>65A6QE/3-$ M)W9E6QE/3-$)W1E>'0M86QI9VXZ(&IU6QE/3-$)W1E>'0M86QI9VXZ(&IU6QE/3-$)V9O;G0Z(#$P<'0@4WEM8F]L)SXF(S$X,SL\+V9O;G0^/"]T9#X- M"B`@("`\=&0@2<^/&9O;G0@ M2`R,#$T+"!T M:&4@0V]M<&%N>2!P86ED("0X,BPQ,C4@86YD(&=R86YT960@82!W87)R86YT M(&9O2`R,#$T($%C8W)E9&ET960@26YV97-T;W)S('-E M8W5R:71I97,@<'5R8VAA6QE/3-$)W1E>'0M86QI9VXZ(&IU6QE/3-$)W1E>'0M86QI9VXZ M(&IU6QE/3-$)W1E>'0M M86QI9VXZ(&IU2<^/&9O;G0@F4Z(#$P<'0G/DEN($UA2`R,#$T('1H6QE/3-$)W1E>'0M86QI M9VXZ(&IU6QE/3-$)W1E M>'0M86QI9VXZ(&IU6QE M/3-$)W1E>'0M86QI9VXZ(&IUF4Z(#$P<'0G/DEN($UA3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]B,34U M9&8T,E\S,38S7S0Y-3A?83`X-U]A8V,S8V9F-S1F9&4-"D-O;G1E;G0M3&]C M871I;VXZ(&9I;&4Z+R\O0SHO8C$U-61F-#)?,S$V,U\T.34X7V$P.#=?86-C M,V-F9C'0O:'1M;#L@8VAA'0^/'`@'1E;G-I;VX@9&%T960@1&5C96UB97(@,3(L(#(P,#2!H87,@&EM871E;'D@)#8L,#`P('1H92!T:')E92!M;VYT:',@96YD960@36%R M8V@@,S$L(#(P,34@86YD(#(P,30N($%C8W)U960@:6YT97)E6%B;&4-"F%P<')O>&EM871E9"`D,C6%B;&4-"F%N9"!A8V-R=65D(&5X<&5N7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X- M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'`@2!I2!D871E(&%F=&5R('-I>"!M;VYT:',@9G)O;2!T:&4@:7-S M=6%N8V4-"F]F(&5A8V@@3F]T92P@870@82!C;VYV97)S:6]N('!R:6-E(&]F M(#8W)2!O9B!T:&4@9F%I28C,30V.W,@ M8V]M;6]N('-T;V-K('5P;VX@=&AE(&1A=&4@;V8@8V]N=F5R2`D,"XP-#$@9F]R('1H92!N;W1E(&ES&EM871E;'D@)#`N,#0T(&9O2`D,"XP,S0@9F]R('1H M92!N;W1E(&ES6%B;&4@:&%S(&)E96X@86-C;W5N=&5D(&9O2!A8V-R971E9"!A&EM871E('9A;'5E(&]F("0R.38L,#`P('=H M:6-H(&AA2!R871E(&]F(#$S-"4@=&\@,3,U)3L@86YD(&1I65A'!E;G-E(&%S2P@=&AE(&-A6QE/3-$)V9O;G0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE3L@=&5X="UI;F1E;G0Z(#`N-6EN)SX\9F]N M="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E'0M86QI9VXZ(&IU6QE/3-$)V9O;G0Z M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2UO=VYE M9"!S=6)S:61I87)Y+"!396YI;W(@4V-I96YT:69I8RP@3$Q#+@T*5&AE(&-O M;G9E2`Q."4@;V8@=&AE('1O=&%L(&5Q=6ET>2!O9B!396YI;W(@4V-I96YT:69I M8RP@3$Q#(&]U='-T86YD:6YG(&%S(&]F('1H92!D871E(&AE6%B;&4@9'5E(&]F('1H92!C;VYV97)T M:6)L92!N;W1E2!A(&-O;G9E6%B;&4@87,@;V8@36%R8V@@,S$L(#(P,34@86YD($1E8V5M M8F5R(#,Q+"`R,#$T+"!R97-P96-T:79E;'DN(%1H92!C;VYV97)S:6]N(&9E M871U2P@8V]M<')IF5D(&]R:6=I;F%L(&1E8G0@9&ES8V]U;G0@;V8@)#@X-"PP,#`@ M870@1&5C96UB97(@,S$L(#(P,30N/"]F;VYT/CPO<#X\'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0M86QI9VXZ(&IU2P@=&\@0V%R<&5N=&5R(&%N9"!T;R!P2!R;WEA;'1I97,@9F]R('!R;V1U8W1S(&1E M=F5L;W!E9`T*=7-I;F<@=&AI6QE/3-$)V9O M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^5&AE($-O;7!A;GD@2!A;F0@=&AE('-E6%L='D@:6YC;VUE('=I;&P@ M8F4@2!O6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M3L@=&5X M="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^1F]R('1H92!T:')E92!M;VYT M:',@96YD960@36%R8V@@,S$L(#(P,34@86YD#0HR,#$T+"!T:&4@0V]M<&%N M>2!E87)N960@)"TP+2!A;F0@)#$U,"PP,#`@86YD(')E8V]R9&5D('-U8V@@ M86UO=6YT(&%S(')E=F5N=64N(%1H92!A;6]U;G0@2!E87)N960@6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE3L@=&5X="UI M;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^26X@2F%N=6%R>2`R,#$S+"!T:&4@ M0V]M<&%N>2!E;G1E2!$96-E;6)E2!T:&4@<&%R='D@;W(@ M=&AE(&QA=&5S="!$96-E;6)E3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%]B,34U9&8T,E\S,38S7S0Y-3A?83`X-U]A8V,S8V9F-S1F M9&4-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8C$U-61F-#)?,S$V M,U\T.34X7V$P.#=?86-C,V-F9C'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0M86QI9VXZ(&IU2!E;G1E2!A M;F0@86QL(&QI86)I;&ET:65S#0IA;F0@8VQA:6US(')E;&%T960@=&\@=&AE M($-A2!W:&EC:`T*=V%S M('1H92!S=6)J96-T(&UA='1E0T*9&ES<&%R86=E M('1H92!O=&AE7-I8V%L('!R;W!E2!T'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0M M86QI9VXZ(&IU3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%]B,34U9&8T,E\S,38S7S0Y-3A?83`X-U]A8V,S M8V9F-S1F9&4-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8C$U-61F M-#)?,S$V,U\T.34X7V$P.#=?86-C,V-F9C'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R'0M86QI9VXZ(&IU'0M86QI9VXZ(&IU2!W M:71H(&%C8V]U;G1I;F<@<')I;F-I<&QEF%T:6]N+CPO<#X\'0^ M/'`@28C,30V.W,@8V%S:"!A8V-O=6YT&-E961I M;F<@=&AE(&9E9&5R86QL>2!I;G-U'0^/'`@ M6QE/3-$)V9O;G0Z(#$P<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^ M#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE2<^ M26X@,C`P."PF(S$V,#MT:&4@0V]M<&%N>2!O8G1A:6YE9"!L:6-E;G-E&-L=7-I=F4@ M;&EC96YS92!O;B!T=V\@<&%T96YTF%T:6]N('=A2X@56YD97(@=&AE M('1E2!B92!R M97%U:7)E9"!T;R!P87D@6QE/3-$)V9O;G0Z(#$P<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^ M#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE2<^ M26X@,C`P.2P@=&AE($-O;7!A;GD@96YT97)E9"!I;G1O(&$@<&%T96YT#0IL M:6-E;G-E(&%GF5D(&]V97(-"G1H92!P97)I;V0@;V8@ M:71S(&5S=&EM871E9"!B96YE9FET('!E2!A;B!A;FYU86P@;&EC M96YS92!F964@;V8@)#$P+#`P,"!S=&%R=&EN9PT*:6X@1F5B2!B92!R97%U:7)E9"!T;R!P87D@6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^26X@,C`Q M,2P@=&AE($-O;7!A;GD@86-Q=6ER960@4V-I96YT:69I8R!.86YO;65D:6-I M;F4L#0I);F,N('=H:6-H(&AO;&1S('1H92!C;VUM97)C:6%L(')I9VAT2!D971E8W1I;VX@;V8@9&ES96%S97,-"G5S M:6YG(&YA;F]T96-H;F]L;V=I97,N(%1H92!A8W%U:7-I=&EO;B!O9B!38VEE M;G1I9FEC($YA;F]M961I8VEN92P@26YC+B!H87,@8F5E;B!A8V-O=6YT960@ M9F]R(&%S(&%N(&%S6QE/3-$)V9O;G0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE2!-971A;&QI8W5M(')E;&%T960@=&\@=&AE($-O;7!A M;GDF(S$T-CMS(&YA;F]T96-H;F]L;V=Y+"!S97)V:6-E'0M86QI9VXZ(&IU'0M:6YD96YT.B`P+C5I;B<^ M)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ M(&IU&ES=',[("AI:2D@ M=')A;G-F97(@;V8@=&5C:&YO;&]G>2`H:6YT96QL96-T=6%L('!R;W!EF5D('=H96X@'0M86QI9VXZ(&IU&-H86YG92!P2`H86X@97AI="!P'!A;F1S(&1I2!T;R!M87AI;6EZ92!T:&4@=7-E(&]F(&]BF4@=&AE('5S92!O9B!U;F]B2!B90T*=7-E9"!T;R!M96%S=7)E(&9A:7(@=F%L=64Z/"]P/@T*#0H\<"!S M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E M'0M86QI9VXZ(&IU'0M:6YD M96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU6QE/3-$)V9O;G0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V M,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE2<^3&5V96P@,B`F(S$U,3L@475O=&5D('!R:6-E6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^5&AE($-O;7!A;GD@ M9&5S:6=N871E2!M87)K970@9G5N9',I(&%N9"!I;G9E28C,30V.W,-"FEN=F5S M=&UE;G0@8VQA'0M86QI9VXZ(&IU'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU'0M86QI9VXZ(&IU'0M:6YD96YT.B`P M+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`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`X M-U]A8V,S8V9F-S1F9&4-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO M8C$U-61F-#)?,S$V,U\T.34X7V$P.#=?86-C,V-F9C'0O:'1M;#L@8VAA M&-E961I;F<@9F5D97)A;&QY(&EN'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$F%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M;G5M<#XD(#(Q+#`P,#QS<&%N/CPO3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%]B,34U9&8T,E\S,38S7S0Y-3A?83`X-U]A8V,S M8V9F-S1F9&4-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8C$U-61F M-#)?,S$V,U\T.34X7V$P.#=?86-C,V-F9C'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D M>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]B,34U9&8T,E\S,38S M7S0Y-3A?83`X-U]A8V,S8V9F-S1F9&4-"D-O;G1E;G0M3&]C871I;VXZ(&9I M;&4Z+R\O0SHO8C$U-61F-#)?,S$V,U\T.34X7V$P.#=?86-C,V-F9C'0O M:'1M;#L@8VAA7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$6EN9R!N970@=F%L=64@;V8@;F]T97,@<&%Y86)L93PO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$2!R96-E:79E9"`D,3@P+#`P,"!I;B!*86YU87)Y(#(P,3,L(&%N M9"!W:6QL(')E8V5I=F4@)#,P+#`P,"!B>2!*=6YE(#$L(#(P,3,[("0S,"PP M,#`@8GD@1&5C96UB97(@,S$L(#(P,3,[("0S,"PP,#`@8GD@1&5C96UB97(@ M,2P@,C`Q-#L@86YD("0S,"PP,#`@=7!O;B!C;VUM97)C:6%L(&QA=6YC:"!B M>2!T:&4@<&%R='D@;W(@=&AE(&QA=&5S="!$96-E;6)E7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\>&UL('AM;&YS M.F\],T0B=7)N.G-C:&5M87,M;6EC'1087)T7V(Q-35D9C0R7S,Q-C-? :-#DU.%]A,#@W7V%C8S-C9F8W-&9D92TM#0H` ` end XML 15 R8.htm IDEA: XBRL DOCUMENT v2.4.1.9
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS
3 Months Ended
Mar. 31, 2015
Notes to Financial Statements  
Note 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS

BASIS OF CONSOLIDATION:

 

The consolidated financial statements include the accounts of Manhattan Scientific, Inc. and its wholly owned subsidiaries Metallicum and Senior Scientific. All significant intercompany balances and transactions have been eliminated.

 

USE OF ESTIMATES:

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amount of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. A significant estimate includes the carrying value of the Company’s patents, fair value of the Company’s common stock, assumptions used in calculating the value of stock options, depreciation and amortization.

 

CASH CONCENTRATION:

 

The Company’s cash accounts are federally insured up to $250,000 for each financial institution we hold our accounts in. As of March 31, 2015 and December 31, 2014, we had cash balances of $9,108,000 and $2,140,000 exceeding the federally insured limits.

 

INTANGIBLE ASSETS:

 

License Agreements

 

In 2008, the Company obtained licenses to the rights of certain patents regarding nanostructured materials developed by another company as a result of the acquisition of Metallicum. The purchase price paid for these licenses was $305,000, which represented its fair value. The Company obtained an exclusive license on two patents and a non-exclusive license on the third patent. The value attributable to license agreements is being amortized over the period of its estimated benefit period of 10 years. At March 31, 2015 and December 31, 2014, accumulated amortization was $202,000 and $194,000, respectively. Under the terms of the agreement, the Company may be required to pay royalties, as defined, to the licensors.

 

In 2009, the Company entered into a patent license agreement with Los Alamos National Security LLC for the exclusive use of certain technology relating to the manufacture and application of nanostructuring metals and alloys. The purchase price paid for this license agreement was $33,000 based on the fair market value of 2,000,000 shares of common stock issued. The value attributable to license agreements is being amortized over the period of its estimated benefit period of 10 years. At March 31, 2015 and December 31, 2014, accumulated amortization was $21,000 and $20,000, respectively. Under the terms of the agreement the Company is required to pay an annual license fee of $10,000 starting in February 2010 and, may be required to pay royalties, as defined, to the licensors.

 

In 2011, the Company acquired Scientific Nanomedicine, Inc. which holds the commercial rights to technology and intellectual property with respect to the early detection of diseases using nanotechnologies. The acquisition of Scientific Nanomedicine, Inc. has been accounted for as an asset purchase since this company had no tangible assets or liabilities and did not have the business inputs and outputs to be considered a business. The purchase price totaling $1,300,000 (fair value of 21,667,000 shares of common stocks issued) has been allocated to in process research and development and is being amortized over its estimated benefit period of 10 years. At March 31, 2015 and December 31, 2014, accumulated amortization was $499,000 and $467,000. We subsequently dissolved Scientific Nanomedicine and transferred all remaining assets to Senior Scientific LLC.

 

REVENUE RECOGNITION:

 

To date the only revenue generated is from the sale of field technology developed by Metallicum related to the Company’s nanotechnology, services provided and sample materials.

 

Revenue is recognized when the four basic criteria of revenue recognition are met: (i) a contractual agreement exists; (ii) transfer of technology (intellectual property) has been completed or services have been rendered; (iii) the fee is fixed or determinable, and (iv) collectability is reasonably assured. Service revenue is recognized when specific milestones are reached or as service is provided if there are no discernible milestones.

 

FAIR VALUE OF FINANCIAL INSTRUMENTS

 

Effective January 1, 2008, the Company adopted FASB ASC 820, Fair Value Measurements and Disclosures, Pre Codification SFAS No. 157, “Fair Value Measurements”, which provides a framework for measuring fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The standard also expands disclosures about instruments measured at fair value and establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:

 

Level 1 — Quoted prices for identical assets and liabilities in active markets;

 

Level 2 — Quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets; and

 

Level 3 — Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

 

The Company designates cash equivalents (consisting of money market funds) and investments in securities of publicly traded companies as Level 1. The total amount of the Company’s investment classified as Level 3 is de minimis.

 

The fair value of the Company’s debt as of March 31, 2015 and December 31, 2014 approximated their fair value at those times.

 

Fair value of financial instruments: The carrying amounts of financial instruments, including cash and cash equivalents, short-term investments, accounts payable, accrued expenses and notes payables approximated fair value as of March 31, 2015 and December 31, 2014 because of the relative short term nature of these instruments. At March 31, 2015 and December 31, 2014, the fair value of the Company’s debt approximates carrying value.

 

STOCK-BASED COMPENSATION

 

The Company accounts for stock-based compensation based on the fair value of all option grants or stock issuances made to employees or directors on or after its implementation date (the beginning of fiscal 2006), as well as a portion of the fair value of each option and stock grant made to employees or directors prior to the implementation date that represents the unvested portion of these share-based awards as of such implementation date, to be recognized as an expense, as codified in ASC 718. The Company calculates stock option-based compensation by estimating the fair value of each option as of its date of grant using the Black-Scholes option pricing model. These amounts are expensed over the respective vesting periods of each award using the straight-line attribution method. Compensation expense is recognized only for those awards that are expected to vest, and as such, amounts have been reduced by estimated forfeitures. The Company has historically issued stock options and vested and non-vested stock grants to employees and outside directors whose only condition for vesting has been continued employment or service during the related vesting or restriction period. The estimated fair value of grants of stock options and warrants to nonemployees of the Company is charged to expense, if applicable, in the financial statements.

 

BASIC AND DILUTED LOSS PER SHARE

 

In accordance with FASB ASC 260, “Earnings Per Share,” the basic loss per share is computed by dividing the loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Basic net loss per share excludes the dilutive effect of stock options or warrants and convertible notes. Diluted net earnings (loss) per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents, consisting of shares that might be issued upon exercise of common stock options and warrants. In periods where losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive.

XML 16 R2.htm IDEA: XBRL DOCUMENT v2.4.1.9
CONSOLIDATED BALANCE SHEETS (USD $)
Mar. 31, 2015
Dec. 31, 2014
Current assets:    
Cash and cash equivalents $ 9,556,000us-gaap_CashAndCashEquivalentsAtCarryingValue $ 2,528,000us-gaap_CashAndCashEquivalentsAtCarryingValue
Total current assets 9,556,000us-gaap_AssetsCurrent 2,528,000us-gaap_AssetsCurrent
Investments 2,000us-gaap_CostMethodInvestments 2,000us-gaap_CostMethodInvestments
Property and equipment, net 204,000us-gaap_PropertyPlantAndEquipmentNet 144,000us-gaap_PropertyPlantAndEquipmentNet
Assets received in Settlement Agreement - see Note 8 6,938,000mhtx_AssetsReceivedInSettlementAgreementSeeNote8   
Intellectual property, net 916,000us-gaap_IntangibleAssetsNetExcludingGoodwill 957,000us-gaap_IntangibleAssetsNetExcludingGoodwill
Other asset 2,000us-gaap_OtherAssetsNoncurrent 2,000us-gaap_OtherAssetsNoncurrent
Total assets 17,618,000us-gaap_Assets 3,633,000us-gaap_Assets
Current liabilities    
Accounts payable and accrued expenses 447,000us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent 426,000us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent
Accrued interest and expenses - related parties 19,000us-gaap_DueToRelatedPartiesCurrent 19,000us-gaap_DueToRelatedPartiesCurrent
Note payable to former officers 450,000us-gaap_NotesPayableRelatedPartiesClassifiedCurrent 450,000us-gaap_NotesPayableRelatedPartiesClassifiedCurrent
Convertible notes payable 896,000us-gaap_ConvertibleNotesPayable 896,000us-gaap_ConvertibleNotesPayable
Total current liabilities 1,812,000us-gaap_LiabilitiesCurrent 1,791,000us-gaap_LiabilitiesCurrent
Long-term liabilities    
Convertible notes payable, net 1,681,000us-gaap_ConvertibleLongTermNotesPayable 1,616,000us-gaap_ConvertibleLongTermNotesPayable
Total long-term liabilities 1,681,000us-gaap_LiabilitiesNoncurrent 1,616,000us-gaap_LiabilitiesNoncurrent
Total liabilities 3,493,000us-gaap_Liabilities 3,407,000us-gaap_Liabilities
Mezzanine equity    
Series D convertible preferred, authorized 105,671 shares, 105,671 and 105,671 shares issued and outstanding at March 31, 2015 And December 31, 2014, respectively 1,058,000us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount 1,058,000us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount
Capital stock $.001 par value    
Preferred, authorized 1,000,000 shares Series A convertible, redeemable, 10 percent cumulative, authorized 182,525, shares;issued and outstanding - none      
Preferred, authorized 1,000,000 shares Series B convertible, authorized 250,000 shares; 49,999 shares issued and outstanding      
Preferred, authorized 1,000,000 shares Series C convertible, redeemable, authorized 14,000 shares; issued and none outstanding      
Common, authorized 950,000,000 shares, 518,378,036 and 516,378,036 shares issued, and outstanding, respectively 518,000us-gaap_CommonStockValueOutstanding 516,000us-gaap_CommonStockValueOutstanding
Additional paid-in-capital 62,142,000us-gaap_AdditionalPaidInCapitalCommonStock 61,894,000us-gaap_AdditionalPaidInCapitalCommonStock
Common stock to be issued 125,000mhtx_CommonStockToBeIssued   
Accumulated deficit (49,718,000)us-gaap_RetainedEarningsAccumulatedDeficit (63,242,000)us-gaap_RetainedEarningsAccumulatedDeficit
Total stockholder's equity (deficit) 13,067,000us-gaap_StockholdersEquity (832,000)us-gaap_StockholdersEquity
TOTAL LIABILITIES AND STOCKHOLDER'S EQUITY (DEFICIT) $ 17,618,000us-gaap_LiabilitiesAndStockholdersEquity $ 3,633,000us-gaap_LiabilitiesAndStockholdersEquity
XML 17 R6.htm IDEA: XBRL DOCUMENT v2.4.1.9
BASIS OF PRESENTATION
3 Months Ended
Mar. 31, 2015
Notes to Financial Statements  
Note 1. BASIS OF PRESENTATION

The foregoing unaudited interim financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions for Form 10-Q and Regulation S-X as promulgated by the Securities and Exchange Commission (“SEC”). Accordingly, these financial statements do not include all of the disclosures required by generally accepted accounting principles in the United States of America for complete financial statements. These unaudited interim financial statements should be read in conjunction with the audited financial statements and the notes thereto included on Form 10-K for the year ended December 31, 2014. In the opinion of management, the unaudited interim financial statements furnished herein include all adjustments, all of which are of a normal recurring nature, necessary for a fair statement of the results for the interim period presented.

 

The preparation of financial statements in accordance with generally accepted accounting principles in the United States of America requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities known to exist as of the date the financial statements are published, and the reported amounts of revenues and expenses during the reporting period. Uncertainties with respect to such estimates and assumption are inherent in the preparation of the Company’s financial statements; accordingly, it is possible that the actual results could differ from these estimates and assumptions that could have a material effect on the reported amounts of the Company’s financial position and results of operations.

 

Operating results for the three month period ended March 31, 2015 are not necessarily indicative of the results that may be expected for the year ending December 31, 2015.

ZIP 18 0001477932-15-003367-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001477932-15-003367-xbrl.zip M4$L#!!0````(`$-TLT96=M"TR,#$U,#,S,2YX M;6Q55`D``QV"6U4=@EM5=7@+``$$)0X```0Y`0``[%UM<^,VDOY^5?-ZZ M5+;*LD7)DB4[,UL:O^SZXO$XMB?)?IJ"24A"AB08@+2M_?77#9`225$2*%*> MS"2NRL06`?2#1K^AT81^^,>+[UE/5$C&@S=[]D%[SZ*!PUT63-[L?;QOC>[/ MKJ[VK'^\_>__LN#GA_]IM:Q+1CWWQ#KG3NLJ&/-3ZX;X],3Z)PVH(!$7I];/ MQ(OQ$_[KN[MK^%./?V(=';2)U6H9#/8S#5PN/MY=S0>;1E%X10>.\%_+6!\($]>)'NS MEYG:<_>`B\EA![H=_OK^^MZ94I^T6"`C$CAT+^WEL>!S63][.!P>JJ=ITZ66 M2#RET3W$QX]$+D9&@&O:+R&!IVXT[Y!MW#O4#W--66G3OF[*TJ8N+;23U#F8 M\*=#>`#M[6ZK;;>Z=MI)HV9)(?=>SC=?/3+=(.L6Q-"`GG'<9$ M/JK&R8,2,/!$<(_*TC[J24FG@`=![)?C@B-6M"*"N;,^VWNE.\` M&/#CI$NVERH$"=2*5V-[1L:5D\62J5@B' M::4=#EZDNY<\1KIO]B3S0P\$ZS`=2BN+PX.(OD06<]_LC>2',0QPU+([K07- M>5,:1"R:S3^=?\Y&PV'E![K"4 M7D(M!'YSMP2%4IWH[6("/75B`?"OK\_>4_^1BB_&SOG`DDY\FN'#_)$+8%Y"CSDLTE@M MET%+[;0253RY9`&+Z#5[HNY5`/R/CJ2DD7PW>T]^X^+,(U*.7IC<>XNR M>+*9)S\TM$-'L0))#$P74'\<@^R0C()H9\X^)1<#-_B4"V9P&Z8="FXK_04PNVV'7']>U:?SD"V8@])?AOZ@QMD MBOTO?H\!]QGW0Q[`GUF76YSS:ZL(K+"(,!GP=K$VI$ M7/PI'$7:+#_I+^HI_GA"4QZB@WM]HB+"G>\-CZC\-N3EG#Y&5^!"1(R#Y*.) MDNE^XV%W8=/^UY)_^QOQ[M>>%.^^2C+K:XQ-GRK/\*-$[B@&FI^7A_OB0$/B4R%O1M1(XVHKQ[Z=$4+F2 M1,($U6AK&H#O=@4=ESV!]"WS%OO>X.$JECPL"U\%'A0QEHV:(7I.`^ZS8!/9 MS7PITBT;.'V>XX(!0V^!S(8E"^%7\P5+]?56T#$5@KKW$7<^@TI^$$J%755R M<4N%6D8K$=D[/'[QX-VM[\&D293`XTQ?WKVH"DT'^((8Q2L*-LY@S*TZN)JE%5FN%[+F!F0 M;`AE'3.V!5GUDQO*W)3)].`G1'I7`3@?"43/^*,=>Q'"` M!V3+(U:CM3SC4EIMG"&E MIIQ'GER).3:GN>44U]-\U\#B'0WA)T?SW4J^KJ%G/+]*])I:R!*B&SC;U')6 MIGS6E/DY4N:]?.3J=,WM3U6ZC1N@LY7RM(;6EOJYAM9NC-#9!NG9C1DJHYH& M#B/'B?U8I;K.:2A@&%7R"+][%'\9!>[(YR)B_U&?WPH>4A'-;CT21/`,$VBA M;QQ(8-HH@[4-`C<\R@4R3>%YS7E6K[I>QY&._=4SI'J)\5J&M+\UAFPLF%S' MCJ/^\5?/CZH%I&OY,1Q^*_S8H`:=5YGG'7VB04QE#N>:TJJUUKV7U]UT["HT MR\J,UM%<0T[YQ"N@`#XSNG@):2#I)1?JO/B6S,BC1YN8=7\10ZTG5A-75`F1!J!)F1[3SNUD"6F)$[ZE`61DU8B&Y&M/*C5R2\A7%<0S2UFP7K@#4W MC7B#?*A?0F5+()4-864@^;*C2\*$2DIOO>OI]?LY""O&KP'#A`]V?V"_#HP- M16GK0`Z&NV:56>'$D*-(#,1N8$]W`Z9 M,EL?!)LPV$!>$HNV,0=Y`I"X@(W_U!0#5$/_^*Z*MKZQ;HTTR MP`VE>#N]#(REH:L3-DX.FA%>1.-W=,)`06';B/>=F/K?M^]'-_\:/3R,;JS[ MLZN+FX>KRZNS>^OJYBP;Z>?'+MEW@%&`B/8J<.G+CW1F3#Q;3;ARM"RY<^XH M"_0P"\VG:+=;/^GQL]W+AKU5)787N@#/>/QL"=_*T;+D1O#452['(Q-C,F.0 M#:HIY`;(CGP6"X$?@U4FWK\I$57GTDHK?=>-MBP`OU#/^S'@S\$])9('$+9C MREX8D[WA60%8,=HRV9^Y![Z'B-DE\Z@PSDL4R!5&*1%OS8<[&J+7"R;Z*B%C M:O_&*K]-HRU356C.@-T3+LQ5ZAY,"/2SYL-;6#=+@ED60F[H,D702ZX%^!(^ M,Y_L3P4E6!II-3F4L&K$\/D[(IDS`E%G7@Q;SN42&M.-U:IRFA;6TV0W-EN"VNGL-N[6UA0+=7[VA[=/IF1@]/@5R?!2K*CM@3;9![@W[^=&<#R0805N7@\?&P#L)[XE&9 MI$I!;1O1Q4&>9P426R"HRI."$FX`D"3+KQEY9!Z+L)I$1YG;YEJ.EDYKR\>O M!<1(NY;*"LR`J&,I73AT'@NP7CH$3?Q;-"W?G%2Y[L5@!P^FM'N46<2-F)J9 M186K"*K7,'_)2:Q^U?$+SD/GHYJ5J!*+='QL`G\!IA'T6TE2V0E&NYM]@>#+ M@3>1H)+#7"/160T_GSX_(T+,H-?(WY"BKY$][:P]ZL@CJ(NV?JZW#EI]1>2V M?J[;+SA:/9PY$:.0^KAO#PRH*-G1CVYXX-3SX/DRI-*AMZ9O5@A5F7[QWD\( M="Y>'"_&?>@_.7>?F>=MRXYA+V\_36@UA<^L7J1?&]_*XK%B3%KE#/PHO[M9 M1Z,N'C.QVA[/&9?@:J,I=Z_`1,D(FVU?>51X1;5DZ*WI5]/1#,1#G;` MJY/QD@ZW[KZPL!^K0+)AM"8\;!#M>4P?>*%/3>DJE%BL)%`/BI&L;0L%MN,8 MDZ4\Q8Q-XYF(3D'WS4DVC-9(XHZ6ROZW19MIL75T>]0^7F5#*I(SRED=#;M; MD*L?Z]K]0O14.OK6$+8JTC."<$==2GVBMDH!4A;<\R#"F]O!:*G4_)B/L[G5)F*4&!U>Y_RCV7"JF':6SSN8E0$\"VV[!61=8< MDUJ#;CX.:HJXV6%8NU^2=UM+_8Y&A`74O2`B`)&2N3>`QG@CV=:LZ'<[1YV" MG&\BU@P\$V:UCH;'=E$-J\(;N2[3KQ_>$@:;F3,2LHAXF7=-MN4>B'3Q+=:- MM)I!9U3LWK$+2UL=7>:1SD56?3NZY/BEX%C7D*B)QN@PJ"!>!FBR5W1D,I,+ M_U"!,R^2G03,>[,70027^3:LK6BLF*\!C7<9&E6K7)NGL?T\SDIYM:L9;4-M MF[GIW(1Z94=]E=$]C2)/76,YF@BJ?KFG*C,^:&J"-4D:F:=A-_O6F#G!9:N0 M/QVH^4Y`\96.%X/!<6_8ZV6.LBM"V<%,MJL(;7PF-S3"MYQO!G#D1.Q)Y[M*BH`;*2(]+MR]4`_2[B=8N4[.;B\5R38XP:O` M$93@F[7Z_U>!2?:RD94[RL?UVR'9W7RJ+E3A=6T!"VAN=)$BLICX3! M,J?MC2Q/\6AZ&R"[FX[!ZJQR_YM7",BKH$0'NTW=/5*\<:4*_::Q-\"^[,TV MA0MMFN!6@5EKJ-4$5KGT>U`5F(H*L;PI?7$:Q3MYN55%A_//P1[0IAB8O2^P M$O%F85>^`*)7$W9)P9[=B$&$P&E51:!=E7A5KK2ZQSUCXN!@5"G(`Q\YO\=, M4+,+K\SYLLDTU`-0_4V"?'&0,7'#8$\7U^PJFMW$R^9!59:]`H/K(2JI%\,K MDM2;@DW?]E5\JVD5K3J8&O"D67*HTB1PZ(?QJO.%K=W!X'@E,TJI-@*S`?:L MD+=+<`6!\RJ;3'M0N.BR'J3=3[`!KB,B,);J$C,PF$_$4]_"-"_,KG7)TE(] MH1&UQB!N57_XNA"[)N=TQU^2B4:*TR\FR9N#J-^_*&Z$&E%WNWCD6`%`T^`K M1T-M(]4R`Y]6SN!A]([BFTTDFMGH:BKP8M\[J77"1) ME'LJGIC3T(OI2=!7A6Y36.NRZ1T-5)T)UDW@:1-^P^`E)5$L\+T*CIMUZO[" MHFE3MR=VDJKMZM2;Q5V7<0^"!'*,!P`Z\:9N[R`BI*BC\\LX34^:ZZO6[D!5 MSDKDCL)K0RK:#KQP`[QJDL.K<.;S]CLO.@TM&\FT>G# ME%IC+NB$(YXX(+'+\""0X229;XUU>$H\H)Y\9Z?\[F]V]W1*GJCU2&E@A:CK M0O6Q",Q-N&@1K&<086NBW_?W9OB$AC@R64P_%`S&#CV8`V`HHG?[*/CT_N+L_2/P>G?#ZR1 MFBW,Q)OMXW"2:BPE/+-<;@4\`N#XIA>U@"<6'RL,+I..Q_&^8&D)JI(9"I\Q M[X#O.,['0*V<^LHNS10@,/*!I0Y1_`7/A5>3T])%/;`><`*&(F#)*8\]@$D! M,E%+#[+\6QRH)9FODT*1CEX`*<@_E*NKD`CC!\] MI1/[<^TM0RO2KQ3`1C2]QLA5;]5G.BG.*@D^4!@^PFH(+"U64-6R`"-#Q1=N MR1B4:A4G%3H6H*8&4;I&!7'`CY)K\U)3WC^5I9,]SW;!CW#P#)@H M5(N&(Q(GBJ%OJJ&.LHTN@^44UAB\CG8.JT5`CZ2[*<=*+&PG6&(RJ!8,'JSD M]L9Y`6@V]Z,I4.C(YRFF/['=F)=5+!G9:`I!G04[&Y!#+:9Z093W>8^70:6N MIZ?$#WU\:LX9&!*8(Q@$O.*H:,;5DOMDACX4U<-1/K+@XA!2T4CN,3<]S[S5OD/]^6%\F0K-_&O:Y?GWY,`F!@1B/#F7V`#`\`>_<#Z'MFX"-T*NC'0$@7<7C0I'2T3[X&Y@[7P MR+.^5E&`$BJ&[5O/8$)!MTEB%U%/_R^&Q<<%LX?#CM*Y*32*GGFJ<+"PSU,. MOJ8%QIAJJ9+QHV0N(UC4?&*]IQ'X(N;$OI[2?C8473S,(%1T[BG$/2(S!^OZ M^BP7Q18;Y&+:#X@]T)&;W4&!:P_VL^8%C%T2HQ8!*NFU>_NPA<+_+/TUZ"CW M)9;)4?D"$`L0I8,OH/=_.!M4*G[H;L9XW:F6JH@ZTX![?#+3_CK9H:IU1X92 M@6J;ED$`XR$T$'&HS,^\+UL$,*#GO.53_6U/E@R)0]4^0&T5<*W1VVG;`.+L MZCOO],8U)::C:QP"G8S@$L:-$#D)0T^9/O1O:GL'1@\LGR"M,5*;"'#REH\R MI/UAZ!'TA#PW$QV+.!BC"32=ZOX]ZYF+SZK/8@()DAS5!+#>3BV)/>HS)@,* M[O/UW.`7#Y5+U/(QEK`X4H++!'W*?N6I$/'_8SXCROA7"P,IC[D-X&:8Q M*24&_D_A2]8)A!)8O!33&@!*8 M%0>**7J*Z;Y8A==ZI"GU]6)AKCNCCN`=8J$$0.]VK7#*("K@X50#42N%RJT4 MCD-;ETH`BX--J1>"=#'/G;/P*;4S\TB?ON"V2[T9!P&K6A:D^@M$2'X(#A3M M`?0%P2RQ9@I"B45;9(WF0R:BF+&.Z4Y&[Y)F:G>4>G00"XD[$E4HI,7^#:P/F3W#B3%,]T3)@22U,,BJWKTQHB\J4 MHH3JA%KI`"I6["L&`H^U:D=36N)K0BP;D(F_DGC8D^AJHN7I9*E'ZC'ZI/U!4:0S\U.[350P"M3T4@![ M?^.`/];V"%LZ.EV)J-)4(%>[-6#/7$K`Y6ECI=9$"27L/]4T53*2$@_F`=V? M&,!6JZ5,#TY2_0$+HC;+CC?WUV@'D[@H&P%92B45#CGS'[EGO?_7PZ]_YAU9 M`+9PEFYYX-]GM7!4YYE1L@-KGG#7GA^6!(N_D/-WE&=V.[BHB=DLB8Y5S+SX M4W\!IK8?Z58B$SN7-URWK;B_>7^5B[!!EC'0I[_'25C%)&S&GNA*&-HX);$> M,@!3C(+Z8)*4ENHL#TQR:7(ZI8*N/N(1VM08C8G$K`A#PPA;DHZ]W^\/5+R. M![3P>;00T42((*)488:%&37/`DP!A5?E-OUY>%17]28)/')GA+Z/SGTR@&N;83L3%;>B:@`[N",E*V,=1>\LBVBK:*#60QH8Z+FH(<.A MF]S#L76,,&`MQ4)4TG]ECHZ*%^T)\\BB80*30AX`OYNH*YU.?E+-3)BNF(/: M`8M#-I00!!C^"$QBG,_'U4][W[D#U[WKFX\7[R[/+Z\O?EX`$/VHQUH)@/>@ M*;7O@9GS\9]7-94T*C';DHN!^&7 MSPK2T-FG@BBJ*D*-_MY8':Y<8B>*\_6\LF:P^GC)@'.^A+$;$A!`K7^CX,QG M;"2!L'G,'TF9AVO'@1@4E?-Q@<_"#-D,S,QK@E'LF$QZ["8&MA"H M'?#O?S(=6>?I69D?C4#T&ID_S#,R074"N#7D7B.61P_]7^;I`>HHLW,D9L@` M"+2E=9)X@NAPSM!L$9S$;G9P?Q"+%D&A8/L8MCHSNXZ^5]JG&>E/L+%W!:J@ MU2#!7<-N5A'N M'8@4-L=)!\)#R8=OTC@7$V`SQ5?RW(FYOG9K\<2"@CH>SD>JFIMCB.3A(`\N M0*D"AB4[J$`Y!B,R1:4LP`F=`LC?.;#2R#*R4M1&=S[!5X`;5B\I'/.VU[_L M1S?OH_.;Z_[-U>6[WNWES?7K[95D[$G7$[$,`B.0$G-1!7)`W"+D#Q2KE*[; MK)(H$GD>TLB-(#GQF7!@"(POO(CV>+%E@E:V^O_ODA$RI\J:H`F#KB*+_\I& M('@F/]9Z>7%;_:5_@2?_HG][^;%W>]'?\E/_#!`.7!`TD'/5Q,*(FP`T9V,0 MCN_C)KO&(#&,ZZB!QG#`.(RS6`[!H9]=&-]&,!S!CB!G4+3>J#-YCB; MJ.=99DH+N?W$C$2GEGR-Z)'20Y;#3-@Y`Z>$D&OKGG;=2;%'>-)(]%PDHP$! M.&499E1V0[$K"=%/3FHVF[!.R09/#@(97A8[,YHU^S"...Y(8Q@^<3 M\G623/=10Y,`C)7W41]?K]B]MM%M17[%FT<91J>VEQ.6&DD_V^ M"WDJ[KC8K3IC*XUID'QE=Q/*?$:NJC@$R7N?$':4;%G.6*!KJ.#.&D0%O4C< M\4J05O782.8ZQE1IL&H^V\VU(`_F8:G/"7ZI*Z#@S\YAB^%:$MNEH"JCR,FV ML.*3"^EIB3ZT$5.XR"H>Q^$?`U*.$5`4A#[3"1:F^@]D+F(HU<_[>;A'T ML@)>/=N042>V\#&3PZU$0T3NM#J65[?/NDQQ\3@")4:+`]!B-?X+)V-L(+UF MD3X$3V"C)EL$H];PJ[)8)"/"A/-,#!PC5B\1$Z\HMUH$T%4_\RGJQY;E&-)$ M&N>-S92KH@+S&38;)I,(9$6RB1:$N#1N7G/@)1%`N83CD"LS5735F3>9#Q-B M%M9`L6Y=',7E*/AF(X:SCAG`A0DLC9C"(1W7NT11AX*M(6[`2"6KC7<"<$\O M7LS1X.?=Z&C);;:AIA]THZ/`;6[C:LVVP.W^EOOL';Z\:ESE!&V9"<8IE#K# MC.B]TQ9JSQ(RZD1/C=YG=^4<0X.P!F(U\7HN$;T,#O'G"7:A?-\%,]AK82XX+H=/+FB<$B<2K40";LP+"L M!+XY('E=B0.'B0;F"DCX2)O;J=L#85P-5TDJCGG!@ M1L'6SU-BT8EYG-9)3%8RK$LZUY]`&&.N` MP:L%144$]*:X9,,44ML=G#=\B7+R_9D73V$E`^N>G5EUI,LT^.ZH)%%`EB*3 M4$1NL0[R^>*WB^LO%]'GB_.;#]>7V^Z=*6S:83$9+8Q+D[V^9(U4!"\W"D"5 MC#+V+&/,SXU3NP:5$P$I.6%?&6O`&>1QT44<55J\8BHEFQA*1N%GP9&)%;?- M!UEVBE2807$_(>;V])"Q43=$'Q@HDG#A!Z`9([G4;-4]EM=,`B@//P$,F!085+'L*=H,BUK)R([@P'SY%&65VVP:V2L1K M`&>C3^&W'E@+P[.8?^774#278\:&_Z_+)W%5U>]V\_?_EX<7W;WU[B7%`$ M#"W7_P%[%&V+=C`?,"VFZOQXW^N_C7K]\^@4S*+H/6I<7%KL(T-*;#3+`A]@ M3I]*'"ZEB!17[("!HNOB(&H?G<0.F'K)B!9?+9XL5@KY&J`3;5@FXXQR'%"K M97P+ZF..3L@(_`^]WJ<#GCC_VLEI22HUZ+E(B.B:A(RTU3"X%":.(,HD?4PFF*B#L"!SU%LD6WX,#NUWRL&8/B:RGND"V2HX%-"Z.B`\]N/#V?-)YG#APZ,#4R MP#D#"7='D5-,&1^A'D)&A0SDY'N+Z2:@,P%;V9&W6!.\0JI%;;WQ1^TWT=_G MQ8S0SR2=*=./\(LFXS,<7:=B1,2\^&A76XRH9:IV5E/5P$>)GN:>K*9I]._E MNQ,U!@UMDHPDF`NIH,!?>6,O*R:C[@/W(M:*ET3@K28K+?&13*XCP?TU\Y,4 MQRE9B?)N?&-YB*W=\F-SZ!Z;WRSI=37-6ZRPNE$X3*Z]GQ#LB2`"F2W\&>V2PZPR'F+,)(4M6!B%`=2= M:D^\D9K/2]M5V9)H\)+F+T:2NVB3-4$;$FXM6''*,+-0J;"5+>J(R2`>F.[L M=L!#5KI$1&^S>8)TW0A2E69W,XWY;0@QX5SAK^)[Y"Q@5R'#$$4!>M$,)[W% M>_#>H[^/^!'%]C77S!"TG$:!%9\7?"5VH/*,0L(2'K5;'&.9O7*VCRX&]YK& M%E8TY9KU]!OL,F00@$9V:[R=]W=[\T/SETV2$1C9GSAB/-4:+(4[Y+* M=@ZLL:HE?6PBMQZ`3^Y3Z0)8_AGG\/?*._@/EG=QHV*UPXF57[D#.?[DBWHT@F",WQO M#&*44C7'TU&QR#B=.`5K=C##?!F,U8&Z/)Q)="A'%^584T@L6)C*6]UEL,:) MI*4-P?0&'M-IM8[W*++[A&E=!"$B_*^M?^?/FH",FIB-ZC)-F!:P9K+B9,'` MCGC5`[-EQ=X`BZ0D(O$RM!N\F6%L$6-Q0GNLM)56PIFH\E]@_%BA6'>9ZSCE MP*4P0R+'@/Q+C!M'#]5)^]0'-2G@&%;I0HP#!P%#"Q*V$ZBEQ4>$Z5HI5(%( M`O]F^G+X%BGR=I3`F>L/'@IDTO(:6E6$[4#S1PNTJF2A4A:\OAHXPB(1(BU, MPR'%RLR+2.M\'CAS@M'J_1%%]@2@@7,89Z`&I`=$);-^^6[-68VA&R8$>:-0 M>9`M-,:=*70'&X9SBZ52#6UO;-;F^N`Y#]!2G'UKPRQ'"5/Y6XCN_0?0>HN2 M4PX%&4;E"#S8.'U6SB`+R7CC'G4>_Z M7?3N\NK++8C?JYM^/_IT\3GJ_ZWW^6)[*7/9K!=NX@>=XY;K]]?NP32C3R`; MJ6EM;/W^#".A0..HJ"J\'2Q+Z.S",9Y+U>\TE^)&G#Z*M7QJ<#07!.+4#\/G MGZ21+BO7W$TWFE`[71<^(G@2I[FOY.1: M`K:6_\(J=FEO,I<"-.VW6?T_B+3!,WY/BJ=5T2Y^>8\^[4X]DN(D&-?,7"FA MR]_WEZYJ_C.6#ZR>:F8[Z?"!E7HX0L\NLMX-H@A]4>0?>MEQFJ@0".N?3TEF M(2Q+()CNP"&&2&7$56@^40@5:64"KYR%%0>I0O/8Y%"8C5Z^3C6UV#PGDY&* MTIMX$Y8)V%?2!0O#;I8^['=-Y[)BMTZ^YTO*,Y;I^?FHSA%S:O;RH0A5Z_U+ M!%F8)U'M@&F"JB"VJ:"?ITF:ZL_/GN]3GLX>\-'6JU_L1_%[I0Y&_`-T*%W+ MK)C:1_&DT..I/BXC'K>F7S>&>,[2WST@O(*K#E"@3U74W,^>\A)_Q8=,@965 MQ-B%_6V6;!LWQM,4U=8K84GL==%J@Z`@.';H0%MMK/NC2_$D_V?O62),;+E;C=GQ+WI\3]81*W MNS*]RXEQFLR!6GY70L8IO"--@M`+`QRFUE;`_6+4L\]?RO-N<7ZMAXEBW9;2 M73>"F2#RUM/V:=P^[3BLL95G;1 MC8^.25U;R3"PO.\]9K[/&MFGQ#OBP^/3^.3(YQX:SOAF_G'RDW_\Y!\O@7\0 MQGOGM!.W.XQIH!A,YDI@/-IK[Q+I*>CFG(_(S7E?%O,IAW.'J-B6[O7%K)1: M@M,&K&(E=Y,^,(A(F28+D\FH:^#XY:T M!WW>Z#I17O(_?G*DGQSI+\>1C%NF&W3+`*LY/(P/#[LKV`TJ,L)P$@.%6>5R M;)^<6#/`Q[EP'Q#G?;@*6.4/IM*(!?DFD#8,P29DW-'UY]WY>7?^S+L3,KO] M"B<3-)/+_)&Q/2+UY$911I6D1I`T=6H3M)[OL[?N1^E2OBI65Z\D+$W+/V%$ MP7WA979W)/`S\HPR.G_(LV%DNW3>#(:PJD6,&-Y4:3$$T MU.C9T@Z8BNH:SS$OFTK"9C*=*UX'I2M$#%\@`83J_._=]G=[&7RNA4"/4O>Z;M/4UFIR/O/_&-XK1HN,/U6<9&$C8>5+,;>E/2P%S5GS>W.PGBLY*F+GF%%J=YB<-`P[=_)3Y/&-N>(A\.64P;XHR&([/YD% M"46>JO%QXCJ.:P%R=P[K]E8#4V&'PQ'#K('7HK/6N6@8JJ>%[)J[JDX.>WEM M+2WGP`PSRN-1(4?K4\&WVO=3YL#R,.4)24!E`2@OT&XO:66=,Q:)4D3-+C\Y?D!WP5`;<-42C.3,6GM7:T;RR)/4FO!=Q\TTYT3A51,%6FA8]EN5B M^>KVV5$S;.7\==;C#/7[D3?18 M8`(9%<$HA6FU#[NO<,[MPZ-7;TQY?4,0?:P#"NE!]%[8`PW)RE3CH/B"SU/R M;)Y(XP"%:6[4FV6O$?OUCM6N\@`2DCO=3H=WHD?X9R"/LA!35;;Z2LL8DH2B`J)L=/=Z%:JX:B.%1O+SAV;-+HLQSI8 MKZ/=]EXTIFN"37I%"^$/5L%&<@6%+2#,88XIF.>1VZ2-"J8@\V_^,U>;B^VZ1+`UUT)].-GB MQA;@##1/IQ?`57)7@'52E+8,MX$LX/,8$DHITY5[E$C+UL0Z)-W\+TS#Z%`L%&3+*RS)[+`94;U3+#8HZ7Z^8ZQ&A MMH>%]'##&=B'QEQ]B`KM1E+G4++4W(&I&ACJ54\3K6U]X&X/KJ$R!>^)`I4C M]=4\P6][=>MI8-.9VA3\E6EPJ][UE?YFSR;LF^[CD@&K=%M[[M7)V#RR M40$\\9[J+-CYR"GXV+_$EC=SKFK!.[Y0M8)EW M\YGM8DRQ*%S(?`I+084LH_IDTG2!2D]AU6@]JU96/HW?E`?#'IRSF(CH/^1A4(;`['Y-\I(%C3Y#42R'@:(XTOM5[ MU@N(?I2C,FL7..Y=K+JVAA>&FU)X[N/1HG;+],:S6]>$E]@W@5]F-B!=.JCL MN12D`4[>[?#!\JJ5U'Y)W3%< M5D#V(_]1K;&(%M0R5%O?D";^VD1B'#'-G'.G?)J_JK?.PG#8AGZCX7D:@CB%TPUIE,PG<,>$OS/%Y%`3 MBY_5QSNRD9WG.4;BF@1Q?#=$@"F[`XS,D@D[DLFU_Y]OV'LN@7XVF[%(,@_" MZQ\)`/6!FUI_!IF%'9U>F&?`@.C;QMFR[(:(.+1K=;@TDIB7&\EZ(UUP#5H2 M>MU!EZSV-HBERN%!/]?`7E=T!\TK;C)-*(SH)%Z2:J6XS8HFE8I"0_-.I;8; MAA38$*(2@MQYSZUO;7QF@U$"\K_1@\:LQ79@W6)^O`0!&#P5!F!68X_&E8K2 MD+9DF+.B9P;A)CXH)1/34PWW3?:H[NDAKPUB=ZGB3@*'IX0Q[A.L9DK3\)0X MF,Q$6K49)2ZTS;'S6^3,')G2^(5^>N?4@$5P-!B_W4)O?RT&YD)(0M1ZP[$? MTW1BDOXJ_HS[24TD$26F#XN*"KBOZ%5']^1)8B6")>)@EE%JEJT=)I^QTV,P MPHB?T'\$F@P78`$ICE1SW&D*D&-,;)"Q M4-KMKA@DB;03$$RBFID#`6<3%/_2U-2:)0--BTC&C80KQ\2T(+@:A:+UU*GY MJN:;7XHXFG"84X3K.!%%-*_@%UBN"]]DKJ6F>7!_GDBQY;9&,\/ZI)3&1"_6 M8Y&GVM+<:*;D>!OF&.GPI(4;26%M!?_HG.]:B=+P^FS)9.+0:X]I.)ACFCF# M_HS<;YH1"[0U[-4.,1\(''M;<1'8QFSN13;*A;$'-W/5'M7W\TN5W0POA!-6 M+V0'"09BE?&%D6[G? MVWQ*(&0M28)J-)G1?GN,?,9EQY\82!\A[,\,GD]4X=P,C(2#)*EL*8Y[(-K._UAZ)(T?(#1>5R MHCVS>W1=ZS\S%WX!)^!*(JS65MA>;P7UC8<#9+_OJF5&,Q8GH0F2$%=D9S!R M:G$4:XC:!JGJCF%M->SW-\:.Q0]L7-PP];1PS]TDZ,TM5SZN$)7M$;MT12B M=.F9D3H)96Z%'R6G<%ZF\@)_33L7^?6\FW`>Q4<$>[*3Y64ZL'__#NV1TYV= MR='HT-YI=1R,X%FW";9;FB^;6&O9/8_<=U+UDE3A%@;>('WC3:_36$TV)EY1 M;K-CDJ]Z&!>G%07Y&#IQHD;DU0'+7"<2?^YS$9H%P;C5=6D/O#194B[A>)BX MYY)4&7C`AH63.1IVVG1)4NE&VD\71G$Y"B7K9(3P%+=UL:C6,0.X,(&E$5/@ M_&(WB,O@7>0&TG#.Z%"==15BV:1]WHV.EMQF8Z7]J!L=!6YS#3_;:7W+?:Y9 M_8VKC'77&+NDU"%$$U5K9&K/DM+T(\G]&E;$:N+U7")Z&1SBS^<&&!+SW.:* M6W4"\M=PX<:@_@V`7,Q?R1$@>8.@W(JE8T.D3I381U$M<<('7&QP7V>2WF,VZT+%`4=H&2=U(?M\C$&IMS M?)ZQII?O^A8E7./CXY,5C$OS??>6)(7FE*B)R%#+TX>"]A>%G5.D?G-4T$@\ MQ0\W`)">!>$X'>O1Z::I[[&-1>Q4]U(T'@=7,9BFP4`V6[98>Y3C5>N51FWE MR;^`'@YN7#0`51#)I7::[G%I3R;Y5T!S>QWMYGM.*@;*!:LJ<,[:&W@F=^*^ MJ%'84[`;E"E[?A*^QD53IT69WYV-HX+TJ7Q/'"9<_2W_RJ]I*KFT*<5@;/ZX MIU!!YO.BT215,:&,!73,E>B@QDGT!8=9+BY(!"Y4K-R0O+(#K:D$,T:OE%G--A)%AMH9S?#]^KTNK1- M45^,F^?"(`\51L95G$YK.D]:3-6&-7V[3D&[C:AE+JT4^$N"6VE=R3:%"N;T MJ<3A4G('T_'NPT#1=7$0M8].W/Y?2T:T^,K8";K+YE*IU#(99T]%R;6)Q_0J MBE5'M'.$_4.O]^D@0)P8E0$]]:8/DXFQ#B4?QFA!E&B1 M,ULU$`RCXR)*G'Q.(1VPL^18Y]G,+:$)N&C=1X33#I%Z5U1*T#X ML?(B$,D=:&)NMU\6!3P:Q''&0;Z#`+XVV2L`J2 M#-0"BHC#$K[F8^`%-&DQF6VO>-$0C:;%3<7]I]W>\JI1$E\)'9@:&12?7`E( M<832E=M]\D#4$=8DN2 M.91+AK-U(3ZAT!8AZ8EY\=&N7D+QB3^5JIW55*W@.HR24JPO_&-Y:'&2];?FP.W6/SFR6][@9!$,V6L-E!&#PP")T-HO9-*,'*++11 M=%96[9/+F[?8BG"#*2!RX._2XKYZ<#M&1KNV,Z::$6/8@H51&$#=J?;$J82U MT!40X1=$CZ:$;V>E(9IN1DKHVP3-@D0,-W6P8%H^\XJ`S:BSJ*F3H:<:.UIB%M/(,:C'C"?+V;R3Q(2@3.$19_7/B*G,GG,% MW-55_H:PSAZRWS2!1/P'$.73"&RM%V/1 MWWJA"CE"I/RAXWJ?`W<#9T&;+6@N`BA-?L?B6;2M? M.@T;,,+1.[--@6@>PE-8/0N6QH?#21YW2..=065#0YK$ M\L[NN$X@@7/-_5)WL,\#N)CWO''F5N5#Q5.0U,VU$%L3,!N&R#]?;-0EST52 M(O^K/F4EC?;R@E27S2(&QB_<.6ZY_EQ=#&T6K"BB)<5.OCPQ?0J+C(JJLL7_ M:(.`AO,97Q6J(*CGB!ZMHT7<&"T79ZXT"_DI0TZ@."Q@+)@E90LDZIL2[G7* M+#::V!Q$;VFR6'BM-F'"\RBN.![F1`SVL4O[]&GW:FS6>47]/66O^\OO9X^LL'R@9^E>!0R@QP,K=2#^7CZ MKK5::X4IV7N*TT2I)_R-4LM-$>Q&[L.I4,7+D!:67"1`QMCX-4H7EL M^9-HO:%;YC`?,P,\1$@::2ER6UR! M2G-/HMG)C/R^-^5W?_O9-.GJQ7G6IQN&+S*S2^*_7$SZ$W%38D$5__Y]49Y+ M]NGS)LV#N/.^O'X/,S_%_SJ.%K7Q'#:X:4_*S/;( M4+@9.HU7KHMZNEVONAEN.+M.Y]BRT74?\6;TCD*=)%UOAC9?>%/%\_;A1U:J MXEAKLUJ5@0?^P$I5[,8X7E.'ZH^M5&5,YD:UJN@'5ZIBN[E9K2I:4ZE*CFSX M%"X_J(J_VO28-BHN>>;ACZ^V%/V(2DLAV@KA-O.`]E#/YDS7MPO[R"=N'=Q# MWPA;N]4'4L@O)\P$/Y3?I`,MD1B=HSKK_?Z3!7K\YZ]?[\I1_AK_#S_^/U!+ M`P04````"`!#=+-&4WMLX"4+``#:`L``00E#@``!#D!``#M75MSHS@6?M^J_0^L MI[:JY\&Q'7=FNC.=G2(V25/EV!Z#>Z?WI4L!V58U(+<$N[K=P0[-B7RI!:;=U;T-^4,7+QI7*+ M/E[ORG[Z<=WL7W7Z_]^6/WMG3`J0>(A^^ M$Y?_?3[LBE^]=^9Y][+;O[PXE^S'1W[`]_UTG]YUN[TN_&S(/SC$^WHI?MTC MCA4PA<M7RZ9\ZNCWYG)\Z>,WQ+,MI').'DDH?BC:B%_-"CTKY$C]&NL,/9YGHRYA%4+.$4,5+3"/K&0<[*TB5PJ$%T$*!8V MY9/%9"W&*[!E(25G68#OPV!C632`T<9;3L&`%L$< M))AA1UCR#NAA+LT3_X5LR_)AM"8^!'R!GDZ\Z$`,8\HW\H"K.JK11 MXI[C;P%TJ#V(43P__)/;USMH[;ZH:/`Z9%\OV"'V$7'X&#$Q<3SD#BXE=U/= M"%X46`$6E8_P164OSJFR&:"HZ/(<7G.&*(KB14RS@,$:PPJ<,*4;P><8!7[R ML6=C>\='P'OI`A,N"R;=S4]/:2L[JNB_R+.5#0LEQJ,ZV?,7CS'!ST':_6(" M_A],QL9DI`]54QLJU^I('0\TQ?BH:::Q6Z_OI':H%9/4$1L&]""SV0H:[@HL M$+\/MP8"WEXBM.Z`9_0[V/'Y[HKPE7Z[V]ON$/RTO?Q%Y1P0#`+&(OF$@^ZQ M$W;[9=ONH%FG/H'%F@R\1_S1O@7D`7P=9FW5'X!+/\/P'VXFI0.1)#\$&/$C ME5D*939F5ZU>M[OK"3$KYC_'&S;;%ATN9B_!J$W`-W;T"T;=+(UOM4M/`1.U M#$C14AXQ6:Y\D+]62VX0YOE<P^8^VXTUTT( MD^3FI@S83(H3P6H@\QADC<3:5G('Z=1E(!G*) M=CI.DL)[&1L19]C"D`&!JR0L5@V,15;X+L$.@D4A#G(V>?OJ-BD,I*%QI'N0 MIBT)).\;-.!+VI/E!.(NW2VE]B-QG/1XDJ.6L^%%77%51`6-LU^XXMK*33TK M+Q5-:2YGH5_JLE`FR,:99$30/7&(3W#^TB"I;9U9Y68C:+>>ATD&KK``VT4P M%6)2?WZ:#NTP5RVNG,;YYC#`)MWN[$T1D[)G%DW].:VT^?*A-\Y:T;VU`\D= MQ#E9$&SGFJ\0D_I38&E[GJ"EAZ:[(!2;MJ-;B+)`*]^5V\CQ75$"C7P5Y21O[[?XDM4?QI)_=%:1/W9P%]+ M_8-$)Y`T1#YQ_;E]$9/(*J-QH^J`NB[U0JCA+<1)X(>/.!!OF95I91#5G]OG M&TX&1T,-IMHV$2I`SA016_>VA401*!E[71*T]6]_2YM/7A6-L^),%.=XV-80 M\\#;N&I9@1N$VP)#O"`6R5BRR=#6OT4N;45Y550_LT5M3*B-BY?(4D64NQ58"N13UI][RZ)+7[_]0(O1(@@S&C;-0[]G?6(M M33T?U`.=+'7/QPQS?R/^%'K$L,ZV=W5;JBONTF0-]B]B6W\6?:+E2U%GMI-\ MZ!RJ9`2?7[^F-/D1OUB!:5^^P%1Y$^/W\VN5R>8\_A>#\S8+CF'"GSMM#%`F M-\IDJLU44X<&RIOY6)T/=6CSX?ZF+GPK7#J,7,+Z)]!4HQR,*I(Z:.#DPC&((RJ`A_@!.S2LI,NU7`Y9 M_6F!K-VD\#?.:GMT.LQ@+AY1+C-81!O7N=V.',QGH&POP)E5JD<-&S0<'"O^ M,,%,1MG4-%H>6'ID'4-KUUPW@GV9`#EH5K^7)&,D8KI(O&KO>R MWS026QM=R*^-!JKQ4;D93?[;E+41&%2@FS+Z0$!3U\]S+IXTV`^"J@7)]J:& M@HH'N`.X=KQ63!SZ7\3W_Y/;*;%9@BD/BR`3`[YI\V"X1[79#^_EE)CL6S5B M!BS?8$FJ*'.^3+D-,\3W_I#PL(!=O&:(D27QD!,*LK]N60Q'GR4_N#U3D$F`R9> M#33$F[^ZMWMN!1"$Y:Z;!Q:S*W^+<:F_PJ$2\Y^BRN:M?8Y13!E>(R)J`<([ M/=O5FQC/OC]G5\0UY/C57T#Q2DY21+T_@KO(//=VRDB2S:_^JH]7'E-DU%M] MO8[8'9@D/E+@+BBP".1N^^V%LF(>WJ3&=HH7->S[*WT60YEOG^T/0<[A[ M9%+5^A80AE/?KI$.OPB/QNX_%'2"PW>2%%;C#Q,=-["R\ZSRHT.:;[UOU[$P MMOD-.)'ZO3F69H8S,L/:VR MA#;_1(68P+\>"CR9W:IC_7^AG(HZ'D8*9JL4^Z4G*<1`O3L$9SP:71O:'W,AN/9)U-XT<&`].N4A!NFB MW`%6>;/KKM*G2\H^^R&FDJ.9_Z4JV7:K[/NM]LF;`L='Q'`?)1!)\])KHSGA M0(D8J*,$(G/N>FUT!B`,^/4@[I.3`=]':E(7Z) MTQ+ARM]02P,$%`````@`0W2S1OR_K)$1"@```6,``!4`'`!M:'1X+3(P,34P M,S,Q7V1E9BYX;6Q55`D``QV"6U4=@EM5=7@+``$$)0X```0Y`0``[5UM<]I( M$OY^5?X'&3!V-O'&MR5`.*KB;1'D-O?%-4@#S$72L*-1;.[77X]X M,0*]8@GD2OS!,6*ZY^E^>GJF6X)\_/W9MJ1OF+F$.O>5^E6M(F''H"9QYO>5 MB2XK>DO3*I++D6,BBSKXON+0RN__^OO?)/CY^`]9ECH$6^:=U*:&K#DS^IO4 M1S:^DQZP@QGBE/TF?4:6)Z[0/YNC+KQ<3W5:M/3T]7#OV&GBC[ZEX9-)TZG7K,P#M=]H(_/U[7ZK>U1J/^^$?]ZGD& MJ-N(PWOB\C^OVS7QJ_Y^?%V[JS7N;J]3SL,1]]S=/+7G][5:O08_:_&/%G&^ MWHE?4^1B":APW+MGE]Q7]JQ[:EQ1-J]>@V3USUY7-Q;81C)Q!"4&KFREA)8P MN?J'#Q^J_KO;H4P/OJVNW]P?2F)4[X%VR9WK M6]*E!N)^\"4BDB)'B%?R=I@L+LGU:[D!1+IF96N"1ZJDP6]1QJ45,B%:SB2SA7WV!,7>3,"8*%@UPB!BX:($Y M,9!U,MI0+05`%VL9"T[=P6RP%*D-N,SDY'@-!4-N(7?1L>C3R8B/%.0$N(E< M`NJ'#+LP4:K5%2.2$Z@!FR.'_,]7#6LX/=^)@CD!U#W;1FPUF.ED[I`9Q#XD M&\.@'F0;9SX$`@V"74`PPI9@L@?RL.TFP7^EVKQB&"T)1]:8(<=%1KIU%BV2 M$Z@.Y&_,!C-P"EC(^ZKE`>1$E@0M6B(G2&-L+!QJ MT?E*1Q:&P-&]J=P%1S@N5N8,^]DE"64F)7DM,,RYY2O>S0`3]SSN(6M]M+5@ M#6`X;R0OJNRJ1Q9.7?_CXRR:M[1L%):]#]9I33.,,2, MK6UA@_=1152KVZ)9E*FW/M@%J&"&-\6R20"7ZQ]G-Q/M.V^GA3B\"D.KFS'5 M4`7%X]Y-)IO41B0CZ&/I,R#V9Y)M;$_%22<3W*!H\5B1965#Z`L4C\NA7,D* M;2MSUIC$,^19_.2@W(H',<-EXA"Q&W7A90`W?N;8,;&Y12X4OK:_!)>%DMKZ MIR[)TE9J_T_DF-):A13041CTY-91`/>`OE_.9%%"I-:BOY)ZG0'_SZ727'MJH`1[\2B M)JYA4==C&%XT%5WS,0]'J@[X?28*1)K%YK.8EE?`I`^')K64H396NM)XI/1UI54T/RGZ7_MXZ[5# MO)W!J*>.@`'P/?A4Z@_&X.VA\D5I=M4"@<=TQP*`ZX>``P#%NAA_4D<%`LW6 M(`M@OS[$/E9;G_J#[N#ABZ0K@%X$M3YIRA#C:E^'UP\CU4^F1:[H$SIF`:L: M1ZM8'8^[/NP7`WS3>I/Q!);"@]J'3-45RU=5=+78=!719`M8<'..=KO7^N1S;32;MY?MG>_ MMZZQJ!'PAR5NO].#^P3[5=(,N5._5/)<>8[0$LJN>J.*+>YNKXC.2T.NU3?W MVW_:7'[<'<>`!*S!G[NXL-`46_[5 M>NT%"X0K-N\KG'DA)I^1I8[P+>Y"F)L:G*N=.0$3%->%DJZYZJ'_4M:RD.LJ MSR0F\C(IR97?T*Y=$I]!FNCIID02759*7PP0SU:U-SW#$V@-5Y0KM<>]S0A> M3Z$L->EQ'CLF_KKV73+_6`^Q.R_RMSW$$[/XV:/#=T94@#1.#9#CVS/^`Y== MZBH6LBG,+SR-+!T;'B-\U>VV>ILV^Q')0C)9\#$LF%]':K#]GYVPV,5(,QL7 MN8HOF[\WI^`A8GRUWYAHKO;?B=^1L^@H]X:44P(.X9J<\&QN+C+!ULBKZAM=(5^;CE.A7G-4-XH*,+0%(>4C]60%NP9;X&EZ[P>W;D,NR7VHY_Z MHY_Z/?53=]C%HN>K%K67U!%WJ.+KM02QZ];C@9?J(Z1V;`3DW)L' M.1V>%HCA)H*3G#`-4NWZ(4JH&YRYGRV;JY1X#WOP3F-.I>1-\J$3U4'FKY''^V(_5Q! M:/?WG)\U2&?4T8<[0C][\*.5_:.5_3VULMMXRC7'!1Q^&1#;OPX;6^ZF=;1U M93L*!Y&F>7PS6N(R_>H87\>1\@:>N,V/FS)WJU_-WUF?&6I1YQMF7#PVZA\( MDEJE(8,OU==+C'^:"GE)VWN*8<">9G8)FA(+'(G=EL=8TB,FX2)OX9F1&.3E M;)AID!:@+.7JL^@-8A&-T=2$#"X]*5&8W\+&WT&$^45FVKUE)U!Z6N)PE[/+ M%40\<=#Z\2]LBC)2?+`U+4DAHF^,KB@+\FYE1>SV`T;FQ$%6!QEXW2"=A7T[ MPL&VGR!57@K2@D_1=[KXLFDAQE;$F2MVEA43E"HO4VG!1S%UF^\Z$><1S+&Y MGGDP.SP^1BR4)+'R^C\U^B@"WEVH1?NZ[UW<;VQ>'WT+3.HO)HGNW&Y\(7Z) M_RD`KOP?4$L#!!0````(`$-TLT:Q/@0,PR4``/3H`0`5`!P`;6AT>"TR,#$U M,#,S,5]L86(N>&UL550)``,=@EM5'8);575X"P`!!"4.```$.0$``-U=^W/C M-I+^_:KN?\#-WE4F5;;'GLED9R;);E$/>U21)4>4)YM+;:5H$K*94*1"4AX[ M?_T!X$-\`"!(26#/I7836>IN?@`^-AJOQO?_?%I[Z!&'D1OX/[RX.#M_@;!O M!X[KW__PXM8\-+B:YL8KSY\]G?O!H?0["/Z(S.U`S9P;;T,:YK?5# M_/3;Z_.+M^=OWES\]M/%V=.*H!Y9,?F-?OT_KT?G]%\7[Y:OSS^=%6%$FL*//CQ%[@\O"J7[_.8L M".]?O2::K_YU/37M![RV3EV?-HF-7V1:U`I/[^+]^_>OV*^9:$WRZ2[TLF>\ M>97!R2V37UV)?`%)Y'Z(&+QI8%LQ8U3C8Y!0@OYUFHF=TJ].+UZ?OB&M$SDO MLLIG-1@&'E[@%6+%_!`_;PA+(W>]\2@H]MU#B%=\,%X8OJ+ZKWQ\3QK("I)6"@LU_N2K53IE6ZP-SAT`V?L=T-=U>X)/GEW MPGB/`A3UM1=A&<26UPE\45,[[!GN5N,[/?TU33H3W*VF"YIEV![]=99!6*X1VB6=9ET2*R_KI*9!9'C6 M.HAFS+]:GHGM;>C&S]/I\!JO[W!NAI4AL:.D]:J*DNH;80;5"NV&\J82K^R` M=`:;^-1+:C917X7!N@68M'H"997?O+O\64FM$CB"0I7$0ARQ6*!5HQ9+UJZ> M4YQKC^C1"`O[I[?FBW\0191HHDP59;J(**-$^_M7NT=V(55:+%:DE17=L7)M MH]-[R]J0\EV\>86].,J^H?1[ M-J((Q]'@^=KZ/0B'GA5%QI,;52JIDP4=Q-RC:)2D'=1[)VQWS%7R*EI`OU(; M_]Z7PP+':-HN]F-WY=HSRP_6>.VXMNOCB6^+W6*SCC:GJ`H_=XE-"KWSJPW* M*J-V:JBD=X*()OHUT=V;28?QA@OLL9B3!)O/R]#R(\NF#IQ0O_B+Q!FV,:#3 M%[8O6-$5JFOWSM3.D*NT3<40DSNNNQL27%N/.-M8[-[J,MK[KZJ`KV3 M0(:JVLX[,6"^B$XWX35QG>,_MR1R'`;K3>"3/V6Q6(..3H^C!+_H9*0*O5.J M#T1".IG$!UBD3ED"#%>XL*KDR(0.YGW$ MGN=,([2:UR"":"=YW/BT&#&+W09/2IO+$$/, MW45=I/=FE^-J&)$1/?P4\_XF=AX6IR>HDA@%EF1D4($#7XR`3<2(41DT9$O`]V9'YL2*`R"A1_`]'R'$#"SH+*]-G*^786NI]+4I:*G.YVY\*L$J`D!(H)/&1" M2B3")(1PV":[/MAA$"`.!7/I6?><R+>\7;(5B9R`6U<6`)K`9&41R('C1`*XVFY6(HT0>485>G4,2 MK/R,/>]'/_CLF]B*`A\[DRC:UB8R%.3UAI,-L,MAI4`8!(E4$%:9-(FR@:F% MJ.;I'U059;HH4?YG?Z3Z%'A;/[;"YTO7PV%U5E0BIY=$`IAE\E2$`)&&CTQ& MEEP#,94>&9(ZPP7>!&'L^O?)&0+Q\$L@KGD,*P5=&+L',!Q-%F6R/[B58 MKP/?C`/[#_/!(E4RW\;L=!>AK?B-D"II=C4*!:@X'(D&(#(IP!3-JC%-Q%1/ M4**,"MI]3K\D,7TRXK\DW_%Z,HFL[FD8(=SJ5$Q-$`23FM`)IV32H5710Z;F M`\9Q)%M-5E#2N@U6J0"E?;%2C=YYTPHF;^=LIH=2191HPMBWE!Q;$?!+)*1S MOQ(?8'&O4EFB=[Y(8=7FBDUSO#0A42$=P2DQHB:KGQ@"N'5^5`2!T82/3C1M M;#&=#S!H,[2B!\-WZ'_H)NY'RV-;O>.A%8;/)!9GJ2`$A5?4U4FK5L4ITDQ) M$0SMVJ"MT9`H(3+00C;]@'?J,`A9>J-4WKH>_5:CO])*F+B0BJ&YV@3L8/D< MD%UR53"(,0RB^!K'#X$S\1]Q%-/87K1-6R"KU1/)X)8\#T\0CJ>1H*O-+>\D M8%#F)@PV.(R?;PA,MH.4.+L-Q3?#(M[U3M`+;>Y<;8\[`=;TG4MDD]Y4%\ MXV'(.(\?<)B6BK2V-*H7R.JDFQ1ND5]<03"$DJ&K,HC))H$^#,HDN*5#F#Z& M?.*Q'L1!GG1T!VE4-W6M.]=S8Q/HQGJV:/3E M.^2;<(N=>A%%WK:-!:V=5ONBE7HV=74PO&R/N3;H2RV@36*"33E8B1&$GS;8 MCZ!0=[3%RZ!PL+Z1J3(%K1DL&H&7,ED(I<'0KA$BAV6,4"X9NQ$P<3*QE;(+ MG:(PS8*P28S!X!O+VI*^697"TFR9[LK%CIR`K2SH9&2'HA4IVD(=#&?;8ZZ2 MF,UX96XR#A!-JT#&D<%JY=HX!$+::HZBM,3"I0Z!M-YE(RGD\L(15Q0,R>3X M9"FB?)8B*F47#"HI1X1]!WYJ\5W/85SC+(9RR%9>KP8WPBB48S<3ISYPY>GT M1"8Q?`&OZ@I@/),*RGK.>__^E`1L:W@D*[A.BG))0+;K[OA:/75[LB((NC^> M"ABRJ>%4[@X!+>YP7Z,VKQP`9Z;LQ,#VCXTK/$D7Z<'U7X7"-!>W-\XT,`4L M/^2L@,:%)5YO@M`*GY.4T@VADE!:)T<:(!?Y(A`%TU?)\54I=(W_^LOR71^S M;5GQ04\)[W/#A8/QVF*C3I\T7TQ*31YR/TFGVY*BW9`G8N(UG6S+M+&F4[^" M>MG3IMY[,`Y0_/+5&'L8!,/L0Y2B=N\+#HG?1"-D%X*U36;B!%G;^"$(W;^P M@R[.WYY\^_<+%+'#SB?YWW3JM_P;D[A[0FXL3=LLG M2VLZPC9+DIM]^\T)(C8VV([=1^P!>2/90>^'P'-P&"FY=9F"WAL>FH"7KW<0 M28-Y"QHAUBB^G`]__#B?CL:+KTPT_NEVLOP%O1R-+R?#R?)K&/0:6AN7Q#(- MG*I)Z3V6Q(58/H!4$@%#&3ZN^J$B)H4B2C#TWV?GYQ=T_0H]TH-(Q[I#C;E? MHS!2WCGY2F$4Y/7=G:8`>W=OFD2X=XJH(JSOZ.=VD2?GY^?T_UE'F':O1K%[ MI=U;9IWVHFB#24'\&-G;]=:S:*]7-OKN]H2%XS3^6P*SSE"T/BJ13A?CP=E'E:T'C]MBC_'?KF_%9%&Z.75$*%X[UQ6QUA?!:$:)0J^3YQI@8)(]4Z+1FA\]Y8.FN,`W>'43\%P1`L<6ZZ/G;$5^L171H:=CK*P M,\(KUW;%T^7-BGKGQ%4+4I[X;M+JG7&MH7+V(F>"R$DD87"O/E.I/*79]QRQ MVMPPK/5B(3[^LG&T$_\J2E?_T,N40$"FA8MGW7Q'F4_-:GV=.9050G0`D:<# MBWF*:&L\G"^-*2J<4D3&;(2.NUS1-N_GC45WY3S@V+6%RQ.=+/2?$51:M.;T MH%SUWGO3[IA;)`Y%)3LR2GX)"YNOM3;:(P[O@@BWZ\AJ6"5KG.97*'46,/JP M?`Z/%8LP9Q[2JQJPP^9/;G#(DJ<+JD)566]2JS8%*J>W4M'LW8=T@BN@Y9)`G_AZH&J4G\T%!5`3+^J!E#:"6`VTBV=,]W-NAYU->HF6<(5 M+X#D`IK7EBK`*DM(Z:^]-[T0DF"[FG&"4KGC[LM06$WL<=VP<840T,LM0R5N M9$UOKW@JN?R[YO853!P7?X34KM)IXEV;'F9V6-J>XB52D9#FEA4LA/(E(+5Q M\W+GKJ%U[009*&U%ZG/_4?.F(YB>N@Y+T-H#;:YZT.2K!STYZX'46P_@N>N! MBK\>:/'7`R6'/>C38_,@5ML8J,_FX!*WMK;M>TH[]?K\_PZFTZ[#$K3V M4)O3'C8Y[6%/3GLH==I#>$Y[J.*TAUJ<]E#):0_[=-H\B-4V!NJT.;C$K0UY MSVK+"7\ES9[VL+:9ZE=0ZYUN[;$*-G^9(&?X:Y?[-D[O2S5Z(IW*Q+Y$'"+) M%*?TR^0Z^'S^D4CJ:I7LE5ST(:A"%2RJ5K:IE0D':K-KBHG@UE5YII7[: M`]X5\2U`*K'L^,/JXG8=UH&S.\SFJ_D&AQ;=IT^WIK&+,@C`38@?L!^YCW@: M1,IW.WKSTK@;L!K*/-WNE\X()(MXKM3*/Y"NV,PW"QIN7A:($?L;_% MXAOT:E):=V/S(99VLY5%>N>7'%>5+JD`#$*D!/7OQVGV\H8<'!)YK;<\-<$N MW?0D$@9#G":$M1N?,GED!Q&8BZBOL$]@>?36!F?M^BXM`CV5F19*4/9&+9V\ M4BQ"D5T-*F`XIH:SRK14*[E&HZ0'[#:-!8XPJ5EZI_:(.%@O8'>,RJG7H*/W M?)L"_/+1-HD"&-*IH*SWCXD.XYRSTX+!LYJK5G7I/7>02ATCK'-%(GC\`VU! MN4\L7SJ-8C/*=/`U*8/HX5:3\:UM=IL&\UQ,I-YT41/41ZGQ#)Q_>4)+(^E`^/=XUY?A5>P%P; MK.AKAN/&N*LBH[63Y,$K=8A%`5A1%@]:[;:Y\1)-9L/Y]1B]G,Y-$X@'R=*M M9#L]&B(KL;A.KC2!+M)&)`NFNVH`6.71P#`G0Y8I8C29WB['HS*KT,UX@9`(,K[OA/HR73Q\" MQ,]7([44G6)!#)I1/+F^FA/+-*W`',BXYAFH`U9(9>KJ`)9[?T..4IS:&V28']'E=/ZS MB2X7\VLTOQDOC.5D=H6,X7+RB27*E,YIP)FCU)M9L*'%.+AJ4Y0X+O>7,!R5 MX?R^C6+F1Y?!`M-V`>5V.6+CZ M-0KYHVCZ_#![&+TBO1*\DI_IES:-(S;I@]'=,WJYC5B@^W5A"Y"5/W_O^5]! MC$M72N>%!=5\F?2"%U?)I+5%L^OLU.426'^JJTXHMH M3YM?`5?+.9S^#H4U$FS2FSW2:[)608@B'#ZZ]OZKV@*_,L)W\BI0%MWJ=3P7*'U$J[]XZT,^3:-`ZQ@9Q4.-E: MD9I)*%GX+;,$PW.-\(;TY2X;\M`C!^L@C-V_+`YIE31T^C4%Z$4W)Q'OG8?J M&.O$VVDDAS\*.C`H1H+1$%L1'N'DOX7P4^T^Z38&-"\LMBQ8925141L,/5M# MKO75#^0OFLW`+XX!H@BGYP"\W0TE0/:#U(M,N@+JR.DI9!J#1F3G8X4HO$0M M+8,9^QZT.$V;"2:S3V.SS68"C1>26<_I@J-A_[EU0TQJA!0S?KXA):+SI_0J MP(WDP&D;`UHO*FM=L-*E9V97[1/?.`AH7[/?> M'L49?$D>_O">_8L(C]J511@>I1$1^5]J[DL)B"Y=W_+M(P5$K8T#>%TZ5HC" M:]/2,O2`J%MQF@*BR\G,F`UA!D1A8&/LL--4;-XXG6X0=;="<;VWLLI!E^]C MY>K0HYGA7H0Z/7%,6DQ1&3C M*H%DG0RIG'YNJED\8$:583!Q/Q]_E([C2XH&#A\%?!'!<[NR*,TMKC*3X`)H M6@%DD$S_0P?*CY9'!],W.'0#I[HD(:C&=B:T7I;0H7"ERQ-:Z,.B=@?D@DPZ MB[%ACLD'Q&):FA"%?1C_=#OY9$S'LZ79TRDA?A$-\DJ'X3-YU=C-2NJM6E'4 M?*IHPUK&C*TP;M^L(NBU40EU2W0ED/DGO#-P@N[PO>O3<[^T(T_`_/]LUC<] M-.O8E\Y@M@/.'6KR7LL3-";?SB]IJJ+)?`2CNS&WFTUR(,+RLL.^$W\5A.MD MTZA\0D996^OYA'9%*AU=4%,%,V9HA[=VD^+MS[=@L(#>DIP:3W1"1H)%2I2^E-%U2#6$T#E(H`XP<-5IP4[J1E3,4#4R'SA MC#01^;A;??$=SF"2'LKQ@FC;F`5R?[.Z!UN'J(1J3+>/33#T/E!!%+M4D_:I ML_F,=:N%S1@D'CS*2H3@C"%W6O$R"-,MN69ZPK%29>U4M9TK;%F8_$2AHE[O M3.T`MN:=!9/![#SK)MV'?>1SK0/LXY5KNR1`#8QKEY!GU.A@$38[HF^(Y70P'#U/A>"U8,O=RR`- M@2QOE\I-EKI/14L;L=6+D#.W604&-95QUI8.V*8$PJM=]V0WHEO@I'GCB33"'?XS6^]R.5$FE MR^`._`PP+\N1"L9]UUZ?H?GBRIA-_I>]8FQJ($T!.9])5W0UKA6Y][Y+HG>+ MY:])'<@-J17;)=U2PWNDJJQUI:A5@4H+14J:8)C<"BZ7GV_.D'E[?6TL?J&] M@3FYFDTN)T-CMD3&<#B_G;'YK)OY=#*7V)I!=B[7-(2X=XIIHJ0RZIOSM#0N)G0R=+EPIB9 M=`H4C+M+QWHW5A@_%TNF'CNTLJ#WUNG612O?0:VLWCL_NV/F,O;M&:+KX>,% M<8/$`1+'AF;S)7%Y-\8OQF`ZAD'=+`6=&DV%TGJSKTDAES.O<47!4$V.CTNK M;\_*-$*G:+[\.%X<:_83VP]^X`7WSZ;%$EF8VSL2#+`<+METD[0;;6E`WZQF MEX+M9C#;:/=.M\Z0N0S\^QE:CH6MX5]G%H><2+TQVR\ABOFQUM'-VGF#E5NQB!P=@] MD->(2UPF>D=&)N/E,EEUWW&4L??Z=GE+8LNK\8R,I*=T2$(W3P.)+\F;&N$_ MMZ3\XT=V8+YI!"V6U[N]L@%V>4.E0+AW+JHBY#K+]W0T/##'/]U2IHT_->VZ MW\KZIC^.(0GKQ`:7Q[;<4Q#J/\!\FJS:$LZW. M"7WXLM0V-R7&Z:5.!?-H-Z.$,D.(/`*EST#I0_(?87C?TH0N@_;%\9LZGDQ&D?>JW$9ZOQE'LKLEK(#J\6A72 MR2(^P")ORA)@F,*%5>7&K[B+N55`C'>SHY&#G8A:9V=H(&+YV15[;&#Q;&K.K"9UH-$PR>@;B M'!>8#,&VF-X\1L)+]*NCKIUZHX10HJ*8*A81NT52I>&I,% M^F1,;UF(F![!,:9H,C.7B]OK0TSG'&B.D-[6/;`B[`R#-#!A*=\=>FZI9SH<_GI+A\7A$HM7KF_', M!!2L5J^T5^OE&[5TLE6Q"$5F-JB`8:$:3MY4S)`MNHPFTUNZ\6LZ-TV:ZP*9 M'XT%D(T1^?[,I22E8E5([^6:/(#EZS6+$F!8PX55,J%TRSL%3TO/6AMV#YVOK M]R`<>E84&4\NMSU:J&O.A@_T829I(N[Q`[=;N`]DW'#-J3W^*S=VL5EZFH:=P\K%Z*PB;A1 MIW-P MYG7V;X>NE*(7/I3MWM^2(Q6()>:B9" M]U0A207@N.35)F\1D'Z+9:!A=]D[HVU(=Q4EF5(9;G;[IS#T;U;4.Y92+4AY M;-6D!8>TJE`%''29*LL5E.8(`LW`9"V@/0&+>@#X5R^&`OUV2M#95T.J3+X3 MQ'1!6L&`#`2DG!E+UC21LZ3\60:Z/.8F*UE+:;T'TD M@3,*5BL[8'B7GZ`#@L+I:JA_VB&"Q$O">!'P_A MA06S6A%_'T;%NY=&.+9<+YI9(=VL]RC*U-K9BK:YN^Y%S*?RVIOH MG:O[X:[-)S-#*+.$DO16J2V4&D.YM6-E4TU38H^3Z]L)*,EU;4H:^G*G*D'? MI4R5BL,@EQ)&859SG&@Q-W?0&]P$W#%L.]RR%17V_#RM8!.#U/2T\:A-,7(V MJ2C!X%0+I)S94ZJ*W(QAA>2.`*\(3.%.7>O.]9(;MK9A*%U>$,EK7B^0PZXL M`/"%>R>;*L)&DH'B5,4C<_([2R7[N+6#`Y5W>4=!#`QWQ-B:.CT8;*&`=]MW M\\V]@M(*I76GK)%`KJ:LX8B"88\<7WVA/;D("_DX3L:#-*DQP&ZM7*Q;/UW' M)`-E-V*'EI6J@ZO7']$DQ1!3CJ,$E'QBI+43GCM)EBH>.:G\D8+V>>C>N[[E M75HV3D\>-,7KC2K:0G5%\'F4WB#?.WE:@*SR)M-"*Z+V!?FOS.T::V77557I MSVOQP8L=5EF^=[JU`%FEVTB#:Z(C`4R&EPD0>EL,O5PCIKLLV0LA&MW*=;3. M(ZC`+\TAR!1ZYTL;E+QA'4ZW71&]Y/:>7#/Q4STF!FPS%;^?/5!I`Y6GY_31?M$MS]W,-)<^Y^O.PW M:`<**KAJI\23GX_DWW9GU[&[X7JLJH0V'\2'EGN5\L\P_`07DZ!!49A(':EA M1SBR0W>37,>0.Q,>:)&DMH:60\T;G"\&H^&EV.KQ;R[,[K[*Q'4P(25?8QER MN7Y84(')YT`J!)`!960-[1\V._ACU?GA;EUP`EM;&Y!GL<$FVW/.:PL%I+49 MW&T4!VLT3A+QGO72&`3FUHLM/[[&Z[OR=E>N`+!*YZ,#6-%9.GHZEB1A=S;[ MQ;:&Y=^S(6>AJ`47U$(;5A-U@0ZP_:9!9'C6.B!C+0K4\DQL;T,W?IY.AX)7 MIUD%5DLIXP78/.WB=E#5SL76$+_W4L>F[=+,-RO7GEE^L,9KQ[5I`@'?%KP` M30JPVD$1+4#RFSBD>:,+$YL+[)#PGKND)!,&UB#-2.$VQC9^"$*Z*"IJ@%P` M9*57T8&MZ$%C30]@5W4='MRZ+KR*S=7.%0;9`C*D;J0R!O2S+$!352(G9_=^*%ZT*Z]-JQV[0*]ED@]MX%V1E!J!>W,(&H' M44.]O*X'S2``JA&5L+;/)-"+5SW>`7U03=8"<>>#^KVTWZ%/;8%J-36P74YO M]1\^MM[7":IEI!A5]W?VLZOL2*G1036/.N".*=)[:3J54R?B[9JMM&$U9Q?H MM?,UX^''V7PZO_H%F0:]UG$VHE?4GTXGP_',)']?+<9C>K%93U=H)%<]R+*S M%`4T7X-1PIVVC!Q7+8I@4BNUDL6U"ZY:&^JSIVI42R?$R=(#IWHEX*I5 M71#MF[\%*#,BK53W.T&8U<_!)VV!G7S_C=!0]3`K7*6:>ZI:-DOW$'@DZ(KH M]1LQ_P;+FA2@BI:`JU_AM1/]"B7"R(CCT+W;QBQ3)QEBWU@PJ$ZC+J76:=(! MU%;*4"5O"K)\)VV[GAIIOL'T'+A_G\['<;U230A0,XBQU:8V,DF4B?9=YQ/? M#M9X*KCRA2,&L=XYZ,0UGPBCEU3\ZYZJOS(#S:OZB@B@:AI?" MXL9#*)'JS;'8(;9H=M#DOQ/?L-DQ2!H@L+EW=A;L473WP,GF\CNFB>![^&';N/R:1AX),OMN2[],?`Y_)B M/XN`^'&@@E1Y0LPBMN:6&::77;^DM@E=OD:[8V:"SG"E1E!FY00Q.R?YS,JF*1F2?H\P\1_) MR.R0'D'1(B`:'*@@+3U";AZL1Q#4RZ7K6[Y]2,HH6H1/F;8%:4F9W#Q8RE#P MQ&^R;2O$X3U:'G6.R35UU<",1Y`V^H#HT`DV=\<.[2K8AX(=TH\P2X@3B_;4 MSDKI2.&T3PV2(/4-[[4I?C4EG\C7V5?D7W>D$<@W_P=02P,$%`````@`0W2S M1@HV]];_%P``?5$!`!4`'`!M:'1X+3(P,34P,S,Q7W!R92YX;6Q55`D``QV" M6U4=@EM5=7@+``$$)0X```0Y`0``[5W=<^,VDG^_JOL?=+-U5;D'C;^2W9G9 MY+8H67)4*TM:24XV]S(%4Y",#44H_+"M_/4'D)1,22#8H`@!\B8/F1D;#7;W MKQL?C4;C^[^]+KW&,PY"0OT?/EQ]O/S0P+Y+9\1?_/#A8=)T)NU>[T,CC)`_ M0Q[U\0\??/KA;__[G__18/]]_U_-9J-+L#?[TKBE;K/GS^E?&P.TQ%\:=]C' M`8IH\-?&3\B+^4_H/UOC/OMG^KDOC6\_7J)&LPGH["?LSVCP,.YM.WN*HM67 MBXN7EY>//GU&+S3X-?SH4EAW$QH'+M[VM7R*7K]>7UY]=WES<_7U'U, MZUL4L=_Q'__W]>TE_]_5I^GUY9?+FR_?70._$Z$H#K??N7S]='EY==^?N$]XB9K$YY"X M^,.&BOWWJ MHBBQJ-+/-`I;\'\U-\V:_$?-J^OF#4,GG'W8*#_18$`]/,;S!O^3VU^_D">,H+..QE%`W@R,4 M,!4]X8BXR*O,K;`7#:QS!\4,6P5%*RO`?-++=1^-3UZ$MEC@\Z MJ(GA%@H)ZWX4X)!]".1=$I*:F!H&"^23WY.NF0_#\2XEK(G!2;QAB/4$>9H8SB1^;?:8(/\3.(L#)Z%+&I5(G=3D8CB(OZ7C[ M!?;A^SB*D9>N5SWF`YBM-\J=2KVKVD:)QQ#_%K,/=I[Y*%[N_N+V9@>MS2\T M#5[[W9L5]A9'B'CA``5\XG@N'5QJ_HR^$5Q5,(4NM(_PJKRK]Z1M!E!E'=[# M*6<(52F.ZE0FV"JWYNRS'^R0X-<(^S,\VW3$Y3MVA\E^S#NY3/^[:C0;&ZK\ M7Y$_:Z1=-/)]9*QOF/>HN\.OQ_?>M'21D,0\9+PZCV$4,!_==.2A1^PEW7_E MM##2BRK,9KI-H@$A=C\NZ//%#),+QO\-_PL7Y*9Y>97%`O[$?O0UY6&,%X1_ MVH]X_$7`.6LJ;KG/:-XDG,!MT&"&`X;8ID\4N#N&]X+TV`:O_6)K4+I32A[G8<_O/GWQ)QB%U,>S7AC&;Z$?T01<2`)$YL\V(0/2@CEX?J(>V[VS M37V7>+G@J@B6@Z9`./YB'QP%4AM#N,HR?Q@ M1B)U$2D=>%=G'SX0A9C<=Z3+D'0=WF4_*QC(),VAX%BUYRX5WSPF?&D(1B37 M&(J'E=OQ`M$%:'Q_(0R\ZHO*EN?%[(1DKQO-QC9/@OV]/1Q,AOW>K3/MW#9: M3M\9M#N-R8^=SG129SRVD,N28"R`[F@_F*/P,;&I.&PN$%JESH"]*-S\9-\K MLA]_=<)0+D+6<+^=R9@L&(F-&Q3(4/]X="P.V>H/"L=!B-@J"-5M?)#FCQ>@`R8U%=T%`T"HBV03BCGA` M5S(8]*T`BE#"G/(9[W/,?CGKIU(74E+L[Y'P^@>1T]TUO.?<1@E MV9`27Q,W-Q9$5AD)I:+:X42C@*YP$*U''DJ7GLSY5YS/`9;XE)S*6&Q9!1N( MX,="5+#23/D;8Q>39\Q,0Y#.-L&8YXU\*EAS*O5@+*`,@D-9')N\I\?4Z"_( MHX=3$9CM=%Y=+^8QBCM*9R_$\XJ]"$9M+`"MXDTJBK`#NB03*V.6^F[9*J*@ MN;%`M`HX4E'M0"/EKFP19S#B_KM3Y!C\0C$4]Z+=VW"AN;#4)7C29( MY+;#9W(,@N,*,AISX6B`Q@NQL3K.D.6-;])_V3*3_22(V0!P((!D[%/IQ%P, M&PX-K2Z>3>#>QGA*LTL`(Q2`L)310*'3%II0AJY<`W8@E4_!WV/70V%(Y@3/ M2J%3Z@2*I;;XA#*6%71D![AL?G]F&WF^]Q#=!!1%E`H(H*!I"UPH@U8BNQT` MJQ0JPP^]R@T.?^HLI M#I;*`Z28$(J7MK`'#(7"L5*F#CNP$PJHZ%]PG+2%2ZK@)!7]'8V?(#05#I&M M&AO?"UY3O%S1``5K?CP4K8J39*>1]MC&Z3Q^`L>;"A&+\CNX6BK"W\4H8=K5-:F^PA211^HA[3 M;PAU5AD-%$D]MP.K!JW+M6`'6EDMBG*(#AI"<=$660&H>#^U2BBKIN2""0[X M")];[;XY>4$V@9P$JG!M49$B_5&H!"?0=ROW:2>.GFA`?G]+D!;JNX@$JF]M MX0ZPON5":]5W6P@U4//EQ%`,M`4DP!A`%6')L/]VIR=)*)7?<=INW"5$4*2T MA2)*D(+(8!-"SFQ&N.Z0-T)DUO,S\7+\2PXJ`;10O+2%)&!XP=6@:9C+?6E* M6SBY25TTJA6T!67C5?Y,!C$JK'V)+&W MTSJG%+MCPG!J/LHV>X\TQ.;'YVU4.!&6:6<8)*XW2S8X(QPD51N*#0!*;_H6 MI7*\3TTQ=JR6=GE.ZVU(HRE"60_I3-^V/!*\(D5HC6TQ"W'%I_UO89]M&]-W M[>`*%C!_BD`X+"18P6:UQ5^KJ/3$)BH-1^PV,7U]K8HVZPU#2#4ICX"^L50E MZ*DMYEE%IQHBGO(3&>@Q3`77UW!3Z0C-"B35JUF`][<4W5_?I:)*&CWA`-"" MC@"M2H7=+%@6%XEPBF-"Z(E@E4'`@@R#`@E.H5G`(-!6'02L6J6V3S@(M*&# M0+O2(6E4DJQV;X-QAE'HX`T1L/'%>/7D)KA/K0(2',:1$QK/HCP%-5P1# M$UB%LTJ19(I3C+XT^>-!LO'P6[$J<9%HE5)V+-@2@.0IQ,OHT5G)V[@[QV;? MRH[-)E/VQWUG,)TTAMW&<-09.],>:]#XYF'@/-SV6!MMAV=B(?@SL+RD#8.% MJ>\)^R%YQGT:JE1JK=RSR6,VY.%PC)^Q'V-I>;:#AK8]8"EH)F>DC357(0%JP`[`#T13& M2O,E856!*93VW#/WMH+U?+8T3>8!`)#YQJ9/M2M#>2CQN8,YH#[=E2[32?EZ M!D!J^JQ=%6BP-NP84.\0\;DQ9@6=IK1/(K)(M/M68U>R?(&1FS[BAX-"JXAG M$Z#;B]EEBYB#AJ9S!JJ"5""Q^K#Z.1U6?;S@8%LPL.((,C_N-3-=`%=YP!1) M>>YSXN8.S.8$I'PJ+*8PGG*BBFB9\'8,E#]CLGAB?NX\,^D6>!`O'W$PG!^$ M;ULH)&XQ;HK=&,]V*06''B.>30"_C2I=IH0V]9D)QXS5MZ`4TT'"-]_X$B_F MP2OY$>X171I/QU$$_FCMV6$$!?:;9QAV8J7IFF[(!Y7]:,:_AT MNR4PGMNE"%N)Y#8?.O*GQ+H>?2DX<_P.?N;8=B8_-KK]X<\G/W/0O[:S70`Z;D2>TZJU@@D!$.^IJ7\;3RL++>%POU.C MCNT8?K7N5+4MA6M&0FU;:[2"R[_B[*DY7IS?I;Y+/+S#\)0"-0-XJ%3+UTP? MBVJU'9T`:A9MJN""5%&8/H`5:O^*4P'[R6(F>3$I8F+(E/()]QM M6YD^IST%_D+!S8->X-ZW^#&Z)6'R#@]/Y0G(@OC(2QC?_MQU`\PA*O!XQ3Y, MG_">:A"HI%H[%A*WF('BDA02?^8L:1"1WU&!#6144B+3I[TG]'R`\NQ`F8D> M8!3B6YS^F1,67*17I0_3A\4GM`%UU=IJ$ILWVI@E)V]FI$_URE\14>O%]/%T M!:S*P"Y7VOFO_PZE'@5XA0BO"9B(LSGDSQ*$R]YYK=J?Z6-Q#>:CHLCW:$B0 M=R&KC#[R_HP?QVL>&%2@A9[_C$.- M)RS*_9M+5]!XQE)1RW:LN=G8G.U)'/>WF`282<=8CM8C#R61`WY1=25/UU7I MPWC^0LT@TLJ:>"\KJ.,4JFO,L2#E0JNEU:/U=SKO=8F/?%??O*?"ZB+\2Q)0X2]3EM,8;P<4LT`[5>FE6O*/CSY(0>OG\TL'/)\#(`4 MBK"^JT:G0EBJ.SN@/DX7N@9["XIL:362>K1^[@L.K@*VC.=_\*7\,_+X5#K" M`:&S_0!8L:6I]6*N#E@=BX++- M%+WR;:P<^$A*AX':@LA%G0'V7_?4MB.G/!/L+GK[HT3"&W'\_ MOFUVJU93@+PPW=&F0):%,4TPT`K2 M:T6PA?WD&5;^2#%_$3QD*NUB%''FPY#R5%0\^YE$3SPCN0!'Q3Z@:&I\);U^ M-"OI41.FTP#YX9S?TT[3O9*[^BA883ZO;ZL6"6Z83##F(>)/!3C7T"\4>XWO MKM>/?6WZMN%>-J_>P-;THUR?6_9V;F+_N=%LO.F'_:/E3'K)Q>O1N#/I#*9) MO>^N:0I%M M<(%AL$!^=NN")\Z6E$'_R[XC#,=WSJ#W?XG]-YS!;:[Z^1_N`*@#FE/_6\@A MQ2(_+`WG`@G>@)@RV%N>].BP_B^=I3/J4K@-OCR)ETL4K(?S"5GXA*W04')Q M+AMU1DQ4-WT7/9NG[QD]6[V)/?W3OJ=/'N[OG?$O?-*;].X&O6ZO[0RF#:?= M'CX,IKW!76,T[/?:OF4X[XS\&`TAL508;P,6A]&?IN&K* ML<$=L[L(R8J9R54\J7[>=[6V,^I-G7YC.G8&$Z?];S";%A4=.E2AS`^2P+V4 MY+Q,OUP>>ZR]2X,EWQ8R%V5SBC#[*F_T5Y?[1M\=CN\[8S:]L(F%31B-P7#* MII*1\XO3ZG?>M_77]99#,JN/4!"M\^:BM$Q4ZN2\O*F*A/;X5]ZCFLG]1K%? M7>W[U8X?\1W;],?.^`]_@A1W2.M2@'VGD.`L_:1$?!M\8HK=)Y]Z=+'F[URQ MC=Y-II_WC8-@?WOW2F#C,4?@>9O+0:K(M36

2>HOOVW6*PNP"37M[BBY;F2GV<5Y.4T%`>_Q($*YGW-_'48R\[#DK M-FORM$?Q#N;JYB!8T)E.^XF[O#E.XE+W#],'MK.YZPPZ8_;GN-/O.)/.O^?N M1D'M9;Y5K:OS<[%C5&:%I\6/(?XM9OUUGKFL8G?Z]C#VUIIT_O'`G:CS$Z_Y M^[[]I:Y4Q5U=0R)HQ23GY2OE\MCD$Y7"UIM?B%WHNWK#UXUO-I^KM:AVH>@@ MR4O#COA!%9,BDE M]]SVVQDK>JP=.[%&[$"+V17;Q$1I8L"8A+^V`SPC$?^;U`F+B8S5-SZ%#Y;I MR@Y0[RB=O1"/OU/<8YKW%X37O4IRNO;_G0XEQ5!7Z,I8@6/M!E!9KW:81?96 M/*_ZR72C-.T"2(V5--8..UAO=L#<121(;J?E\EQZ/I,P3K8591X/)#=6S%@[ MW$KZLP/RY'&D%@KQK$V7O%!FFN>TRI*?>LF\19XQK_]4:@"5.C-6UUB[.1RA M6SN,8_\1+?"@7TIHK&JQ=M"!.COC$,LMCA#QP@$*^'KVN2"3XR`Y_MA02_;9 MQO:[%L1<]E6A)?92_!&C[Y=DP<:IO.C4?KLRQS_P#EO.`>^ZLDS")J:QB^`N7*$9%1WL!EOK>_0O&K0] M%(;.*Y'`H]3)&>&F)%\Q?_BV8V2&$II]OJVBE^8-VN'[L MV,`4976VUOG?R,=9E3[L<$?0,*LB5NX`Q1(PRP9245L[P%$W20EP>D?#"5L( MLZT@6R$/D$^7>#EC2V.VEO)=Z5A83F;Z#;MB2]K)*@**KZF&05(_[)77-67; MDBZ>\2PF;]WS^79ZUB=+(GP.*+T<`J`T_0L+4,Z[MP.[6Y=+?7SO3: M76I3^Q<&A3+JVC.Q*2[VV#HKDNY0#YN97@J#-"IF7:M"\SMEJ4I%#4UO\\%* M+9;2CDVE.)'$86LX?Y&,AZWU6Y/L"3?G!06S--:)A^FC!74!#V?RL MXV.F[LFH[C0U:MH24^(U5GGA5;:5C@-^X)T^,,"%"G<*"(A6;N6TIJ]8V`[58#5JJ96E/^_2@$,)#61.V&(N#@+IH8I2)R8O?5='>?\Y/'6UZ7I"(7MLI?/*%]R825CR MGFGR=D`)D='[O,>#!!%1*RB.ZP9QDBB4\+"MX0Z`!D9J]-)N/0"IZ,B&^>ZP M6!QLGCNH1"HL'J=[?LMS+V0>4I<$1F_#H=W! MMZN4\A-&4=LS0D'$OAUGB;N<01+:BRGL`*38K*2@Z,]$3]]0BGB*=C*NEIUG M"1N;/H`ILY>]@RV)P'8$?[(%7Y^@1^*E3X67;2PE).=R)E(JM1W@[&V7"EYK MRUH+&Y_-V85$5#NPV'7\;5D$Z#R1(SB;@XD2D6W$Y<%':=8LGO'M';_W#45( M2'HVAP]@-6@*K@P#LB`^\KK(Q5F]$$!(K^U2F M5V45W40LO,;P(X[P+/T8?R!V=W4H"3W*R8P5'U+R$:CX-D050>7V08'&ZX/7 M7\#E]W4''R%%W!7CD<=U:;X8G/3*[*:%T2A_':")"[J)')")-L(0LQ^\O]0 M2P,$%`````@`0W2S1N.$G>Y'"@``2E4``!$`'`!M:'1X+3(P,34P,S,Q+GAS M9%54"0`#'8);51V"6U5U>`L``00E#@``!#D!``#M7&USXC@2_GQ7=?_!1]55 MS=44`9+)["2;[)8Q)L,6P0QVYNW+EK`%J&)+1)(3V%]_+1OS:HPAS([KDGQ( MC-3=ZNY':K7D)E>_3P)?>\1<$$:O2[63:DG#U&4>HY=:@[GE%AVP7[4."O"E=H,IYD@R_JOV&?FA:F%?Z[TV M?(SE7VKO3JI(*Y=S"/N,J&+\7)R[+)\YF M(7?Q7%8PDI,_3ZNU\^K96>W/3[63R0"T;B`)?:KY/Z>-JOI5^^"<5B^K9Y?G MISG'D4B&8CY.=?*A6JU5X2N3KT*(?PH_]KRUAH;=_ M/"#+FWZO3Z?X?B)N:F\'/?^A,?U$N7-Q']CHOFM^__+TR33C(:^$.\(!T@!G M*JY+2UY\.CMA?%@Y!0TK7V_;=D17B@DO)SZA]VGDM8N+BTK4FY!N4$[ZW$]$ MGU54=Q\)/)<,O22#GE`A$757Z#TY9U@F/J_$G2ND))7T?4Q*$M)0E(<(C>>T M`R3Z$>VL`WAJ9^5JK7Q66V+AS,5E50258'Q`,?!YC*)N-!`P]0 MZ`,8#R'RR8!@KZ1)Q(=8JODKQLC%N\0EJP!1RF"Q0%B8M:BV\9C`:H"&?URI M:7.IO.J`[IIZ@&"P1;CJK.O5,*HF:.PBF>^-ZR.;;5;#=TQ&UI=;^L=P]3LCZ;IV*]^7W%L%W$PF[9W9[O\EW676[T;O=/Z'GE:TSN-I4CT,AUOAT&`^-0: MV&1((:EV$:2HKLM"R"OIL`L1QR58@,][V%>AYQ;XX4`=PW(H-[52[-9-I]5L&7K'T73#L.XZ3JMSHW4ADADMTXX@[9GM**C=ZHYC]EXH MK@8:$XE\AR,JD+N\S:=T9.-QL8Z'H7=;CM[6G)[>L77C!:\>=2S%W!K`U(=Y MW6$20RX[17T?Q\[.Z,_T>:VZ[O.FU;LU>[`$8/+#I-8ZE@/3O:M_T^MM\V4Z M?]F=90NR?!X[/:4]V]FU=6>O.%?M&LY'L_Q@=T29SX93&_D80KD=]LMM MF,Y48'W(<91.QG[/1YH-Q>DZ%(YI?.Q8;>OFFV;K`(8*\/9=O0SQWNS8\/FF M9T:9Z\N$Q\92QC=D_%2.!DR]Z#(1NJLXUMVG2<=H3% M`I4(K]L[YPZVBQNS`[E66^W/IFZ;+W3+@$4A\$,(]IB/Z@279%)KK=F^?[>9 M(M5M\].=\KCY69WC7JIS#TI(DXYG9;5S(=G0G1\WN]7>)..^T`/Z@6@UL$3$ M%QW$U4GR$3\+^@UAV5-@XR+@N5-@-KXV5^"%SH64LTTZSGD(LS'`=M^N$H'*@==-D`;MPNIAZ]78/8ZD*5C=1AK M)GRG&Q<5N0]L_]^0JE^J\*2'!UI4L'*IRB"N2X($8W4[%+>-.!Y M$`2FG4P"/R%1HC,*5J(YL>Z-V<")",3=#2D;!34@A(TQEY#?5!+E$P&22,6^ M_*Y#4^-`PEPYALD^ZN]K,K!@_P?:VE;RCVHDS+Y]C5R;L#_(5&,QRE$-AJ6S MK\&KJ^T'V=N8#[)L[JP*J+(H`YI]7B\5N@+#&9<:W2@ZRBHGBPOAVLR-1&6P MJ$_EA*^LFLJUT_)9[60BO(6F^RBQ<,-^2B1\!R@121/8/1FR1P"5K%1_;=$B ME4<]E!?,>F+'-V8D8U M52[45*F]?Z8RARFR2XM9-6&4#45EN&TF=!\%#/(=)1_Y-G9#3N2TW39N<=!7 M[Q24SK`AY*$DOJ\2X>N2Y*$*.ZK:]!+"$6&>$T5-+^2S&H(XBL85FI<>"Q"A M+8D#1096AWT!T2I4I#>/K4BR+`$F6/;9+X+.ZN>@@R@(<>,0E%+>HNVI- M#KJ?;HNJ>`E]B(-R5?>4]B+H^JAV'5`B.A%M:)S>^]/UGMUC=1&7TU6=4WM^ MNKY95;0ZR.3(E8D%^6C1["FQ:7\;8PJ00NCP2-.>I55)KMN7@[!PQNE"@((] M[&(X[GDMFO(ZRL;1(OF0F+D?RTX#X]1*)EW]V'%@..X3N6IUP"B<4/GT&'$9 M-,!"7PH$/>R!\G&IP"PF9],<;)G+L??#3:LOJ:V'OGP)6RXLP1@"6.INGJ.EAK*X2&5BC5 M(.I[DZMJKG840M?ZUMVA>,C7TZ"O%PO[^E;PZP5$W]BZ;18/?2,-?:-8Z!M; MT3<*A?[N+Q>ILG[U^A#RC#''(TP%I/MM)C*//0>+*MR^O?/K/7G=D,)0.&-O M$*%6VD&NEEB72;&'^G]OSMG`?:E>AJIZ(34).1D2BOPH9,S;75`B5FYV3;$G MT^'6_]@CKE)8C0-3<'%4:#+>Y7B,B`=1Z9&XJL8N-CL_>5$-KF.*!\0ER(^/ M?.J_3#0QDB''NA`,.F!I?B%RI!!.S-Z7J:C&1Z53`U6B$]_/-#D+#,3'0(3Y M[.[083FN=XXAJ*A.BBY['=:$]4P5Y(LXO1[-\U`6+HRG5-$Y>"+K/JSD^3:5 M37/HA;),9!QC*J>4Q?AK53$;=NW+5`1#]ZC]W[#W0-Y"F+VMJ#=7.??Z2CV6 MM,*MYL,,6R\7.XZ[MDLMG-M4OFU.7(S50:N)/;42_&F+JG(XKTT"(L4B%N8A M+>@;C!PETQM'E'U8"@=L_A+D=;L/X2R<^2V5?V$AS"#@_[B>^/)%=B6WI_M]17%9LY.57K1]_>I?%6) MBR/A\7]02P$"'@,4````"`!#=+-&5G;7*41!``#0?P$`$0`8```````!```` MI($`````;6AT>"TR,#$U,#,S,2YX;6Q55`4``QV"6U5U>`L``00E#@``!#D! M``!02P$"'@,4````"`!#=+-&4WMLX"4+``#:"TR,#$U,#,S,5]C86PN>&UL550%``,=@EM5=7@+``$$)0X```0Y M`0``4$L!`AX#%`````@`0W2S1OR_K)$1"@```6,``!4`&````````0```*2! M`TT``&UH='@M,C`Q-3`S,S%?9&5F+GAM;%54!0`#'8);575X"P`!!"4.```$ M.0$``%!+`0(>`Q0````(`$-TLT:Q/@0,PR4``/3H`0`5`!@```````$```"D M@6-7``!M:'1X+3(P,34P,S,Q7VQA8BYX;6Q55`4``QV"6U5U>`L``00E#@`` M!#D!``!02P$"'@,4````"`!#=+-&"C;WUO\7``!]40$`%0`8```````!```` MI(%U?0``;6AT>"TR,#$U,#,S,5]P&UL550%``,=@EM5=7@+``$$)0X` M``0Y`0``4$L!`AX#%`````@`0W2S1N.$G>Y'"@``2E4``!$`&````````0`` M`*2!PY4``&UH='@M,C`Q-3`S,S$N>'-D550%``,=@EM5=7@+``$$)0X```0Y 9`0``4$L%!@`````&``8`&@(``%6@```````` ` end XML 19 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 20 R7.htm IDEA: XBRL DOCUMENT v2.4.1.9
ORGANIZATION AND OPERATIONS
3 Months Ended
Mar. 31, 2015
Notes to Financial Statements  
Note 2. ORGANIZATION AND OPERATIONS

Manhattan Scientifics, Inc. (the “Company” or “Manhattan Scientifics”), a Delaware corporation, was established on July 31, 1992 and has two operating wholly-owned subsidiaries: Metallicum, Inc., (“Metallicum”) and Senior Scientific LLC (“Senior Scientific”). On June 12, 2008, the Company acquired Metallicum, Inc. for 15,000,000 shares of Company’s common stock. 

 

Manhattan Scientifics is focused on technology transfer and commercialization of disruptive technologies in the nano-medicine space. The company is presently developing commercial medical prosthetics applications for its ultra-fine grain metals and plans to commercialize the cancer research work and nano-medical applications developed by Senior Scientific, a unit of the Company.

 

The Company’s business model capitalizes on inventions and technology from which profits are intended to be created through licensing. Manhattan Scientifics is dedicated to earning profit for its 8,600 owner-shareholders by identifying, developing, patenting, supporting and marketing technical innovation by harvesting top technology talent to bring game-changing products to market. Manhattan Scientifics assists and acquires early stage technologies and assists entrepreneurial founders and management to stage them to become commercial. Our investment philosophy is defined by our desire to help build innovative companies with exceptional potential. We emphasize novel technologies in the nano-medicine space with the potential to be disruptive and the ability to establish sustainable businesses. We are patient capital with experienced business-building partners who bring the perspective of merchant-bankers not venture capitalists. Our approach to assist scientists to commercialize their work is by providing a forum within which the commercialization process is fostered through partnerships with existing companies (Fortune 1000 or larger). We believe the entrepreneurial scientists and engineers who join us are enticed in part by the offer to potentially create personal success and wealth by virtue of ownership of our publicly traded shares common stock under the symbol MHTX.

 

On May 31, 2011, we entered into an Agreement and Plan of Reorganization to acquire Senior Scientific and Scientific Nanomedicine, Inc. (“Scientific Nanomedicine” or “SNMI”). We subsequently dissolved Scientific Nanomedicine and transferred all remaining assets to Senior Scientific. The total purchase price was 21,668,000 restricted shares of our common stock (less 7,667,000 shares previously issued pursuant to an option agreement). As a result of this acquisition, we own patented technologies that can use biosafe nanoparticles and sensitive magnetic sensors to detect and measure cancer cells in biopsies or in the human body with the potential to transform how cancer is detected and treated.

 

ADVANCED METALS

 

The goal of our licensed proprietary process will be to enable our commercial partners to build super-strength metals and alloys to make products that weigh far less than in the past and without significant cost premiums 

 

NANOMEDICINE

 

Our acquisition of Senior Scientific gives us the commercial rights to technology and intellectual property with respect to the detection and monitoring of diseases using nanotechnologies. The technology is intended for the early detection of cancers, quantitative in vivo assessments of tumors, and similar applications with other diseases identifiable by cell surface markers. The technology does not require surgery, biopsy, radioactivity, or exotically expensive instruments. Nanoparticles are introduced to the body, for example, by intravenous injection. A sensitive low magnetic field instrument is used to magnetize and measure the nanoparticles that have bound to the specific targets (e.g., cells of a specific type of cancer). Other tissues, bone, scars, etc. are all transparent to the magnetic fields used, so the technology can be used to image detect and measure tumors in places inaccessible to other tests, and including tumors while they are still small enough to be treatable. The nanoparticles are nontoxic, and the low magnetic field instrument is not harmful or expensive, so the tests can be repeated as needed. 

XML 21 R3.htm IDEA: XBRL DOCUMENT v2.4.1.9
CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)
Mar. 31, 2015
Dec. 31, 2014
STOCKHOLDERS' DEFICIT    
Preferred stock, par value $ 0.001us-gaap_PreferredStockParOrStatedValuePerShare $ 0.001us-gaap_PreferredStockParOrStatedValuePerShare
Preferred stock, shares authorized 1,000,000us-gaap_PreferredStockSharesAuthorized 1,000,000us-gaap_PreferredStockSharesAuthorized
Series A, Percent 10.00%mhtx_SeriesPercent 10.00%mhtx_SeriesPercent
Series A, authorized 182,525mhtx_SeriesAuthorized 182,525mhtx_SeriesAuthorized
Series A, issued 0mhtx_SeriesIssued 0mhtx_SeriesIssued
Series A, outstanding 0mhtx_SeriesOutstanding 0mhtx_SeriesOutstanding
Series B, authorized 250,000mhtx_SeriesBAuthorized 250,000mhtx_SeriesBAuthorized
Series B, issued 49,999mhtx_SeriesBIssued 49,999mhtx_SeriesBIssued
Series B, outstanding 49,999mhtx_SeriesBOutstanding 49,999mhtx_SeriesBOutstanding
Series C, authorized 14,000mhtx_SeriesCAuthorized 14,000mhtx_SeriesCAuthorized
Series C, issued 0mhtx_SeriesCIssued 0mhtx_SeriesCIssued
Series C, outstanding 0mhtx_SeriesCOutstanding 0mhtx_SeriesCOutstanding
Common Stock, par value $ 0.001us-gaap_CommonStockParOrStatedValuePerShare $ 0.001us-gaap_CommonStockParOrStatedValuePerShare
Common Stock, shares authorized 950,000,000us-gaap_CommonStockSharesAuthorized 950,000,000us-gaap_CommonStockSharesAuthorized
Common Stock, shares issued 518,378,036us-gaap_CommonStockSharesIssued 516,378,036us-gaap_CommonStockSharesIssued
Common Stock, shares outstanding 518,378,036us-gaap_CommonStockSharesOutstanding 516,378,036us-gaap_CommonStockSharesOutstanding